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Abstract
Peripheral neuropathies are a debilitating problem in human and animal patients resulting in diminished the
quality of life. The current gold standard methods for repair of critical size peripheral neuropathies have
limitations that overall diminish the quality of life for patients. The use of nerve scaffolds composed of
synthetic polymer-based materials to heal damaged nerves has become an attractive approach in
regenerative medicine research. Studies have shown the biomaterial characteristics of graphene oxide to
have potential in applications for regenerating damaged peripheral nerves. Studies have also shown that
incorporating Mesenchymal Stem Cell (MSC) therapies into neural scaffold designs can significantly
improve the quality of tissue healing as well. The hypothesis of this study is that a novel synthetic thin film
composed of electro spun polycaprolactone (PCL) and modified with surface coating of Graphene Oxide
(GO) and cultures of Human Mesenchymal Stem Cells (hMSC) will have the potential to regenerate a
critical size peripheral nerve defect. The first objective studied the potential cytotoxic effect of graphene
surfaces with different oxidative group saturation levels to rat adipose derived stem cell (rADSC) cultures.
This objective also manufactured PCL materials of fibrous and smooth surface topographies using both
electrospinning and polymer-drop techniques. The second objective assessed the In-vitro capabilities of GO
surface modifications of both fibrous and smooth surface PCL material templates seeded with adipose
derived hMSCs for materials effectiveness in supporting and guiding trans-differentiation of hMSC into a
Schwann like cell lineage. The final objective involved the development of an approved critical nerve defect
model in Rats to assess the In-vivo performance of electro-spun PCL films with GO surface modification
and hMSC platform to stimulate nerve regeneration at a critical nerve defect. The degree of nerve
regeneration was determined by exogenous detection of gait patterns in the rats during nerve repair and
tissue identification/ measurements thru Histology sections. This study to date has shown that neural wraps
composed of electro-spun PCL surface coated with GO can support the hMSC in both static and transdifferentiated forms and can stimulate nerve regeneration in a critical nerve defect rodent model.
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Chapter 1: Literature Review
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1.1 Biomaterials for Biomedical Applications
Our current definition of a biomaterial is a natural or synthetic material intended to interface with biological
physiological systems to treat or replace tissue/organ functions in the body [1]. Biomaterials are an essential
component that must be incorporated into the design of medical devices so that when such devices interact
with surrounding tissue/extracellular matrix (ECM) they stimulate the surrounding native tissue to behave
in either a state of regenerative potential or an inert homeostasis. The effectiveness of a biomaterial to
stimulate tissue into a regenerative state is based on the materials ability to support proliferation,
migration/orientation, and differentiation of cells while ensuring that material structural failure, foreign
body signaling, and toxicity are minimized. This can be further characterized by understanding how
biomaterial properties like surface chemistry, surface topography, bulk porosity/geometry, and by-products
created thru biological degradative processes can stimulate particular cellular chemical and
mechanobiological pathways.
There is currently on going and rapidly expanding research in the field of biomaterials to understand how
these characteristics of biomaterials can target specific regenerative cellular pathways to become active and
how they could further enhance tissue regeneration. Such research has also been discussed for the design
of biomaterial scaffolds for the application of regenerating severe peripheral neuropathies in the hopes of
improving healing time and the quality of regenerated peripheral nerve tissue [2].

1.1.1 Biocompatibility Assessment
The term biocompatibility is defined by D.F. Williams as “the ability of a material to perform with an
appropriate host response in a specific application” [3]. The Science community has discussed throughout
the conception of biomaterials as to how to characterize biocompatibility of a material and to what degree.
Thru decades of research in both In-vitro and In-vivo models, the term can be subdivided into four individual
categories of analysis that must be reviewed for a material to be labeled as biocompatible: toxicology,
reaction to extrinsic microorganisms, mechanical effect, and cell-biomaterial interactions [4]. This has led
to the development of both In-vitro and In-vivo methods for the assessment of each subdivision and the
development of standardized procedures designed to insure these methods answer with high certainty the
public concern that a device or material will improve and ensure public safety. The selection of In-vitro
methods should consider the type of biomaterial and biological components being assessed for cytotoxicity
to determine any potential toxic mechanisms or material property effects due to reaction with the assays
involved that could give null or false readings. Most of these procedures are standardized by international
agencies such as the International Organization for Standardization (ISO) section 10993 “Concerning
Biological Evaluation of Medical Devices” and the American Society for Testing and Materials (ASTM)
2

while other agencies will regulate or enforce these standards such as the United States Food and Drug
Administration (USFDA) Code of Federal Regulations (CFR) Cha 1- Subchapter H [5].
1.1.1.1 In-vitro Models
The evaluation of cytotoxicity in biomaterials can be simplified by observing how target cells or tissue will
react in direct or indirect contact with biomaterials. If, under controlled conditions, cells react to the material
with normal cell behavior and function such as cell adhesion, proliferation, migration, and differentiation
we can conclude that the cell’s physiological system is normal or homeostatic. However, if under these
same conditions’ cells react with behaviors indicative of cell stress, or cell death we can conclude that the
material can induce some toxic or stressful effect on the cells. In-vitro models have a distinct advantage
due to the methods employed and the environments that can be controlled. Under controlled laboratory
conditions, specific variables related to cell-material interaction cytotoxicity can be analyzed under
reproducible and sensitive conditions. The methods utilized are therefore more precise, accurate, and
reproducible to strengthen statistical models. In-vitro methods can result in both qualitative and quantitative
data. Qualitative methods assess the state of cellular health by evaluating the morphology of cell lines after
exposure to the material and grading the health of cells based on the amount of cell death, cytoplasmic
granule formations, and the percentage of cells non-adhered to the material. Quantitative methods determine
the number of viable cells based on the presence of nucleic acid, metabolic by-products, or the expression
of surface adhesion markers. These methods follow ISO standards under section 10993 part 5 which
stipulates the different methods for collecting cytotoxicity data In-vitro and can be further subdivided into
more specific methods of cell-material interactions [5, 6].
In-direct contact method involves either Agar or Filter Diffusion Tests. In both cases, a monolayer cell
culture is grown in a culture environment while the physical biomaterial is placed in the same culture
environment but is separated by an Agarose gel or cell filtration film as a barrier diffusion model. Over a
designated period of culture, the material might diffuse compounds through the Agar membrane into the
culture environment where it will make direct contact with the cell line. The purpose is to observe whether
the cell lines can be induced towards a cytotoxic state due to direct exposure to potentially toxic
material/protein loading components, nanomaterials and the agglomerates, and degradation agents that have
leached from the material into the culture environment. The advantage of this system is that it is controlled
to look at toxicity of cells specific to the leeched components from the materials, while qualitative and
quantitative assays have their additional sensitivity, and accuracy parameters for identifying the specific
toxic components responsible. The disadvantage is that it does not include toxic effects due to mechanical
trauma, mechanobiological pathways, and cell-material interactions. This must be further analyzed with a
direct contact model [5, 6].
3

Direct contact method involves direct contact of cells with the substrate with no separation of the cell
monolayer to the biomaterial. The cell line is cultured in direct contact with the material which adds the
variable of cell-material reactivity as a variable in cytotoxicity as well as the physicochemical variables
specific to in-direct methods of cytotoxicity analysis. This creates a more complex model of analysis due
to the higher degree of variables that can elicit a toxic response to the cell. This may make it more difficult
to determine, with certainty, what the exact causes of cytotoxicity are and thus it is often necessary to
confirm with additional testing. There is a concern in establishing standard testing methodologies for direct
contact methods due to the nature of the materials (3D structure, Bio-resorption, Nano-topography, etc.)
being tested and the different cell-lines used, adding even more potential variables of toxicity. The
advantage of this method is that it is inexpensive, quick, and sensitive to these toxicity factors. If the
material under a direct contact model does not elicit a cytotoxic effect to the cell-lines, then an initial
conclusion would be that both the physicochemical and mechanical properties of the material are not
cytotoxic to the cell lines. It should be further confirmed with repeated direct contact tests utilizing different
cytotoxicity assays, but the potential statistical power of a single direct contact test performed correctly
could conclude with high certainty whether a material is cytotoxic or not.
Extract Dilution (Elution) test involve suspending a sample of the material in a physiological solution that
will extract elution solvents present in the material during the production phase while minimizing physical
and chemical damage to the material as well as being compatible with the cell lines. Elution samples are
then added to mono-layered cell cultures for 24-48 hours before toxicity assays are introduced. Very similar
to the indirect contact method, this method will often result in a consistent toxicity pattern in cell culture
due to minimal variability of elution solvents that are present in the material during production. While a
good first approach to determine initial cytocompatibility of the material, it suffers the same disadvantages
as an indirect method [5, 6].
Qualitative assessment of cytotoxicity in In-vitro studies involve the use of methods that are labeled as
categorical variables to determine if cytotoxicity is present in cell-lines. This form of assessment will often
use stains for viable and non-viable cells under fluorescent microscopy (FM) as a morphological indicator
of cell health. Some of the more common viable stains in use involve high affinity towards specific cell
structures such as the nucleotides within the nucleus, ATP and coenzymes in the mitochondria, permeability
of the cell membrane, or cytoplasmic proteins/cytoskeletons. The intensity of the stain is correlated to the
number of these structures present in the cell and combined with all other stained cells gives an overall
indication of viability for the entire culture. Some examples of common viability assays utilized for In-vitro
assessment of cell biocompatibility of are shown in Table 1.1.
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Table 1.1 In-vitro viability assays

Viability Stains

Stain mechanism

4`,6-diamidino-2phenylindole (DAPI)
7-Aminoacetinomycin D

Fluoresces to covalent binding to DNA and
RNA sections
Fluoresces to covalent binding of cytosine, and
guanine sites of DNA
Intracellular esterases excitation

Calcein AM
Propidium Iodine
MTT
WST-8
Thymidine [H3]

Assessment
(live cells/dead cells)

Fluoresces to covalent binding of DNA and
chromosome bases
Bulk tetrazolium salt dehydrogenase with
NADPH formazan excitation
Soluble tetrazolium salt dehydrogenase with
NADPH formazan excitation
radioactive neucleoside binding to DNA
sections

Dead cells
Dead cells
Live cells
Dead cells
Live cells
Live cells
Live cells

Viability data can also be acquired by observing cell morphology and death or lysis under (FM), light
microscopy (LM), or scanning electron microscope (SEM) to determine the viability of cells based on
physical cell characteristics such as cell shape size, spreading, or density. Fluorescent stains can also be
used for this type of assessment if stains are sensitive enough to differentiate between cell structures such
as the use of nuclear stains coupled with cytoplasmic counter stains. Cells suspended in media that exhibit
spherical shapes and minimal spreading on surface after 24-48 hours of incubation are often key indicators
of apoptotic behavior, while viability stains will confirm whether cell integrity, DNA, and cytoplasmic
environments are stable. This type of analysis is often categorized into a graded scale assessment of
cytotoxicity. Based on previous research involving similar cell lines, these types of observations can
establish a standard scoring system for cell cytotoxicity as the primary method for assessing the health of
cells based on cell morphology alone[7]. Other qualitative methods involve real-time tracking of the cells
by implanting fluorescent protein or radioactive isotope components or by labeling protein/gene sequence
markers using fluorochrome labeled antibodies that bind to these specific markers, which can then be
detected and quantified using spectrofluorometric analysis, scintillation to detect radio isotopes, or imaging
software.
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Table 1.2 Degrees of Cytotoxicity in the Agar Diffusion and Direct Contact Tests

Degree

CYTOTOXICITY

DESCRIPTION OF THE CYTOTOXICITY AREA

0

Absent

Absence of decolorization around or under the sample

1

Slight

Decolorization limited to the area under the sample

2

Mild

The size of the decolorization area from the sample is less than
0.45 cm

3

Moderate

4

Severe

The size of the decolorization area from the sample is less than
0.45 cm and 1.0 cm
The size of the decolorization area from the sample is greater
than 1.0 cm, but does not involve the entire plate

Source: Vidal, M. N. P., and J. M. Granjeiro. 2017. “Cytotoxicity Tests for Evaluating Medical Devices: An Alert for the Development of
Biotechnology Health Products.” Journal of Biomedical Science and Engineering 10 (09): 431–43

Caution must be reserved when interpreting qualitative data as it will often introduce debate among experts
as to what the cells’ morphology indicates about the health of the cells. This also is present when comparing
fluorescent stains to control parameters to determine if any specific toxicity pathway or mechanism has
activated in the cell-line. This is particularly true for unspecified cell-lines that are capable of differentiating
into multiple cell lineages and are thus capable of activating many different cytotoxicity pathways. It is
important to model the design of In-vitro models to account for statistical errors based on the sensitivity
and accuracy of the assays used by including enough replicates to overcome these limitations and to use
experts to minimize the risk of bias observations. With a categorical data set, it is often difficult to determine
whether a correlation exists between the material and variables for cytotoxicity as compared with
continuous data typically acquired during quantitative tests. This is why it is suggested that qualitative data
be complemented by quantitative data to detect specific cytotoxic pathways and determine if a correlation
exists between the material variables and any cytotoxic mechanisms.
Quantitative assessment of cytotoxicity includes methods that can assess the specific factors related to cell
or death. One of the most common forms of qualitative assessment of biomaterials in In-vitro models is to
count the number of viable cells across a material surface (adherence and proliferation) under normal
incubation conditions. Colorimetric assays are a common qualitative method for assessing the proliferation
pattern of cells. This method involves the interaction of molecular compounds designed to fluoresce when
exposed to the cell that change in response to activated cytotoxicity pathways such as specific enzymes,
cell membrane permeability, cell adherence markers, ATP production, co-enzyme production, and
nucleotides. The fluorescent labeled cells can then be quantified by counting the number of viable or non6

viable cells through a hemocytometer or flow cytometer. The light intensity of the fluorochrome density in
the culture area can be determined using light spectroscopy calibrated to detect the specific fluorescence
wavelength given off by the fluorochromes or by imaging software (ex: ImageJ) that can determine the
optical properties of images taken by FM. This is possible only if the fluorochromes remain bound to the
internal cell structures and minimal leaching out of the cell is observed. One of the most reliable and
sensitive calorimetry assays in use today are tetrazolium salt-based assays that bind specifically to
mitochondrial enzyme Nicotinamide adenine dinucleotide phosphate (NADP) which reduces tetrazolium
salt into a fluorescent protein known as Formazan as an indicator of metabolic activity. Soluble formazan
present in the surrounding media can then be detected using a spectrometer apparatus where the
fluorescence intensity can be correlated to give an estimated number of viable cells that is within acceptable
variations. Each of these assays are labeled as 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide (MTT) with other iterations often removing the extra step of solubilizing the formazan proteins
into the media solution (MTS, WST, XTT).
There are certain compromises that should be considered when choosing specific calorimetry assays. Often
these assays consist of simple protocols that can be completed with little effort or knowledge in advanced
laboratory operating procedures while also providing extremely sensitive and accurate data that correlates
to the physical cell numbers. This presents possible limitations to their effectiveness around different cell
lineages and any indirect methods of quantifying cell numbers [8, 9]. Some assays could be potentially
toxic to certain cell lines and some use radioactive isotopes such as [H3] Thymidine. Other indirect assays
that bind to cellular enzymes and proteins will often not consider other factors that could activate these
processes besides apoptotic pathways that will often lead to incorrect interpretation of the data [10].
Biomaterials can also impact the function of these assays by either activating the fluorescence as a false
positive or preventing the reagent to bind to its specific target as a false negative. It is therefore essential
that the limitations of one assay be supported by the advantages of another assay. This will insure that not
only the data is interpreted correctly but will provide a standard guide for different cell-lines and
biomaterials of compatible assays that can be utilized In-vitro.
Other methods involve detecting and quantifying more precise protein/genetic markers indicative of
activated apoptotic pathways such as pro-apoptotic genes (bax, bak, cytochrome c) and anti-apoptotic genes
(bcl-2, bcl-xl, Mcl-1). Western blot (WB), quantitative polymerase chain reaction (qPCR), and
immunofluorescence (IF) are all methods capable of identifying apoptotic pathways initiated by a specific
toxicity profile. The ratio of labeled surface markers, gene sequences, or proteins to the total image area or
volume of cell culture can be quantified to indicate whether apoptotic behavior is present along one or more
specific pathways.
7

1.1.1.2 In-vivo Models
While In-vitro models are a simpler model designed to control experimental variable interactions to
determine correlations between them, they are incapable of recreating the same biological/ physiological
environment that the implant will be exposed in living organism and there for the full spectrum of
measurements of biomaterial performance cannot be assessed. In-vivo models are a more complex system
in which two or more experimental variables including factors not included in the In-vitro model or
considered relevant are now exposed. Inflammatory responses, degradation, biochemical kinetics,
angiogenesis, and 3D tissue remodeling are complex processes that can only be fully studied In-vivo. This
can make opportunities to observe and identify associations between variables difficult. The goal of an Invivo model is to not only mimic the physiological conditions of the clinical case but to obtain meaningful
data that can be measured and analyzed to find clinically relevant differences in material performance. It is
prudent to observe overall physiological reactions and compare them to the current gold-standard (positive
control variable) and clinical care to determine the efficacy of the implant towards its intended targeted
therapy. This is an essential step in the process of evaluating an implant for clinical assessment and therefore
requires careful selection of the model system and variables to control/access depending on the application
of the implant and the current standardized guidelines described by both ISO and ASTM protocols for Invivo testing.
The use of mammalian physiological systems can accurately represent most of the conditions that
biomaterials will be exposed to under practical clinical applications and is therefore currently the best
method for assessing how biomaterials will perform in a physiological system that is to a degree similar to
that of a human system. There are variables of In-vivo models that we can tightly control such as anatomical
location of implant site, size of the implant incision, species, gender, age, sample size, and methodologies
for assessing material performance in an attempt to standardize animal models. The design of the model
should narrow and strengthen cause/effect relationships of physiological events to the interaction of
biomaterials. The controlled variables should also be focused towards answering specific questions related
to the assessment of biomaterials in one or all domains of In-vivo biomaterial assessments (biocompatibility
testing, bioactivity testing, or preclinical testing), while having the ability to translate these control
parameters to more complex or different animal models.
In-vivo assessment of biomaterials for neural regenerative applications must therefore fall under the same
system of standardization of In-vivo models. The number of In-vivo studies that have looked at repair of
peripheral nerves using scaffolds has created a varied list of the most common animal model designs and
methodologies for assessing nerve recovery in an attempt to standardize such studies. A study from 2012
performed a review of the literature on In-vivo neural regeneration models using nerve scaffolds and found
8

that the majority of these studies utilized rat models to assess scaffold performance followed by mouse and
rabbits respectively. Of these studies, the majority create defects in the sciatic nerve with most defect gaps
between 5-10 mm. The study also reports that within the studies using rat models the most commonly used
method to assess nerve healing is through Quantitative Histology analysis, followed by nerve morphometric
analysis, electrophysiology, and Immunohistology respectively. The number of animal parameters to
consider and the degree of control between model variables has created problems among investigators in
establishing a consensus on the best animal model design and methods for assessing nerve recovery.

1.1.2 Polymers
Polymers are a class of biomaterials that has seen an enormous surge in research and in the design of
medical devices. Research on polymer incorporation in neural scaffold and conduit implant designs is well
represented in the literature, going back as far as the early 1960s. Studies have shown that many polymers
are capable of interacting with the native tissue with minimal toxicity. Polymers have a distinct advantage
over other commonly used biomaterials in dynamic physiological environments in that they can be designed
to incorporate multiple therapies into their design to further improve tissue regeneration success. Polymers
can be easily handled and stored at low cost to the manufacture and customer. The methods for synthesizing
polymers provide a unique opportunity for exploring a diverse range in polymer combinations and
understanding how these new molecular structures impact their physical, chemical, and biological
properties. Polymers have also shown an ability to successfully integrate with cells and tissue in In-vitro,
ex-vivo, and In-vivo models while maintaining minimal inflammatory and foreign body responses over
extended periods of time. Polymers can be further functionalized to express specific traits that are time
dependent such as controlled degradation/ inert reactions, drug and protein delivery systems, mechanical
integrity in response to thermal and mechanical responses. The traits of certain polymers would correspond
to the definition of a biomaterial. Polymers as biomaterials can be organized into two distinct categories:
natural and synthetic based polymers.
1.1.2.1 Natural Polymers
Natural polymers have a distinct advantage over other biomaterials due to their natural origin from
physiological systems. Since these polymers are composed of organic molecules that are manufactured by
physiological processes, they have a higher chance of success when interacting with In-vivo physiological
systems such as immunomodulation, tissue interaction and reinforcement, and degradation. These polymers
also are capable under specific physiological conditions to produce these materials in abundance which has
a manufacturing advantage. There are a variety of natural polymers that are capable of being processed into
scaffolds of different surface and 3D composite designs with the added benefit of being degraded over time.
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Degradation occurs by both hydrolytic and enzymatic processes. Natural polymers are most often
compatible with the host extracellular matrix (ECM) which is expected to improve scaffold bio-integration.
Some of the most common natural polymers investigated for the development of scaffold designs are
polysaccharides (PSA), and poly amino acid chains (PAAC).
(PSA) are a family of naturally occurring monosaccharides cross-linked together with glycosidic linkages
(ether bonds) of both human and non-human origin. The most common examples of these types of materials
used in biomaterial applications are chitosan, hyaluronic acid, fibrin/fibrinogen, cellulose, alginate/agarose,
and dextran. These types of polymers are susceptible to biodegradation and are composed of functional
bioactive sites that have been investigated for applications involving controlled drug release, improved
cell/tissue interaction by modifying existing scaffold designs, and increased resistance from immune
response.
(PAAC) are highly organized collections of either natural or synthetic amino acid chains making them
mechanically versatile with little risk of activating adverse immune reactions. Some of the most common
(PAACs) under current investigation are polypeptide chains such as elastin, collagen, and blood proteins
such as albumin. Similar to PSAs, these constructs are very susceptible to biodegradation through
hydrolysis and enzymatic degradation.
1.1.2.2 Synthetic Polymers
Synthetic polymers have been in great demand as an alternative to natural polymers when designing tissue
scaffolds. While natural polymers have a higher success of positive bio-interaction with the surrounding
tissue and are of a lesser risk of inducing toxicity, synthetic polymers have almost unlimited potential for
synthesizing various forms of biomaterial designs without the need to harvest, sterilize, or decellularized
native tissue. This makes synthetic polymers a more attractive alternative to natural polymers for creating
universally compatible and market feasible scaffolds. The simple and cost-effective means of synthesizing
these polymers and their co-polymer iterations allow for excellent quality control during the manufacture
phase. Synthetic polymers have many different types of manufacturing and modification processes
available for conduit designs. This provides opportunities for careful tailoring of biomaterial variables to
improve polymer structure stability during long storage periods at room temperature and incorporation of
specific functionality traits that can improve mechanical stability, bioprocessing, and bio-interactions in
physiological systems. Such examples for manufacturing physical features include electrospinning, mold
casting, gas or solvent evaporation, sputtering, and printing while surface modifications include covalent
grafting, oxidation, plasma etching, and surface hydrolysis.

10

Synthetic polymers composed of α-ester-based functional groups are the most utilized material for
designing synthetic polymer scaffolds with controlled biodegradation. These aliphatic polymers are more
susceptible to hydrolytic, and oxidative degradation due to the hydrophilic regions of the ester groups
reacting with polar molecules and reactive oxygen species (ROS) resulting in successful scission of ester
bonds in physiological systems. This will often reduce the polymer chains into α-hydroxy acid monomers
(ex: lactic acid, glycolic acid, carboxylic acid, hyaluronic acid (HA)) of minimal toxicity and removed
through renal excretion. Examples of these types of aliphatic ester polymers include poly(lactic acid)
(PLA), poly (L-lactic acid) (PLLA), poly(glycolic acid) (PGA), poly(lactic acid-co-glycolic acid) (PLGA),
poly(ε-caprolactone) (PCL), poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV), polydioxanone
(PDS), polyethylene glycol (PEG) and certain forms of polyurethanes composed of ester and carbonate
groups as isocyanates (poly(ester urethane) (PEU), and poly(carbonate urethane) (PCU)) [11–13]. These
polymers are often labeled as hydrophilic which describes the ease in which water molecules can react to
the polarizing regions of the polymer ester-chains. In the presence of oxidative redox reactions these
hydrophilic regions can become more polarized to be further susceptible to hydrolytic and enzymatic
degradation. Oxidative reduction may take place in the form of redox reactions usually involving
hydrocarbon section of polymer chains that are hydrophobic regions. This will involve oxidative species
such as carbonyl, carboxylic, peroxide, and hydroxyl groups that will actively oxidize the material, thus
polarizing the material to create hydrophilic regions [14]. Polymer degradation can also occur from
enzymatic reduction in the form of both hydrolases and oxidoreductase pathways such as depolymerase,
peroxidase, and mono or di-oxygenase.
The degree of access to these reactive regions in the polymer chain to enzyme, oxidative groups, and polar
molecules will result in different polymer absorption profiles as described in Table 1.3 as the most common
degradation products and rates determined in these polymers. The degradation profile in these polymers are
subject to scrutiny as the degradation rate can change by a large degree in physiological systems when
considering dynamic temperature, ph., ROS, enzyme and polymer degradation product concentrations Invivo [15,16]. Other forms of biodegradation such as chemical functionalization, light exposure, microbial
interaction, mechanical stimulus, sterilization techniques, and architectural modifications to the material
should be considered as they can also have a significant effect on the degradation profile of biodegradable
polymers [15,17].
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Table 1.3 Degradation properties of synthetic biodegradable polymers
Polymer

Degradation product

Degradation period (months)

Reference

PLLA

L-lactic acid

6-24

Garlotta, 2001; Zilberman
et al., 2005; de Tayrac
et al., 2008; Armentano
et al., 2010

PGA

Glycolic acid

3-6

PLGA

D, L-lactic and
glycolic acids
caproic acid

3-12

cyclohexane dimethanol
propionic acid
1,6 hexane diol
pentaerythitol dipropionate
Pentaerythitol
crotonic acid
butyric-2
isopropyl-2
glycoxylate
glycine
peroxides
glycolic acid
monoalkyl ethers
ethylene glycol

6-34

Wen and Tresco, 2006;
Armentano et al., 2010
Lu et al., 1999, 2000;
Armentano et al., 2010
Nair and Laurencin, 2006;
Pena et al., 2006
M.S. Tatlor, 1994

hyaluronic acid groups
Urea
Urethane
Carboxylic acid groups
Urea
Urethane

PCL
POE

PHBV

PDS
PEG

PEU

PCU

18-36

6-39

Muhamad et al., 2006
Xiang et al., 2016

6-12

Ray et al., 1981

9-18

Guo et al., 2012
Webb et al., 2013
Andersen et al., 1999

N/A

Ravi et al., 2009
Blais et al., 1990
Szycher et al., 1991
Ravi et al., 2009

N/A

Source: M.E. Marti, A.D. Sharma, D.S. Sakaguchi, and S.K. Mallapragada. 2013. “Nanomaterials for Neural Tissue Engineering.” In Nanomaterials
in Tissue Engineering Fabrication and Applications, edited by A.K. Gaharwar, S.Sant, M.J. Hancock and S.A. Hacking, 275–300. 56. 1518 Walnut
Street, Suite 1100, Philadelphia, PA: Woodhead Publishing Limited.
Additional Table content added by the Author
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The other category of synthetic polymers is characterized as non-degradable, biostable carbon chains that
are able to resist hydrolytic, oxidizing, or enzymatic processes due to the stable configurations of the carbon
bonds and prevention of access to the sensitive polar regions of the polymer structure. This labels these
polymers as hydrophobic which describes the difficulty in which polar molecules can react to the polarizing
regions of the polymer chain, resulting in extremely slow or negligible absorption profiles that are often
characterized as

having inert

reactions

to physiological systems.

Such examples

include

Polytetrafluoroethylene (PTFE) with carbon-carbon bonds surrounded by stable fluorine atoms, or poly
(vinyl alcohol) (PVA) with carbon-carbon bonds surrounded by stable hydroxyl groups. Polyurethanes
(PU) are most often utilized in inert or biostable medical device applications. By selecting specific polymers
that can be used as soft segments (polyols) and hard segments (diisocyanates) the creation of biostable
urethane and block chains can be created with mechanical ratios between stiffness and elasticity. PU can
be tailored to be more biodegradable by introducing ester-based polyols for the soft segment component
such as PLA, PGA, or PCL resulting in a variety of different biodegradation profiles.
These polymers are categorized under FDA regulations as non-degradable polymer substrates that are
highly resistant to bio-resorption making them overall inert to cell/tissue interactions and highly resistant
to immunomodulation processes In-vivo. This makes inert polymers excellent for blood or cerebral fluid
contact, mechanically intensive, or drug delivery applications. However, this presents limitations with
successful integration with target tissues and the potential for foreign body reactions due to the inability of
cell/tissues to recognize the material as a native material making long duration use of these materials Invivo difficult.

1.1.3 Nerve Conduits
The development of neural scaffolds has been researched as a potential solution to improving the quality
of nerve tissue regeneration over extended regeneration distances. Both natural and synthetic polymer
scaffolds by themselves still underperform when compared to the current gold standard for PN defects
greater than 3 cm. To address this challenge, many studies have begun to look at combining multiple TE
techniques together in polymer scaffold designs such as stem cell support, anisotropy surface architecture,
and surface coatings to improve the limitations of synthetic scaffolds [18]. The majority of these In-vivo
studies show a significant improvement in neural repair, with successful bridging of neural defects up to 3
cm in length being reported. A current gap in neural scaffold development is determining the optimal
biomaterial design that can facilitate peripheral neuron and Schwann cell adhesion and orientation that is
biomimetically similar to the surrounding (ECM) but remains structurally stable over long durations of
implantation. This involves investigating the potential cytotoxic and neuro-regenerative effects with
different conduit materials and their different design/functionalities thru In-vitro and In-vivo assessment.
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The goal of which is to create a material engineered to a specific design that will maximize neuroregenerative output in clinical cases. The following section will highlight techniques investigated in the
design of nerve conduits and the current observations regarding their potential for regenerating peripheral
nerves compared with the quality expected of the current gold standard (autologous graft).
Materials investigated for the development of neural conduits have consisted of both natural and synthetic
materials. Natural materials as structural components in neural scaffold designs have focused primarily
towards polysaccharides of both human and non-human origin. Currently type 1 collagen and small
intestinal submucosa-based scaffolds are the only FDA approved natural material nerve scaffolds available.
Synthetic materials that have currently been explored for potential in neural scaffold designs include
silicone, ceramics, carbon-based, and polymer materials with few polymers being FDA approval for use in
clinical applications of severe neuropathies (PVA, PGA, PLCL).
The vast majority of peripheral nerve scaffolds have designs that are rigid hollowed-out tubes or films
wrapped into tubular structures of varied lengths and sizes as needed to bridge the defect site. This type of
design is most effective in bridging the two PN ends across the gap with minimal tension. The concept is
to fully encapsulate the site of injury for more controlled guidance of nerve healing. Such encapsulation
provides opportunities for more direct appliance of targeted therapy techniques such as culturing supportcells to the interior scaffold structure, mechanical and physical ques from tissue interaction with the scaffold
material, and controlled drug elution/ transport. Over the years, neural scaffolds have undergone extensive
design changes that now incorporate components that are specifically designed to further stimulate
controlled nerve growth by careful selection of material properties, geometric and surface features, and the
ability to integrate with surrounding tissue resulting in higher rates of successful nerve rehabilitation
outcomes. The current market of FDA approved neural conduits and neural protectants/wraps composed of
both natural and synthetic polymers are listed in Table 1.4 [19].
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Table 1.4 Most current list of FDA approved neural conduit and wraps designs
Available FDA approved nerve guide conduit devices
510K approved

FDA clearance date

Product name

Material

Degradation

Diameter

Length

Company

K983007

22nd March,
1999/1995

Neurotube®

Polyglycolic acid
(PGA)

3 months

2.3-8 mm

2-4 cm

Synovis® Micro Companies Alliance
Inc., www.synovismicro.com

K011168

22nd June, 2001

NeuraGen®

Type I collagen

36-48 months

1.5-7 mm

2-3 cm

Integra Life Sciences Corp.,
www.integra-Is.com

K012814

21st Sept, 2001

Neuroflex™

Type I collagen

4-8 months

2-6 mm

2.5 cm

Collagen Matrix Inc.,
www.collagenmatrix.com

K012814

21st Sept, 2001

NeuroMatrix™

Type I collagen

4-8 months

2-6 mm

2.5 cm

Collagen Matrix Inc.
www.collagenmatrix.com

K031069

15th May, 2003

AxoGuard™
Nerve
Connector

Porcine small
intestinal
submucosa (SIS)

3 months

1.5-7 mm

10 mm

Cook Biotech Products,
www.cookbiotech.com

K032115/K05057
3

10th October,
2003/4th May, 2005

Neurolac®

Poly (DL-lactideε-caprolactone);
PCL

16 months

1.5-10 mm

3 cm

Polyganics B.V., ww.polyganics.com

K100382

5th August, 2010

SaluTunnel™
Nerve
Protector™

Polyvinyl
Alcohol (PVA)

Nonabsorbable

2-10 mm

6.35 cm

Salumedica™ L.C.C.,
www.salumedica.com/

Available FDA approved absorbable nerve cuff/protectant wrap devices.
510K approved

FDA clearance date

Product name

Material

Degradation

Diameter

Length

Company

K002098

24 November,
2000/2001

Salubridge™

Polyvinyl
Alcohol (PVA)

Nonabsorbable

2-10 mm

6.35 cm

Salumedica™ L.C.C.,
www.salumedica.com/

K031069

15th May, 2003

AxoGuard™
Nerve Protector

Porcine SIS

3 months

2-10 mm

2-4 cm

Cook Biotech Products,
www.cookbiotech.com

K041620

16th July, 2004

NeuraWrap™

Type I collagen

36-48 months

3-10 mm

2-4 cm

Integra Life Sciences Corp.,
www.integra-Is.com

K060952

14th July, 2006

NeuroMend™

Type I collagen

4-8 months

4-12 mm

2.5-5 cm

Collagen Matrix Inc.
www.collagenmatrix.com

th

Source: Kehoe, S., X. F. Zhang, and D. Boyd. 2012. “FDA Approved Guidance Conduits and Wraps for Peripheral Nerve Injury: A Review of
Materials and Efficacy.” Injury 43 (5): 553–72.
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1.1.3.1 Conduit Designs
The development and assessment of a variety of neural conduits and wraps has provided the foundation for
what criteria should be considered when designing such devices to ensure that the device will perform at a
level that meets or exceeds the clinical standards for acceptable peripheral nerve repair (autographs), while
minimizing incidences of both mechanical and physiological failure during the course of repair. The current
design criteria considered to be essential for successful neural conduit and wrap implementation is
described in Table 1.5 [20]. The majority of peripheral nerve conduit designs both on the market and under
research investigation conform to a simple hollow cylinder structure. This design resembles the peripheral
nerve anatomy to its most simple geometric shape making it easy to manufacture with minimal variations
between completed products depending on the material used (natural or synthetic). Functionally it can fulfill
the basic requirements expected of a neural conduit or wrap design for repair of critical defects. This
includes bridging the two ends of the proximal and distal stumps, holding its shape and mechanical stability
for the duration of nerve growth, allow for permeability of nutrients and waste from the repair site, and
support neural cell adhesion and guidance. However, the most recent developments in both natural and
synthetic neural conduits and wraps is that they must also incorporate both mechanical and chemical cues
into the design to achieve the neural regenerative potential of autographs.

Table 1.5 Design Criteria for Nerve Wrap and Conduits
Ideal properties
Biocompatibility
Degradation/ porosity
Anisotropy
Protein modification/ release

Description
Material should not harm the surrounding tissues
Degradation rate should complement nerve regeneration rate; conduit should
allow nutrient diffusion and limit scar tissue infiltration
An internal scaffold or film should provide directional guidance
Laminin/fibronectin coating for increased cellular adhesion; controlled/sustained
growth factor release

Physical fit

Conduit should have a large enough internal diameter to not "squeeze" the
regenerating nerve; wall thickness limited

Support cells

Schwann cells/stem cells capable of delivering neurotrophic factors to the site of
regeneration

Electrically conducting

Capable of propagating electrical signals

Source: Nectow, Alexander R., Kacey G. Marra, and David L. Kaplan. 2012. “Biomaterials for the Development of Peripheral Nerve Guidance
Conduits.” Tissue Engineering. Part B, Reviews 18 (1): 40–50.
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The majority of peripheral nerve conduit designs both on the market and under research investigation
conform to a simple hollow cylinder structure. This design resembles the peripheral nerve anatomy to its
most simple geometric shape making it easy to manufacture with minimal variations between completed
products depending on the material used (natural or synthetic). Functionally it can fulfill the basic
requirements expected of a neural conduit or wrap design for repair of critical defects. This includes
bridging the two ends of the proximal and distal stumps, holding its shape and mechanical stability for the
duration of nerve growth, allow for permeability of nutrients and waste from the repair site, and support
neural cell adhesion and guidance. However, the most recent developments in both natural and synthetic
neural conduits and wraps is that they must also incorporate both mechanical and chemical cues into the
design to achieve the neural regenerative potential of autographs.
Mechanical modifications to neural conduits have focused primarily on maintaining mechanical stability
and improving cell adhesion and guidance during nerve regeneration. Micro-scale modifications to date
have involved internalizing parallel channels, filament, or ECMs that are more similar (biomimetic) to the
peripheral nerve structure. These can be even further modified with the additions of nano-scale surface
modifications to change the degree of cell adhesion, cell guidance, diffusion of nutrients and waste through
the conduit, and degradation rate. Micro-channels and nano-groove pattern surface modifications appear to
perform the best at adhering and guiding neural and Schwann cells [21]. Multipotent cell-lines such as
neural and mesenchymal stem cells have also shown improved potential for neural differentiation on these
types of architectural modifications as well. From a mechanical perspective, modifying the surface to
increase the diffusion rate across the devices surface such as by creating porous or creating nanofiber or
ECM meshes will increase the rate of degradation causing the conduit or wrap to fail at an earlier time.
However, this can be negated by careful selection of the conduit material.
Chemical modifications are often used to either alter the bulk design of the conduit to attach and release
organic compounds intended to enhance nerve healing, or surface alterations to improve cell-material
interactions [22, 23]. Some of the most well-known forms of chemical alterations have been oxidizing or
PEGylation to material surfaces, or adding nanoparticles designed to resist microbials and improve
electrical conductance on the material. Biological modifications involve the attachment of either proteins,
cell, or protein motifs that can better simulate the physiological conditions needed to enhance nerve
regeneration. The most common techniques utilized have been to bind specific neurotrophic factors
necessary for nerve regeneration to take place such as nerve growth factors (NGF), brain-derived
neurotrophic factors (BDNF), and glial-derived neurotrophic factors (GDNF), or incorporate stem cell
therapies to enhance nerve regeneration by modulating inflammation, releasing appropriate growth factors,
or differentiation toward specific neural lineages (Figure 1.1) [2].
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Figure 1.1 Ideal neural conduit design configurations (Physical and Biological cues)
Source: Gu, Xiaosong, Fei Ding, and David F. Williams. 2014. “Neural Tissue Engineering Options for Peripheral Nerve
Regeneration.” Biomaterials 35 (24): 6143–56.
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1.2 Peripheral Nervous System
The Peripheral Nervous System (PNS) is a major component of the nervous system that serves to process
and transport stimulus signal from peripheral sensory receptors to the Central Nervous System (CNS), and
then relay the appropriate motor response to all appropriate target tissues remote from the CNS. The PNS
can be subdivided into sensory nerves (afferent) and motor nerves (efferent). Efferent nerves can be further
subdivided into autonomic and somatic motor divisions. Autonomic nerves control the motor responses of
soft tissue components (i.e. soft muscle, cardiac muscle, gland secretion), while somatic nerve components
are more responsible for skeletal muscle functions. In this work, we focus on the sections of the PNS that
are distal to the spinal cord where the configuration and organization of the PNS in human models are
similar and consistent with other mammalian models. All PNS distal to the spinal cord consist of neurons
bundled together and divided into specific sections known as fascicles, which are wrapped around a thin
sheet of endoneurium connective tissue composed of elastic and collagen fibers. These fascicles are then
bundled together by perineurium connective tissue composed of reticular and collagen fibers. The fascicle
regions combined with the neural blood vessels that support PNS are then held together using the outer
epineurium connective sheet that tightly compacts the components into the peripheral nerve segment
(Figure 1.2) [24].

Figure 1.2 Peripheral nerve anatomy
Source: Siemionow, Maria, and Grzegorz Brzezicki. 2009. “Chapter 8: Current Techniques and Concepts in Peripheral Nerve Repair.” International
Review of Neurobiology 87: 141–72
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Neurons are the primary cellular units of the PNS responsible for transducing chemical neurotransmitter
signals into electrical signals that can propagate across the cell body to their intended location and vice
versa. Dendrites will receive neurotransmitter signals from neighboring cells. This will cause Na+ channels
on the cell body to open, causing a graded potential to occur across the cell membrane at the region where
the cell body integrates with the axon known as the axon hillock. If the summation of potential difference
is great enough to succumb the potential threshold, the Na+ channels on the axon membrane will depolarize
to allow in-flow of Na+ ions into the axon. Afterwards, the axon membrane will depolarize by out-flow of
K+ ions. This ion channel exchange will insure propagation of the membrane potential difference across the
axon membrane until it reaches the synapse site at the opposite end of the axon. Membrane potential will
then excrete the appropriate neurotransmitter that will bind to the post-synapse of the adjoining neuron thus
continuing neuron communication thru both chemical and electrical synapses thru the physiological system
until the signal reaches its intended target synapse.
The other primary cellular component of the PNS are the Schwann cells, whose primary role is to unsheathe
the neurons and provide neurotrophic factors essential for neuron survival and regeneration. Most Schwann
cells will layer themselves across the neural axon segments as a myelin sheath, ensuring that ionic potentials
are guided and have fast conductance across the axons. non-myelinated Schwann cells are primarily used
for production of neurotrophic factors necessary to maintain normal PNS functions, and repair of damaged
nerves. The last cellular component are the stromal connective tissues that isolates the axons from the ECM
and mechanically support the length of the axons. This is divided into three subsections of connective
tissues as previously discussed (endoneurium, perineurium, and epineurium). During PNS repair, other
connective tissues like fibrinogen and laminin will support Schwann cells during the reinnervation of the
damaged nerve section (Bands of Bungner).

1.2.1 Peripheral Neuropathies
Peripheral neuropathy (PN) is a condition of the peripheral nervous system that currently affects over 20
million US citizens, with a prevalence of 3% in all trauma patients showing some form of PN. Most forms
of PN can be attributed to mechanical, thermal, or infection damage. PN will often present itself with either
swelling that blocks the neural conduction (neuropraxia), disruption of the axon or myelin sheath due to
stretching or crushing stressor (axonotmesis), or tearing or complete separation of the nerve section
(neurotmesis). The Sunderland Nerve Injury Classification Scheme (SNICS) is the most commonly used
method for clinical evaluation of the severity of peripheral nerve injuries after physical traumas is induced.
neurotmesis is the most severe type of peripheral injury where the nerve segment is completely transected
cutting off the action potential to all sensory and motor functions. Often classified as a type 4 or 5 on the
Sunderland nerve injury classification scheme (Table 1.6) [26–28].
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Table 1.6 Nerve Injury Classification

Sunderland

Seddon

Features

Type 1

Neuropraxia

Damage to the local myelin only

Type 2

Axonotmesis

Division of intraneural axons only

Type 3

Axonotmesis

Division of axons and endoneurium

Type 4

Axonotmesis

Division of axons endo and perineurium

Type 5

Neurotmesis

Complete division of all elements including epineurium

Type 6

Mixed

Combination of types 2-4

Source: Grinsell D, Keating CP. Peripheral nerve reconstruction after injury: a review of clinical and experimental therapies. Biomed Res Int.
2014;2014: 698256

Patients with neurotmesis will often experience symptoms of both acute and chronic motor and abnormal
sensory sensations that overall diminish the quality of life for people [29]. Almost all neurotmesis injuries
require surgical intervention to insure the nerve heals properly to regain its functionality. Severe
neurotmesis involves significant gaps (>2 to 3 cm) that require surgical placement of neural grafts to serve
guidance of axons as they grow across the gap [30].
Currently, the gold standard for repair of severe neurotmesis is the use of nerve segments taken from the
patients (autografts) [25, 31]. However, this method is limited in the degree of healing possible at the
damage site [32]. Surgical protocols require precise matching and orientation of the graft at the two ends
of the gap which is difficult and requires skilled microsurgery. The suturing of the graft can rupture or
pierce the perineurium around the fascicles, causing scar tissue to form which can cause further problems
at the site as iatrogenic peripheral neuropathy. The outcome of this strategy usually involves the following
implications: donor-site morbidity, sensory loss, scarring at the donor site, neuroma formation, pain, and in
the case of allografts long periods of host immunosuppression [27, 33]. The low quality of recovery for
neurotmesis cases results in patients affected by chronic peripheral neuropathy symptoms. This contributes
to an overall decrease in the wellbeing of the population and an increase in the health care costs utilized for
repair and management of these symptoms. Currently, healthcare costs associated with PN injuries is
estimated at around $150 billion annually. This presents a stressing need to research new alternative
strategies to autografts for nerve repair that addresses these limitations while minimizing the onset of new
ones.
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1.2.2 Endogenous Nerve Repair
If the nerve segment sustains 20-30% of axon damage then collateral branching will most likely be the
primary mechanism of recovery, however if over 90 % of the axons are damaged then axonal regeneration
will be the most likely mechanism of repair [25]. The Wallerian degeneration process begins approximately
24-48 hours post time of injury and will last for a week depending on how severe the injury is. During this
time, Schwann cells will begin to express pro-inflammatory and neurotrophic factors that will increase
macrophage intrusion to the site and stimulate surrounding Schwann cells to further activate appropriate
neurotrophic growth factors or to differentiate prolific Schwann cells to remove cellular debris and break
down the nerve segment at both proximal and distal ends until the closest stable neuron body is reached in
a process known as Wallerian- degeneration [34]. The result is a proximal and distal nerve stump created
by granulation of Schwann cells that concludes the Wallerian degeneration step. The next step is axonal
regeneration which first breaks down the nerve stumps thru a form of apoptosis which sees a large uptake
in Ca+2. At the same time, non-myelinating Schwann cells will migrate and orient themselves on laminin
and fibronectin chains with the endoneurial tubes at the distal end to create a tubular banded structure known
as the bands of Bungner. These non-myelinating Schwann cells continue to promote axon regeneration by
secreting neurotrophic factors that will promote growth cone formation, filapodia probing, and stimulate
pro-myelinating Schwann cells to orient themselves into myelin sheaths. This will continue until the
regenerating axon growth cone reaches and assembles with the distal nerve section for complete
reinnervation to take place. (Figure 1.3) [35].

Figure 1.3 Endogenous peripheral nerve regenerative process
Source: Dale Purves, G. J.-S. (2008). Neuroscience. Sunderland MA: Sinauer Associates Inc.
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The chance for successful reinnervation to take place with this form of nerve healing is depended on the
severity of the injury itself. We can determine this by assessing if the endoneurial tubes are intact, the length
of the defect, and the presence of lesion or scar tissue. In the case of neurotmesis injuries with critical size
defects the chances of successful reinnervation are practically impossible without surgical intervention. The
difficulty is being able to maintain a stable Band of Bunger structure which becomes much less stable as
the defect size increases. This makes it difficult to guide axonal growth and often it will lead to loss of
nerve functionality due to scar tissue formation and misalignment of axon bundles to the appropriate distal
axon bundles. Another issue to consider is the amount of time it will take for full reinnervation to be
complete for end organ functions to return. While some sensory neuron end-plates can last for many years
before succumbing to atrophy, motor neuron end-plates begin to undergo atrophy in 3 weeks post injury
and can last for up to a year before irreversible damage to the endplate incurs leading to complete loss of
muscle function. The need to create stable neural scaffolds for prolonged stability and axon guidance is
therefore apparent in order answer these limitations that are apparent in endogenous repair of critical neural
defects.

1.3 Graphene
Graphene in its pristine form (PG) is a continuous SP2 Hybridized carbon film one atom thick, with carbon
atoms organized in a hexagonal lattice configuration that resembles a honeycomb structure. The carbon
atoms lateral to each other are held together by both single and double covalent bonds, while all atomic
bonds perpendicular to the film are weak Van Der Waals forces. The configuration of the carbon atoms
gives the material a unique conductance, mechanical, and bonding profile when combined with organicbased compounds that rivals other competing materials. The usage of Graphene Family Nanomaterials
GFN’s has been used primarily as an additional component to improve the mechanical, thermal, and
electrical conductance of medical devices used in research. However, GFN’s have been discussed to have
potential in cell integration and differentiation of numerous cell lines much of which has not been fully
understood to date. This has naturally led to the discussions of whether GFNs might have potential as a
conduit platform to assist in the regeneration of damaged tissue In-vivo. Research to date would indicate
that GFNs can be constituted as a biomaterial that in both In-vitro and In-vivo assessments has shown to be
capable of supporting positive tissue regeneration for a variety of different tissue phenotypes while retaining
acceptable biocompatibility traits over extended periods of time. This section discusses the current findings
for carbon–based materials as a potential biomaterial option and its potential as a component in the design
of neural scaffolds.

23

1.3.1 Graphene Biocompatibility
Carbon based materials have been investigated as a component for implanted medical therapies for more
than half a century, and in this time have resulted in our further understanding of the properties of carbon
and how they interact with carbon atoms and organic compounds resulting in the prodigious development
of different carbon-based biomaterials to date. In-vitro studies on GFN coated substrates have consistently
shown evidence to support that GFNs can act as a bioactive surface coating that can support the adhesion
and maturity of a variety of cell-lines, including pluripotent cell-lines. In this section we will focus on the
primary evidence to support GFN biocompatibility involving its potential for stable adhesion of cell lines,
and its niche properties for controlled differentiation of pluripotent cells.
1.3.1.1 Adhesion
Adhesion of cells to a biomaterial surface is a critical event needed for successful application of biomaterial
therapies. Successful adhesion of cells to any biomaterial surface can be characterized as the integration of
a cell to the extracellular matrix, bioactive surface, or neighboring cells present on the material surface.
This is essential for cells to stimulate a positive regenerative environment by regulating correct cell
communication, mobility, differentiation and stability. Previous In-vitro studies have assessed the surface
characteristic of different GFN’s and have found that they are capable of absorbing cells lines of both
immortal and multipotent cell lines in the form of electrostatic attraction, integrin binding, and focal
adhesion binding pathways. The degree of adhesion varies based on the surface characteristics of GFN such
as particle size, topographic features, geometric configuration, surface potential, and molecular bonding
sites of the GFN surface. GFN surfaces can be modified for specific protein and cell adhesion profiles in a
number of ways depending on the intended function of the device. Such alterations create additional protein
anchors and changes to the biomaterial zeta potential that are most ideal for cell adhesion and ECM proteins
absorption. In-vitro cell adhesion studies involving graphene oxide (GO) coated films have shown the
potential for absorption of adhesion-specific proteins on the surface of biomaterials when placed in plasma
and serum conditions. One study reported In-vitro to yield 25% protein absorption from a specified volume
of serum on GO surface coated films compared to 8% absorption on Pristine Graphene coated surface films
of similar surface area. The majority of these studies have found that exposing GFN’s of different iterations
to different protein solutions will create different protein absorption profiles allowing for the design of
specific biomaterial protein coronas that can potentially improve the adhesion, communication, and
mobility behavior specific cell lineages.
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Studies have also found that GFN’s has the potential to minimize the adhesion of specific cells that could
potentially impact the speed and quality of tissue regenerated. As noted in the previous paragraph, nonadhesion of specific cell lines can also be tailored by altering the surface properties of GFN materials. Thru
surface modifications, GFN surfaces can minimize the adhesion of microbials, granulation and fibrous
tissue, platelets, and lymphocytes specific to foreign body reactions. Studies have found that modifying the
surface of GFN’s have improved antibacterial resistance by modifying the surface with antibacterial
nanoparticles or altering the lateral dimensions and surface area of carbon-films. Common nanoparticle
modifications to Graphene surfaces include Silver (Ag) Gold (Au) Titanium oxide (TiO) and zinc oxide
(ZnO), while Graphene films of higher surface areas have less toxicity towards microbials compared to
films with lower surface area[36–38]. Chemical modifications such as PEGylation or oxidation have been
shown to decrease the proliferation of macrophages and lymphocytes, giving GFN’s the ability to minimize
foreign body reactions.
1.3.1.2 Differentiation
Both In-vitro and In-vivo studies have consistently shown that GFN’s have the ability to not only support
multipotent cell lines conducive to improved tissue healing but also induce these cell lines towards specific
differentiation phenotypes simply by integrating with the material surface or internalization of the material
into the cell. Interest has been focused primarily on the ability of GFN’s to differentiate cells with
multipotency potential (progenitor cells). While the specific pathways and cellular processes involved with
differentiation of stem cell integration with GFN are still misunderstood, the most current research into
GFN have been able to narrow down certain stem cell niches most likely responsible for differentiation
towards specific lineages, giving researches an idea of what pathways and cellular processes to further
investigate.
GFN surface properties have been found to be a key component in guiding differentiation of specific
phenotypes in stem cells. This involves not only the interaction of stem cells with the biochemical properties
of the material (cell-cell, ECM mesh, surface proteins) but also the physical features such as surface
stiffness, topography, surface patterning, and orientation[39,40]. It has been established in previous In-vitro
studies that biomaterials with surfaces of higher modulus (greater stiffness) have a higher capacity for
osteogenesis in cells of mesoderm origin while surfaces of lower modulus have a higher capacity for
neurogenesis in cells of ectoderm origin. This is most likely regulated by specific integrin and focal
adhesion kinase (FAK) mechanotransduction pathways designed to differentiate between mechanical
stresses brought on by cell interaction with the surface. The addition of GFN as a surface coating will often
modify the surface to be stiffer which has resulted in a higher density of mesoderm origin cells to
differentiate toward osteogenesis by simply being in contact with the GFN surface. Studies have also found
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that specific surface patterns can not only initiate cytoskeletal remodeling but are also important in guiding
differentiation of cells towards specific lineages through specific mechanotransduction pathways
(anisotropy)[39]. Studies have shown how PG coatings patterned in parallel line patterns can initiate
osteogenesis in hMSCs, while surfaces coated with GO in a grid pattern array are able to stimulate a higher
yield of hMSCs to differentiate towards neural-like lineages than without said pattern. This is further
supported by studies that have shown ectoderm origin cell lines to differentiate towards neural lineages
when adhered to GFN surfaces.
Chemical stimulation by GFNs to guide specific differentiation in multipotent cell-lines has been
investigated with clear indications that different GFNs exposed to different multipotent cell-lines will result
in different neural phenotype outcomes. Many of these studies have found that when neural stem cells
(NSC) are exposed to simple GO or rGO films that they will naturally differentiate towards glial derived
tissue, while PG and carbon nanotubes (CNT) do not elicit any neural potential at all. However, when GO
or rGO films are exposed to embryonic stem cells (ESC) they differentiate towards neuron derived tissue
instead. There is a clear need to further study these interactions as we do not yet fully understand the exact
stimulant or pathways responsible for neural differentiation in these multipotent cell-lines. It is also not
clear as to how other factors involved in peripheral nerve repair will impact the differentiation of
multipotent cell-lines In-vivo (Co-seeding multipotent cell-lines with Schwann cells and macrophages,
presence of proinflammatory and growth factor compounds, etc.).
While guidance of neural differentiation can be controlled to some degree by adding GFN’s it is still
difficult to determine what pathways are being regulated by the material and whether or not complete
differentiation has occurred, and if so, identifying what phenotype the cell has differentiated towards. In
most cases, the material will only achieve partial differentiation in the cells, resulting in only a few of the
traits required to ID a particular neural phenotype to express. These cells are often labeled as neural-like
cells instead and thus we cannot expect them to provide the same form of repair expected of true neural
cells. The best indications for the type of chemical stimulus that GFN’s will induce in multipotent cells is
from the results indicated in toxicity studies. Toxicity studies have consistently found that GFN’s can
support multipotent cell-line growth and mobility that is essential for neuron and glial transport and
spreading. It is also known that certain GFNs will induce oxidative stress due to interference of normal
metabolic activities that will then activate inflammatory and apoptotic pathways. These pathways have been
found to also be present during endogenous repair of peripheral nerves, particularly when digesting,
guiding, and differentiating Schwann cells during the early phases of repair [41]. If GFN’s can stress cells
to a threshold that will releases pro-inflammatory and apoptotic signals into the ECM, then it could
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potentially further stimulate neuron and Schwann cells towards regenerative behaviors or guide multipotent
cells towards a specific neural-like phenotypes.
The biocompatibility of GFNs towards different cell lines and the potential to co-functionalize with other
therapeutic techniques has created interest in incorporating it as a structural component or surface coating
in 3D neural conduit designs. The toxicity of Graphene in physiological systems is still under investigation
due to the current literature that supports the presence of cytotoxic behaviors and varying bio distributions
of different graphene iterations in specific biological environments. It is also clear that there is still
insufficient data to make conclusions on the cellular mechanisms related to cytotoxicity when graphene
interacts with native cells. Current toxicity studies have identified specific properties of graphene-based
materials that are most responsible for influencing toxicity in both In-vitro and In-vivo systems.
1.3.1.3 Concentration
Numerous studies have shown that GFN have a dosage-dependent toxicity effect. The concentration of
GFN attached to the cell membrane and/or taken up by the cell through endocytosis is correlated to
increased cellular stress causing activation of specific Apoptosis/Necrosis, and inflammatory cellular
pathways. Similar studies have also looked at different aspects of cell stress with respect to GFN
concentrations, such as metabolic stressors, genotoxicity, and cell membrane disruption. In-vitro studies
that looked at varied concentrations of different GFN iterations have found that cell viability will decrease
as concentrations of GFN increase. The concentration of GFN particles needed to observe cell death varies
based on the format and size of GFN particles, functionalization/chemical preparation, and the cell
phenotype tested. Another degree of variability to consider is that certain cell stressors will be more
profound based on the GNF type and concentration tested. Studies have shown how Reduced-Graphene
Oxide (rGO) iterations of the same size and format showed no significant production of metabolic stressor
metabolites in human umbilical vein endothelial cells (HUVEC) at 10µg/ml concentration but did show
significant cell membrane disruption at the same concentration [42]. However, current studies indicate that
regardless of the graphene tested there appears to be a Graphene iteration concentration threshold for every
cell line that is detrimental to the cell’s health.
In-vivo studies are difficult in assessing the dosage-dependency toxicity of GFN at injury sites due to the
absorption rate of GFN’s and the conduit platforms they are bound to, and the difficulty of tracking GFN
in real-time. This however, is suitable for assessing the migration and stimulation of GFN towards acute
and chronic toxicity over specific tissues/organs for extended periods of time. In-vivo studies have looked
at GFN concentrations present in large tissue/organs and excretions over extended periods of time. One
study found that mice subjects injected with GO solutions at concentration of 0.4mg had large quantities of
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graphene compounds located at the lungs, liver, and kidneys at 30 days [43]. The PI’s observed lung
granuloma formations and intense inflammation in the kidneys indicating difficulty in cleansing the system
of graphene residuals, thus leading to chronic toxicity resulting in almost 50% of subjects to die. All lower
GO concentrations tested showed no clinical toxic symptoms with no mortalities in any of the mice subjects
over a 30-day period. The study did not indicate any blood toxicity or the ability of graphene to bypass the
blood-brain barrier after tail vein injection in any of the graphene concentrations during the duration of the
study. This most likely could be attributed to the size of the graphene films, which could not pass the bloodbrain barrier or the nuclear membrane of most cells. This would indicate that the lateral dimension of these
films is between 100 – 40 nm which is sufficient to passively bypass the cellular membrane.
The conclusion is that there is still no consensus on the GFN dosage required to elicit toxic effects in Invitro or In-vivo. When we factor in size, conformity, and functionalization we create different GFN
iterations that elicit their own degree of toxicity as the dosage increases. The lack of a standard operating
procedure for preparing, storing, and validating different GFN iteration concentrations makes supporting
or contradicting studies of similar aims more difficult as the current literature shows. These problems are
mirrored when dosages used in In-vitro studies are translated to estimated dosages for In-vivo models. Most
researchers agree that as the concentration of GFNs increases (regardless of the iteration) a threshold for
toxicity is reached that will result in declining cell viability In-vitro and chronic inflammation and scar
tissue formation apparent in lungs, liver, and kidneys In-vivo. Studies focused on assessing
immunomodulation, genotoxicity, and blood compatibility have also noted this dosage trend which makes
standardizing studies that use carbon-based materials a primary concern for finding safe dosages.
1.3.1.4 Size/Morphology
Graphene can conform to a multitude of different formats and sizes, many of which have been studied in
physiological systems. There is consensus that the size and type of graphene has a profound effect on the
toxicity of GFN. The dimensions of GFN have been found to be most important in facilitating whether
films of a certain size can be internalized into the cell, while the morphology of GFN is found to be more
responsible in the amount of stress that is induced inside the cells [44]. Studies have found that graphene
films of large lateral dimensions and surface area show a greater degree of plasma-membrane adhesion due
to a greater concentration of bonding sites for electrostatic and ECM protein bonding. Such large
dimensional films are capable of bypassing the plasma membrane by disrupting the membrane integrity by
puncturing through at the asperities sites on GFN films. Such disruption of the plasma membrane could
potentially disrupt membrane and cytoskeleton associated proteins for maintaining membrane integrity,
such as Actg2, Myosin, Tubb2a, and Nebulin. Studies have shown that GFNs deposited on the cell
membrane are able to activate membrane receptors that initiate potential cytotoxic-pathways, such as toll28

like receptors (TLR) and transforming growth factor beta (TGFβ) surface receptors for pro-inflammatory
and apoptotic induction.
Graphene samples of smaller lateral dimensions can be taken up much more easily into the cell by diffusion,
and passive, or active mechanisms (endocytosis, ionic channel pumps, pinocytosis, and phagocytosis). As
the lateral dimension of graphene films decreases, we begin to see increased uptake into the cell’s cytoplasm
where subsequent pathways for production of metabolic stressors, and inflammatory cytokines become
more active. Even smaller graphene particle sizes have the potential to bypass the nuclear membrane,
resulting in genotoxicity. GFN films with sizes between 100 – 40 nm lateral dimensions are capable of
passively bypassing the cellular membrane, while GFN films of 40-35 nm lateral dimensions can passively
bypass the nuclear membrane. All other GFN films smaller than 35 nm are capable of bypassing the blood
brain barrier. This behavior in cells can relate to how certain sizes of graphene are more prone to elicit
certain cellular responses that are indicative of cytotoxicity.
1.3.1.5 Surface Charge/Physiochemistry
PG and its different forms have a hydrophobic surface due to the covalent bonding of carbon atoms that
present few areas on the surface for hydrogen atoms and other polar based molecules to interact with
graphene. When organic compounds covalently or electrostatically bind to a material’s surface that adds or
changes the surface properties, we refer this chemical modification as functionalization. GFN’s can have
their surfaces modified in this way to create hydrophilic surfaces more capable of cell adhesion and
interacting with physiological molecules. The most common examples of this are PG films functionalized
with oxygen-based groups like hydroxyl (OH-), carboxylic (COOH-), and carbonyl (CO) groups to create
modified GFN’s like GO and rGO. These groups are usually created thru Hummer’s method that can
exfoliate the ends of the graphene films using powerful acids like sulfuric or nitric acid to bind to an
oxidizing reagent such as potassium permanganate. The presence of these oxidative groups changes the
charge density and zeta potential of the graphene surface making it negatively charged and more susceptible
to reactions with other polar molecules and making the surface more hydrophilic. This creates a platform
well suited for cell-adhesion molecules (CAM) to adsorb to the surface. Graphene films highly saturated
with (CAMs) have a greater success of establishing integrin binding on the surface of cells for controlled
adhesion and migration. These functional groups can also act as anchor points for attaching polar proteins,
lipids, antibodies and drug components as a drug delivery platform for targeted or systemic control over
physiological systems to improve tissue regeneration outcomes. However, preparation of certain functional
groups could also potentially modify the toxicity of GFNs to make them more toxic to cell lines from both
an In-vivo and In-vitro perspective. Great care should be taken to ensure that these types of modifications
do not alter normal cell physiology or elicit toxic responses. Such examples include GO which has been
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observed to increase oxidative stress due to its high concentration of bound oxygen species, or the toxicity
attributed to impurities created during surface modifications.
In-vitro studies used to evaluate cytotoxicity of GFNs in immortalized cell lines have found that PG films
are more likely to localize on cell membranes rather than internalize into the cell due to the strong
electrostatic attraction of the hydrophobic graphene surface to the negatively charged phospholipid cell
membrane. It is here that films of large lateral dimensions could interfere with normal cell functions by
overlapping cell surface binding sites, which can initiate toxicity pathways by preventing cell nutrients and
waste processes, increase intracellular reactive oxygen species (ROS) concentrations, or immobilizing the
cell. GFNs can also activate pro-inflammatory receptors such as Tumor Necrosis Factor (TNF), Toll-Like
Receptors (TLR), and Transformation Growth Factor-Beta (TGF-β). These receptors will follow proinflammatory and apoptotic pathways such as nuclear factor kappa B (NF KB), extracellular signal–
regulated kinases (ERK), mitogen-activated protein kinase (MAPK), and Caspase-3. These pathways will
often secrete pro-inflammatory cytokines such as Interlukin-1,6,12 (IL-1,6,12), Tumor Necrosis Factoralpha (TNF-α), monocyte chemoattractant protein 1 (MCP-1), and Interferon gamma (IFN-g) that will
further cell death. PG films of smaller dimension and size are more capable of internalizing into the cell
cytoplasm thru endocytosis and phagocytosis (Figure 1.4: A, B)[45].
In-vitro studies have consistently reported that high concentrations of GFNs internalized into the cell bodies
will increase ROS radicals as a result of GFNs interacting with cellular mitochondrial processes. This
increase in intracellular ROS levels will often activate apoptotic and pro-inflammatory pathways in the
form of oxidative stress that will eventually lead to cell death if the stress is prolonged. The tricarboxylic
acid (TCA) or “Krebs cycle” is a component of aerobic metabolic processing in mitochondria necessary to
store chemical energy in the form of ATP from reduced proteins, fat, lipid, and carbohydrates in all
eukaryote cells. It has been suggested that GFNs could act as an electron donor that could add electrons to
redox enzymes at specific points during the Krebs cycle. This form of interference is more likely to occur
with redox co-enzymes such as nicotinamide adenine dinucleotide (NAD) that can accept electrons from
hydrophilic (GFN) surfaces. A byproduct of redox reactions is ROS which are the primary source for
intracellular oxidative stress and at critical concentrations will activate pro-inflammatory, apoptotic,
necrotic, and autophagy pathways. Other studies have looked at indirect forms of detecting increases in
ROS such as detecting dynamic changes in lactate dehydrogenase (LDH) enzyme secretions as a direct
correlation with changes in ROS levels.
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These studies have also reported that the degree of metabolic stressors released internally is dose, size, and
conformation dependent. Surface area, degree of functional group saturation, and the orientation of
functional groups on GFN surfaces will also affect the amount of internal metabolic stressors produced
(Figure 1.4) [45]. In the case of GO or rGO, In-vitro reports indicate a greater degree of metabolic
disruption compared to pristine graphene iterations due to the presence of oxidative radicals on the materials
surface. These radicals and the impact that it has on normal mitochondrial processing can increase the
number of ROS in the cytoplasm which presents a greater severity of toxicity due to ROS reactions with
cellular components such as protein synthesis, tubulin structure, and mitochondria/nuclear membrane
integrity. These changes not only disrupt cell function but also induce genotoxicity or epigenetic damage.

A.

B.

C.

Figure 1.4 Intracellular toxicity pathways induced by GFNs
Note: (A) TLR4,9 pathway activation by GFN’s resulting in upregulation pro-inflammatory factors. (B) MAPKs, TGF-beta and TNF-α dependent
pathways involved in activation of apoptotic factors caspase3 and necrosis caused by GFN’s. (C) Passive transport of GFNs across cell membrane
with subsequent ROS, LDH, and MDA generation.
Source: Ou L, Song B, Liang H, Liu J, Feng X, Deng B, et al. Toxicity of graphene-family nanoparticles: a general review of the origins and
mechanisms. Part Fibre Toxicol. 2016;13: 57.
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1.3.2 Graphene Neural Conduit Designs
Based on the current consensus on GFN biocompatibility/toxicity and the pursuit to design neural conduits
that can address the current debilitation brought about by severe cases of peripheral neuropathies, GFNs
have been introduced as a material component that could potentially improve current neural scaffold
functionality [46]. GFNs have been used in the design of neural scaffolds primarily to improve upon the
mechanical integrity, neural conduction dynamics, and thermal stability of polymer based neural scaffolds.
However, over the last decade there has been a growing interest to understand how this material can
integrate with the ECM and cells used in neural regenerative applications and whether as a biomaterial by
itself can stimulate endogenous neural repair. This has furthered our understanding of GFN as an attractive
candidate as the primary component in neural scaffolds devices resulting in a variety of GFN neural
scaffolds designs. The inclusion of GFNs into previous neural scaffold designs have shown improvement
in nerve conduit and wrap performance by enhancing the devices in regards to the specific design criterions
previously discussed (Sec 1.1.3.1).
One of the most studied and often utilized GFN iteration used for improving the performance of nerve
conduit and wrap designs is GO or rGO substrates (graphenes oxidized with oxidative groups). As
previously discussed, GO and rGO coated surfaces can not only support neuronal and multipotent cell-lines
but can direct multipotent cells towards specific neuronal lineages, where as other GFN iterations are not
as effective or have no effect in directing neurogenesis. It is for this reason that these GFN’s are often used
to modify the surfaces of these types of constructs, specifically those surfaces in direct contact to the nerve
under repair [47]. Apart from the proven benefit of being able to support neural and stem cell therapies,
these modifications will alter the physical and chemical properties of the construct surface in a variety of
expected ways that are further advantageous to nerve repair. This includes surface stiffness increase,
neurogenic anisotropic properties, slightly higher hydrophilic surface charge, electrical conductance
potential, and further tailored functionality for absorption of neurogenic positive compounds. This makes
GO, and rGO excellent contenders as surface coatings for enhanced nerve conduit and wrap performance.
Despite these neurogenic positive properties of GFN, a nerve conduit capable of meeting or surpassing the
degree of repair achieved by autologous scaffolds has not yet been achieved. Implications involving the
potential toxicity of GFN’s and the misinformation regarding what pathways are activated or negated when
multipotent and neuronal cells are exposed to GFN’s In-vivo has created uncertainty as to the materials
ability to meet the clinical standards for successful nerve repair and whether it will produce adverse effects
in a clinical setting. This is why to date, there is currently no clinical peripheral nerve conduit or wrap
device with GFNs that has been successfully brought to market.
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1.4 Stem Cell Therapy
Stem cells are a family of cells that are specifically characterized as undifferentiated cell lines capable of
self-renewal over long periods of time until exposed to specific environmental conditions that will induce
the cells towards specialized cell lineages. A common hierarchy of stem cells, starting with the most potent
stem cell form is to start with totipotent stem cells. These cells are usually present during the early stages
of embryonic development. Such examples include spores or zygotes, which are capable of differentiating
into any tissue type possible in the body. After successful fertilization, a culture of these totipotent cells is
created which will then differentiate into pluripotent cells. Differentiation potential of these cells is limited
to any three germ layers, these being endoderm, ectoderm, and mesoderm lineages. Endoderm
differentiation includes lung and gastrointestinal tissue. Ectoderm differentiation includes epidermal and
neural system tissues. Mesoderm differentiation includes muscle, bone, and blood tissues. Once pluripotent
cell begins to differentiate towards either of these three pathways, they will further differentiate towards
progenitor cells that have the potential to differentiate towards multiple discrete cell types, further
characterized as multipotent cells. An example of this concept are multipotent cells that develop from a
mesodermal origin that will differentiate towards bone, chondrocyte, or adipose tissue often referred to as
mesenchymal stem cells (MSC).
When isolated from adult tissues, multipotent cells have the potential to improve the outcome of tissue
healing when directly applied to the site of injury or when pre-differentiated towards its intended cell type
before being applied. Recent studies have directed interest towards incorporating multipotent cell lines into
the design of scaffolds to improve regeneration, tissue quality, and cell-material interaction [48]. The scope
of these types of studies has focused primarily on answering the question of which type of multipotent cell
line should be used, what form of stimulation is most effective in differentiating cells to express the intended
therapy, the time and duration of administration In-vivo, survivability, and tracking of the cells In-vivo.
Investigations using multipotent cell lines for improved neural tissue healing has shown promising results
in both In-vitro and In-vivo models, particularly when used in collaboration with nerve scaffolds that can
act as a platform for stable cell growth, cell protection, and elicit its own biomaterial cues to guide cell
differentiation. The most commonly investigated multipotent cell lines for nerve healing applications have
been embryonic stem cells (ESC), induced pluripotent stem cells (IPSC), and adult somatic stem cells
(ASSC). Although ESC and IPSC have shown potential for nerve tissue healing, there are concerns from a
clinical standpoint due to greater cellular sensitivity towards immunological processes, ethical implications
involved in using these cell lines, and the technical difficulty in isolating these cells. This makes the use of
ASSC a more attractive stem cell therapy option for healing extensive nerve damage. A number of ASSC

33

have already been investigated for their potential in nerve repair including ones of both mesoderm and
ectoderm origins. There is a greater consensus towards using ASSC of mesoderm origin due to its
prevalence in certain tissue locations and the ease of accessibility to those locations as compared to
ectoderm origin cell-lines. Although this origin cell-line best represents the tissue being regenerated at the
site of injury, they are very difficult to isolate making them non-feasible to use from a clinical standpoint.
Neural crest stem cells (NCSC) and MSC are multipotent cell lines of mesoderm origins that have received
interest in nerve repair. Their ease of accessibility, simple isolation techniques, and current results have
shown potential to express cellular structure and behaviors similar to that of ectoderm origin cell lines but
not exact in every aspect which is termed by many researchers as neuron-like cells.

1.4.1 Mesenchymal Stem Cells
MSC are a type of multipotent progenitor cell line that is capable of self-renewal and differentiating into
specific cells of a mesoderm lineage such as chondrocytes, osteoblast, and adipocytes [49–51]. A type of
non-hematopoietic adult stem cell line, MSCs are produced in both fetal and adult tissues in most mammal
species to assist in the repair and maintenance of specific tissues of mesoderm origin such as cartilage,
bone, fat, skeletal muscle, and tendon. MSCs have been isolated from a variety of fetal and adult tissues
with bone marrow, adipose tissue, and umbilical cord blood, and Warton’s jelly being the most common
source due to their high MSC content. The most common natural reservoirs used for collecting MSCs from
a clinical standpoint are cells derived from bone-marrow or adipose tissue. While both forms of these
multipotent cell lines have been used to repair nerve with mixed results to date, there are specific advantages
observed that puts preference of using one form over the other for nerve repair.
From a clinical stand point adipose tissue is more readily available, adipose tissue is easier to remove, and
it is easier to isolate MSCs from adipose tissue compared to bone-marrow tissue. This makes adipose
derived stem cells (ADSC) a more attractive multipotent cell choice compared to bone marrow derived
cells (BDSC). Furthermore, once ADSCs are isolated from adipose tissue the yield of healthy ADSC is
much greater and can survive for longer lengths In-vitro than BDSC isolated from bone-marrow tissue.
From a therapeutic stand point both cell types have immunogenic properties and have shown to expressing
neural and glial cell markers such as S100B, GFAP, P75, and Tuj-1 and are able to release neurotrophic
factors such as GDNF and BDNF. In-vitro studies have shown both cell types have a higher potential to
differentiate towards Schwann-like cells when exposed to chemical inductions geared towards neural
differentiation. In-vivo performance of these cells in peripheral nerve injuries have shown promising results
with the majority of studies reporting a significant improvement in nerve repair as opposed to neural grafts
without MSC inductions. Considering the advantages of combining MSCs to neural grafts for neve repair,
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if this should be translated to clinical assessment ADSC appears to be the more preferred choice for nerve
repair.

1.4.2 Neural-Fate Pathways
Human MSC (hMSC) have shown the potential for induction into cells that exhibit characteristics often
found in cells of the ectodermal lineages [52]. Investigations have found that, under the right chemical
induction parameters, In-vitro hMSCs can express surface markers, ectodermal protein and gene
modulation, and re-orient their cytoskeletal structures to resemble that of neuron, astrocyte, or glial cells.
Neural differentiation of hMSCs can be further modulated through mechanical niches stimulated by both
physical and topographical cues presented on the surface of surrounding tissues and biomaterials. While
these cells will resemble certain traits of neuronal cells, to date there is no protocol developed that can
differentiate mesoderm cell lines into functional neuronal cells, which is a major limitation for using
mesoderm cells for repair of peripheral nerves.
1.4.2.1 Biochemical Induction
The ability of multipotent cell lines to differentiate towards multiple cell types is in part regulated by the
activation of specific intracellular pathways at different intensities and at varying stages during their
development into specialized cells. Specific intracellular pathways are essential in regulating the neural fate
of multipotent cells. Activation of these pathways can guide multipotent cells, not designed to differentiate
towards neural lineages (MSCs, NCSCs) towards neural-like cell lineages [53].
Cyclic-adenosine-monophosphate (cAMP) a common intracellular messenger protein responsible for
regulating the activation of protein kinase A (PKA), cAMP has been found to be an essential component in
regulating the modulation of genes present in neural development such as c-fos, brain derived neurotrophic
factor (BDNF), or tyrosine hydroxylase (TH) in MSC cell lines. Use of PKA inhibitors to induce neurallike differentiation in hMSC have been shown to be ineffective in successful neural differentiation, while
the use of compounds that will upregulate PKA pathways would result in neural-like differentiation of
hMSCs. This would indicate that regulation of PKA pathways are a considerable factor involved with
directing MSCs towards neural lineages. Induction of the PKA pathway has been mitigated by either
increasing cAMP production using forskolin, or 8-bromo-cAMP, or by preventing cAMP break down by
inhibiting phosphodiesterases using dibutyryl-cAMP (db-cAMP), or 3-isobutyl-1-methylxanthine (IBMX).
This method has shown evidence of early morphology changes observed in neurons such as cytoskeleton
reorientation, and cells expressing proteins for neural markers associated with neuronal development such
as βIII-tubulin (Tuj-1), neuron-specific enolase (NSE), microtubule-associated protein-2 (MAP-2) and glial
fibrillary acidic protein (GFAP). However, a lack of other early markers expected during neuron
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development such as growth factor protein- 43 (GAP-43), and minimal presence of neurotransmitters or
voltage-dependent Na+, P+, or Ca+2 cations leads many to conclude that neurite formation is not authentic
and is a result of culture conditions rather than activation of a differentiation process.
Retinoic acid (RA) is a metabolite created through retinol dehydrogenase (RoDH) of retinol. RA will bind
specifically bind to cellular RA binding protein (CRABP) which will regulate primarily Hox gene
activation, which is thought to be an important gene sequence for modulating anterior/posterior neural
mapping during fetal development. A study compared the neural stimulation of MSC by activating cAMP
pathways to that of activating RA pathways. The results found that both cAMP and RA stimulation would
differentiate MSCs to positively express neurogenic surface markers NSE, Tuj-1, and GFAP. It is also
shown that using these two stimulants together can result in higher expression of these markers, including
expression of normal resting potentials and increases in calcium concentrations to that of native neural cells.
This form of stimulation has also shown potential to express electrophysiological changes in multipotent
cells has shown in a study involving neural stimulation of dental pulp stem cells (DPSC) that expressed
active sodium voltage-gated ion channels, which could be an essential component for differentiating
mesoderm cells towards functional neurons.

Neurotrophic growth factors (NGF) are essential in maintaining normal neural cell functionality and
survival, while under certain forms of stress can be upregulated to guide neural cell fate in neural stem cells.
This family of proteins involve NGF, BDNF, GDNF, and neurotrophins (NT- 3, 4, 5, and 6). NGF and
neurotrophins have a high affinity towards tyrosine kinase receptors A, B, C (TrkA, TrkB and TrkC), GDNF
affinity towards GDNF family receptor alpha-1(GFRα) and RET proto-oncogene (RET), and NGF and
BDNF affinity towards P75 receptors. Signal transduction will then follow one of three pathways: mitogenactivated protein kinases (MAPKs), phospholipase C (PLC), or phosphatidyl-inositol-3-kinase (PI3K).
These pathways will further phosphorylate towards PKC, protein kinase B (PKB), or ERK which will
transcript gene sequences that will regulate neuronal development, health, and synaptic functions. By
themselves, neurotrophic factors will initiate neural differentiation in neural stem cells while initiating
neural-like cell differentiation in Mesodermal cell lines to varying degrees. Combined with other neural
pathways will further enhance expression of neural traits in mesodermal cell-lines.

Wnt pathway involves proteins that are involved in regulating homeostasis in adult tissue and early stages
of tissue development during embryogenesis. This includes early neural development from neuronal stem
cells by regulating stem cell fate, proliferation, and survival as neuronal cells. Wnt proteins will first activate
Frizzled (Fzd) G-coupled proteins on stem cell surfaces which will then trigger β-catenin accumulation in
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the cytoplasm which will then regulate T-cell specific transcription factors (TCF) gene sequences specific
to the type of stem cell. This pathway is geared to differentiate stem cells based on their respective
phenotype, where mesoderm stem cells will most likely be guided toward smooth muscle and endothelial
cell fates neural stem cells will be guided towards neuron cell fates. By its self, the Wnt pathway cannot
successfully initiate differentiation of MSC towards neuronal fates. However, when combined with other
stimulation pathways previously discussed will express other neuron markers such as Ngn1, NeuroD, and
Brn3a when used in combination with forskolin and IBMX (PKA pathways) (Figure 1.5).

Figure 1.5 Current identified pathways for induction of MSC towards neural-like cells
Source: Neirinckx, Virginie, Cecile Coste, Bernard Rogister, and Sabine Wislet-. 2013. “Neural Fate of Mesenchymal Stem Cells and Neural Crest
Stem Cells: Which Ways to Get Neurons for Cell Therapy Purpose?” In Trends in Cell Signaling Pathways in Neuronal Fate Decision, edited by
Sabine Wislet-Gendebien. InTech
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1.5 Summary
The topics discussed in this chapter provide the frame work for understanding peripheral neuropathies and
the methods for repairing critical size nerve defects and their limitations. It is also discussed the approaches
of using both biomaterial and stem cell therapies together as a potential novel alternative method for repair
of critical size nerve defects. Biomaterial conduits or wraps arranged as an open tube structure are the most
commonly studied alternative repair option for severe neurotmesis. It is clear that the addition of stem cell
therapies can improve the quality of neural tissue growth along the scaffold channel by introducing
immunomodulatory effects and promoting axonal growth and minimizing muscle atrophy by expressing
neurotrophic growth factors at the site of injury. While GFNs are currently under investigation for their
toxicity in physiological models, In-vitro and In-vivo studies have shown that GO films not only serve as a
suitable platform for delivering MSC therapies but also has neurogenic potential as a possible surface
coating additive to neural conduit and wrap designs for nerve healing applications.
From this chapter it is clear that many approaches to designing different neural wraps using synthetic
polymers and GO coating modifications are possible, with many iterations still unexplored. It is the goal of
this study to design a 3D neural wrap composed of PCL synthetic biomaterial and surface coat with GO as
a platform suitable to grow hADSC cultures. The function of this design is focused towards bridging critical
size nerve defects to assist in axon guidance and stimulate nerve healing. It is also designed as a deliver
platform to transport hADSC cultures to the injury site for further assist by providing immunomodulation
and release of neurotrophic factors. By manufacturing this material and testing its cytocompatability
towards supporting hADSC cultures In-vitro and tests its ability to assist in neural healing In-vivo, this
should provide data that will determine this designs potential in providing assistance in nerve healing
applications.
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Chapter 2: PCL Electrospin Film with GO Surface Modification as
a Platform for hMSC
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Abstract
Critical size neural defects have a devastating impact on people’s wellbeing and has a substantial
component in the overall health care cost of both acute and chronic pain patients. The current gold standard
for repair of critical nerve defects has limitations that require alternative solutions to address these. This
has expressed much interest in the development of new biomaterials that can provide support and protect
new axonal growth as a component of a stable film or mesh known as a neural wrap device. It is suggested
that a new neural wrap design composed of electrospun PCL with the addition of surface coating of GO
and potential to support hADSC cultures to deliver stem cell therapies could have the potential for assisting
the repair of critical nerve defects In-vivo. In this study, the ability to manufacture this type of material and
its biocompatibility towards MSC lines and ability to support hADSC cultures under neural stimulation is
determined. Thru our collaboration with the University of Arkansas Little Rock, we were able to
manufacture graphene coatings of different oxygen content for biocompatibility assessment and create
different PCL films to assess how hADSC cultures behave on its surface under normal and neural induction
conditions. The results of the proliferation and viability assay of rat ADSC cultures on graphene coatings
showed GO coating had the largest proliferation and viability levels compared to all other graphene
iterations tested. We applied GO coating to the smooth surface and fibrous surface PCL platforms and
assessed the prescence and neural expression of S100β on hADSCs at day 1 incubation and the presences
and morphology of hADSC cultures at day 6 incubation using vimentin staining. Results showed that PCL
fiber mesh surfaces modified with GO could support hADSC cultures under normal and neural induction
In-vitro environments. Slightly more impressive cell morphology and organization was detected on PCL
platforms of nanofiber topographies, suggesting that PCL fiber meshes with GO surface modifications is
the preferred material composition to use moving forward to test the materials potential in a critical nerve
defect model.
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2.1 Neural Wrap Manufacturing
2.1.1 Introduction
Peripheral neuropathy (PN) is a condition of the peripheral nerve system that currently affects over 20
million US citizens, with a prevalence of 3% in all trauma patients showing some form of peripheral
neuropathy. Neurotmesis is the most severe type of peripheral injury where the nerve segment is completely
transected cutting of the action potential to all sensory and motor functions. Often classified as a grade 4 or
5 on the Sunderland nerve injury classification scheme [1–3]. Patients with neurotmesis will often
experience symptoms of both acute and chronic motor weakness and abnormal sensory function that overall
diminish the quality of life for patients [4]. Almost all neurotmesis injuries require surgical intervention to
ensure the nerve heals properly to regain most of its functionality. Severe neurotmesis involves significant
gaps (>2-3 cm) that require surgical placement of neural grafts to insure proper guidance of axons as they
grow across the gap [5]. Currently, the gold standard for repair of severe neurotmesis is the use of autograft
nerve segments taken from the patient [6,7]. However, this method is limited in the degree of healing
possible at the damage site [8]. Surgical protocols require precise matching and orientation of the graft at
the two ends of the gap which is very difficult given the nature of microsurgery. The suturing of the graft
can rupture or pierce the perineurium around the fascicles, causing scar tissue to form which can cause
further problems at the site as iatrogenic peripheral neuropathy. The outcome of this strategy usually
involves the following implications: donor-site morbidity, sensory loss, scarring at the donor site, neuroma
formation, pain, and in the case of allografts long periods of host immunosuppression [9,10]. The low
quality of recovery for neurotmesis cases results in a surplus of patients affected by chronic peripheral
neuropathy symptoms, contributing to an overall decrease in the wellbeing of the population and an increase
in the health care costs utilized for repair and management of these symptoms which are currently estimated
at around $150 billion annually. This presents a pressing need to research new alternative strategies to
autografts for nerve repair that addresses these limitations while minimizing the onset of new ones.
Tissue regeneration is currently a topic extensively studied within the field of both human and animal
medicine that has potential for improving the rate and quality of healing damaged tissue. One important
field of study in this topic is the use of scaffolds composed of biomaterials designed to support and promote
activation of cell lines committed towards assisting in the healing of damaged tissue. Studies have shown
that mesenchymal stem cells (MSC) can improve the healing of damaged tissue by differentiating into
multiple cell lineages that can promote the healing of damaged tissues. Studies have also shown that
graphene oxide (GO) as a thin film material has low cytotoxicity, excellent cell absorption properties, and
can support cultures of adipose derived stem cells (ADSC) over extended periods of time. For the
application of nerve regeneration therapy, it would be advantageous to combine these two approaches into
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a scaffold design that can support neural differentiated ADSC cultures while enhancing nerve regeneration
at the site of healing. One important aspect of this design is selecting an appropriate biomaterial as a
platform that can support GO films and ADSC viability over an extended period of time. Biocompatible
synthetic polymers such as polycaprolactone (PCL) have been shown to be acceptable materials for
supporting both thin films and ADSC for extended periods of time In-vivo. To our knowledge, the design
of a PCL wrap has not yet been explored as a suitable platform to support GO thin film in combination with
hADSC cultures to assist in peripheral nerve repair.

2.1.2 3D Fabrication of Neural Wrap
Previous studies have looked at the inclusion of PCL as a synthetic platform for assisting peripheral nerve
healing with studies finding that PCL remains mechanically stable during the period of repair in small
animal models and as a polymer with high solubility to organic compounds it can be utilized in a variety of
manufacturing techniques to tailor fit a design that meets the design criteria of a successful neural wrap. It
also is classified by the FDA as a biodegradable polymer of up to 2 years before hydrolytic degradation
renders the design mute with the only residuals having little to no toxic effects to the physiological
surroundings. Previous studies have also found that biomaterials with certain micro or nano- surface
topographical feature are better suited to assisting in peripheral nerve stability and guidance during repair.
Surfaces of high surface area that conform to groves or channels have been found to enhance neural cell
migration and differentiation under the right conditions compared to smooth surface platforms. A novel
method that has been used extensively in polymer-based manufacturing to produce surfaces saturated in
micro channels and groves electrospinning of polymers into nanoscale fibers that act as channels or tracks
that are preferred adhesion points for newly regenerating nerves.

Figure 2.1 Common horizontal electrospinning apparatus setup
Source: Kadavil, Hana, Moustafa Zagho, Ahmed Elzatahry, and Talal Altahtamouni. 2019. “Sputtering of Electrospun Polymer-Based
Nanofibers for Biomedical Applications: A Perspective.” Nanomaterials (Basel, Switzerland) 9 (1). https://doi.org/10.3390/nano9010077.
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Electrospinning is a technique that involves drawing charged polymers in solution towards a grounded
collecting plate using electro repulsion forces. If polymers are successfully suspended in a compatible
soluble solution and the solution is capable of holding a charge then it has the potential for electrospinning
manufacturing. If the solution is charged by a generator and a grounded collector is located a distance from
the solution reservoir, electro repulsive forces created from the opposite charges will attract and pull the
solution and its monomer components towards the collector. The process of pulling the charged polymer
solution from its reservoir towards the collecting plate until the forces exceed the surface tension forces of
the solution to create the jetting effect is called the Taylor cone, and is an effect that should be present for
successful solution spinning. As the solution and monomers are pulled across the air medium, the monomers
align together as the solution evaporates and cross links them into a continuous fiber strand [11]. By
changing the polymer percentage solution, voltage, tip-to -collector distance, and solution pump rate the
diameter of the fibers can be tailored to specific fiber diameter, surface topography, and porosity
specifications.
The development of neural scaffolds using synthetic electrospun polymers that provide both cellular and
mechanical support at the site of healing and can be designed to biodegrade after its therapy has finished
without inducing any adverse immune or cytotoxic effects [12]. This technique has gained much interest
for addressing the limitations of autografts while providing the advantages of tailoring biocompatibility,
biodegradation, mechanical properties, and surface architectures of the scaffold based on the materials used.
This provides opportunities to test a variety of different materials in the hopes of creating the ideal scaffold
design [13]. Currently, synthetic polymer scaffolds by themselves still underperform when compared to the
current gold standard for defects greater than 1 cm. To address this challenge, many studies have begun to
look at combining multiple TE techniques together in the scaffold design such as stem cell support,
anisotropy surface architecture, and surface coatings to improve the limitations of synthetic scaffolds [14].
The majority of these In-vivo studies show a significant improvement in neural repair, with successful
bridging of neural defects up to 3 cm in length being reported. We are particularly interested in developing
synthetic neural scaffold designs that incorporate stem cell therapy and surface coatings to improve the
quality of severe neurotmesis recovery.

2.1.3 Graphene Family Nanomaterial Inclusion
We are interested in studying the application of using graphene-based materials as a thin film coating
applied to the surface of scaffolds to potentially enhance growth, survival, and rate of differentiation of
hADSC for promoting tissue healing [15]. Graphene is a single atom thick honey comb lattice structure of
carbon bonds that consist of SP and SP hybridizations. Graphene has been studied for its potential as a
2

3

biomaterial and graphene functionalized with oxidative compounds known as graphene oxide has been
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found to be one of the most promising candidates as a biocompatible substrate. Both graphene oxide thin
films and hADSC have been studied extensively for their potential to enhance the repair of damaged
peripheral nerve [16–18]. Results show a marked improvement of neural repair in the presence of hADSC,
graphene-based materials, or both. Current studies have also shown that by treating the surface of
biomaterials with carbon based thin film coatings, we can enhance the growth, survival, and differentiation
of mesenchymal stem cells, supporting the notion that combining graphene-based thin films with ADSC
cultures to our neural scaffold might enhance nerve repair [19,20].

2.1.4 Objective
The objective of this project is to determine whether electrospun PCL platform surfaces coated with
graphene nanomaterial is a suitable platform to support MSC cultures differentiated towards a neural
phenotype. This objective is the first iteration of In-vitro tests that will assess the cytotoxicity, and potential
to support hADSC artificially stimulated towards Schwann-like cell phenotypes as the first initial set of
data for support in progressing our novel therapeutic design towards In-vivo assessment studies that will
result in the design of a 3D neural wrap functioned to support and guide peripheral nerve healing. We
hypothesize that PCL films coated with GO nanomaterial films will successfully attach to the PCL film
iterations and that they will show a high potential for supporting hADSC and neural differentiated hADSC
cultures compared to controlled PCL films without GO coatings.

2.2 Experimental Neural Wraps
2.2.1 Graphene Solution Preparation
With a joint collaboration between the University of Tennessee’s CVM department and the University of
Arkansas Little Rock (UALR) Nanotechnology center, we created graphene and PEG coated coverslips
using techniques originated from the work of UALR as described in (Majeed, Waqar, 2017). 8 iterations of
graphene solutions and PEG solution were created based on the surface coat non-tissue glass cover slips to
determine the optimal surface coating to use on PCL meshes for supporting MSC cell lines. N002-PDR PG
(Angstron Materials) with x-y dimensions of 10µm and ≤2.5% oxidative group content, single-layered GO
(Cheap Tubes) with x-y dimensions 300-800 nm and 35-45% oxidative group content, and PEG of 8,000
molecular weight (Bioworld) where acquired. 0.1mg/ml PG solution was created by adding 3.0mg N002PDR PG with 18MΩ deionized water. High-Oxygen Graphene (HOG) solutions used N002-PDR PG for
their preparations. Both solutions were oxidized using similar volume ratios of concentrated sulfuric acid
(H SO ) to concentrated nitric acid (HNO )- 3H SO : 1HNO For the HOG solution, the acid volume ratio
2

4

3

2

4

3:

was added to 3.0 mg N002-PDR PG for 24 hours and 18MΩ deionized water was added to dilute the
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solution to 3H SO : 1HNO 1H O ratio prior to filtration. 0.1mg/ml single-layered GO solution was created
2

4

3:

2

by adding 3.0mg single-layered GO with 18MΩ deionized water. All graphene solutions were vacuum
filtered and washed with 18MΩ deionized water several times to collect graphene precipitants. All graphene
iterations solutions with the inclusion of PEG (HOG+PEG, GO+PEG) follow the same protocol as
discussed previously with the inclusion of 8,000 molecular weight PEG at 0.1mg/ml. all solutions had 30
ml of 18MΩ deionized water added. All solutions where tip sonicated for 2 hours after filtration step.

2.2.2 Air Spray Surface Coating (24-Well Plate)
Thin film surface coating of graphene solutions onto glass cover slips and PCL meshes was achieved using
a Paasche series airbrush kit. Under chemical fume hood conditions, two 24-well plates aligned next to each
other was placed on a hot plate set to 50-55˚ C. Glass cover slips were taped to the bottom of each well to
prevent cover slips from being up lifted from the wells during spraying. The last 12 wells on each end of
the plates were taped off to prevent cross contamination during coating phase (Figure 2.2). All solutions
were bath sonicated 30 min to evenly disperse graphene oxide films in solution that have settled to the
bottom of the container after 24 hours or more in storage before being used to coat the materials. 10ml were
used from each graphene and PEG solution to coat 24 wells per plate. Solutions were sprayed at 21 psi. A
total of 10 plates for graphene and PEG iterations including positive control plates with cover slips and a
total of 2 plates for graphene and PEG iterations including positive and negative control plates with smooth
and fiber PCL films. Plates were covered with parafilm after coating and UV sterilized for 4 hours under
cell culture sterile hood prior to culturing cells.

Figure 2.2 Air spray setup for graphene coatings on 24-well plates
Note: 24-well plates on hot plate chemical fume hood conditions for manufacturing graphene/ PEG surface coated glass cover-slips, and PCL
fiber and drop coated films.
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2.2.3 Electrospinning
Poly-caprolactone of 80,000 molecular weight (Sigma Aldrich) was used to create PCL solutions for both
electrospinning and drop coating manufacturing techniques. Electrospinning solution of 10% wt. PCL was
created using 1.5mg PCL powder to 15ml 1:1 ratio of Methylene Chloride (MC) to Dimethylformamide
(DMF). Electrospinning apparatus was setup under chemical fume hood conditions with an Aladdin-6000
multi-barrel programmable 6 syringe pump (World Precision Instrument), a 5ml syringe, 19 gage needle
head, voltage generator attached to the needle head, and a rotating mandrel collector wrapped with
aluminum foil grounded to the fume hood box. Electrospinning parameters were set to 16-17.5 kV charge
with the needle tip-to-collector distance set to 7 in and the solution pumping rate set to 1 ml/hr. 15mm nontissue culture treated glass cover slips were attached to the collector. Each electrospin process used 4 ml of
the 10% wt. PCL solution to create thick PCL meshes of random fiber orientation. PCL meshes were
deposited on the surface of cover slips making it easy to separate into individual circular sections that fit
into non–tissue culture treated 24-well culture plates for cytotoxicity assessment. PCL meshes along with
24 well plates were placed under UV sterilization for 4 hours prior to culturing cells.

2.2.4 Drop Coating
Drop coating solution of 5% wt. PCL was created using 0.75mg PCL powder to 15ml Chloroform. Under
chemical fume hood conditions, glass cover slips were placed on top of leveled glass plates. A 200 µl pipette
was used to load PCL solutions onto cover slips. A beaker was placed on top of the cover slips while
chloroform evaporated. Smooth PCL films remained once all chloroform evaporated and placed into 24well culture plates. PCL smooth films were placed under UV sterilization for 4 hours prior to culturing
cells.

2.2.5 Rat/ Human ADSC Culture
Passage 3 rADSCs and hADSCs cell lines were acquired from The University of Tennessee Medical Center
Laboratory for Regenerative Medicine headed by Dr. Tom Masi and Dr. Stacy Stephenson. Both cell lines
were previously assessed for mesenchymal cell quality by observing their potential for differentiation
towards cell lineages expected of cells that follow a mesenchymal cell pathway (tri-lineage testing), cell
surface marker profile, and proliferation capacity under normal culture conditions. Non-tissue culture 24
well plates with glass cover slips surface coated with graphene and PEG iterations were seeded with rADSC
culture for MTS and Calcein AM/PI assessment of cell viability. All wells were seeded with a cell density
of 20,000 cells/well, suspended in 500 µl of DMEM-F12 cell culture media (DMEM-F12 +10% fetal bovine
serum+1% L-glutamine+ 1% penicillin streptomycin). Wells were kept in incubator set to 5% CO and 37˚C
2

during the culture period. Regular media changes were scheduled at day 3 and 5.
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Non-tissue culture 24 well plates with both electrospun (fiber) and drop (smooth) coated PCL films with
surface coated graphene and PEG iterations were seeded with hADSC cultures for cell differentiation and
protein expression assessment. It has been observed in previous studies that during neural regeneration that
there is a marked increase in cAMP messenger proteins in axons as a result of membrane depolarization of
Ca ion channels, thus regulating neurotrophic growth factors and axon extension during repair[21,22]. Our
protocol for elevating intracellular cAMP to artificially induce hADSC towards cells with neural like
characteristics was similar to the methods used in[23,24]. Primary induction medium consisted of 0.5 mM
3-isobutyl-1-methylxanthine (IBMX) and 1 mM dibutyl cyclic adenosine monophosphate (db-cAMP) per
well with the addition of 500µl of DMEM-F12 cell culture media. Wells were kept in incubator set to 5%
CO and 37˚C during the culture period. Regular media changes were scheduled at day 3 and 5.
2

2.2.6 MTS Assay
Tetrazolium is a redox indicator commonly used to quantify the number of viable cells in a controlled area.
The compound is positively charged in its initial form and when combined with negatively charged
phenazine methosulfate it becomes a stable macromolecule in aqueous solution. It is permeable to the
cellular and mitochondrial membrane for most cell types, giving tetrazolium easy access to metabolically
active sites of cells. When tetrazolium is positioned in the mitochondria it is bio reduced by dehydrogenases
enzymes. The electron from NADH or NADPH is passed to the tetrazolium molecule and yields a
compound called formazan. The formazan compound is a chemically stable dye that will bind to the cell
surface and is soluble in aqueous solution. By measuring the absorbance of light from the dye we can
quantitatively determine how many viable cells are in a given culture area and over time observe if the
number of cells increase or decrease as an indicator of cell growth or death. Each coating had a sample size
of n=5 wells for culture time points day 3, 5, and 7 with 1 negative control blank well at each time point to
normalize MTS values from background absorption given off by the wells material and the culture
media MTS cell proliferation quantitative analysis was carried out at these time points using CellTiter 96
Aqueous one solution (Promega). At each time point, the old media was removed and replaced with fresh
media. MTS reagent was added to each well at a 1/5 dilution ratio. Well plates were left in 5% CO and
2

37˚C incubator for 3 hours to allow ample time for MTS reagent to react with cells. Using an Epoch Biotek
micro-plate reader set to detect 490nm UV-Vis absorption, we quantified the formazan intensity of each
coating and compared them to positive control tissue culture treated glass cover slips.
2.2.7 Calcein AM, Propidium Iodine Live Stain
Calcein AM is a fluorescent dye that is permeable to live cell membranes. Intracellular esterase removes
acetoxymethyl esters from Calcein AM which reduces to the fluorescent calcein dye expressed at 485 nm
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excitation and 520 nm emission. Commonly utilized as a visual indicator of live cells and for temporary
tracking of live cells in culture. Propodeum Iodine is a red fluorescent dye that is impermeable to live cells,
which makes it useful in labeling and tracking dying cells present in a culture area. The dye will bind with
DNA by intercalating between base pairs, where the dye is expressed at 488 nm excitation and 617 nm
emission. Both reagents were acquired as Cell Trace Calcein green AM 5µg/µl (ThermoFisher), and
Propidium Iodine 1.0mg/ml (ThermoFisher). A combined solution of calcein AM (5µg/ml HBSS) and PI
(0.5 µg/ml HBSS) was created. Old media from the well at each time point was removed and washed twice
with HBSS to remove any floating dead cells or debris that could obstruct visualization of the dyes. 0.5 ml
of calcein/ PI solution were dispensed into wells and left in 5% CO and 35˚C incubator for 30 min to allow
2

ample time for reagents to react with cells. Using a Light Fluorescence Microscope, we visualized surface
area coverage of calcein AM and PI fluorescence on coverslips.

2.2.8 Immunofluorescence
Vimentin is an intermediate filament protein highly concentrated in the cytoplasm of mesenchymal based
cell lines as a primary component of the cytoskeletal structure for cell mobility and spreading and therefore
can act as a quality control marker during immunofluorescence protocols [25]. DiI is a lipophilic stain that
labels the bilayer of the cellular membrane of live cells. It is often used as a cell tracking stain that will
label the cells for long periods of time without impacting normal cellular physiology. This will allow for
tracking of hADSC cultures seeded on biomaterials during the entire differentiation period. S100 protein
are responsible for regulating Ca levels, which are involved with different cellular pathways that regulate
+2

cell growth, cytoskeletal activities, and inflammatory responses. S100β protein is a subsidiary of the S100
family and is specific to glial cells, particularly astrocyte cells that function to regulate axon proliferation
and neurite extension by controlling Ca intracellular levels [26,27]. Vimentin present in hADSC cultures
+2

is expected to show changes in morphology similar to that of neural based cells by day 6 when stimulated
with this specific neural induction media. Changes in S100β expression is expected in hADSC by 24 hours
post neural induction with this specific neural induction media as an indicator of neural differentiation.
Immunolabeling was performed on MSCs plated on coated glass coverslips. 24 well-plates were divided
into 2 equal sections with wells that received normal DMEM F-12 media and wells that received neural
stimulant media. DiI staining of all immunofluorescence wells was performed on the same day of cell
seeding to track cell growth over the culture period. Cells were fixed at 24 hours post-cell seeding at 6 days
post-cell seeding. Cells were fixed in 4% Paraformaldehyde for 10 minutes. Washed wells with HBSS
containing 0.1% Triton X-100 and let sit at RT for 10 min. wash twice with HBSS and blocked with 1:10
protein block for 30 min at RT. Wells fixed at day 1 were then incubated with 1µg (4µl) Unconjugated
Purified mouse 0.25µg/ml (BD Pharmingen) Purified Mouse S100B-antibody while wells fixed at day 6
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were incubated with 1µg (2µl) Unconjugated Purified mouse anti-vimentin, 0.5µg/ml (BD Pharmingen) at
1μg/well. Primary antibodies were added to 1:10 protein block solution at 500 μl/well and left overnight at
4°C. Primary antibody solutions were removed from wells and washed twice with HBSS. Secondary
antibody AlexaFluor 488 Donkey, anti-mouse IgG, 2mg/ml, (Invitrogen) at 4μg/well (2μl) to 1:10 protein
block solution at 500 μl/well and incubated for 30 min at RT. Wash wells with HBSS before mounting
samples onto glass slides using 1 drop of DAPI Prolong Gold antifade reagent (Molecular Probes).

2.3 Results
2.3.1 MTS Analysis
MTS results of HOG and HOG+PEG coating showed significant increase in formazan fluorescence from
day 3 to day 5, with fluorescence intensity leveling off at day 7 for HOG coating and a continued linear
proliferation projection for HOG+PEG towards day 7. GO, GO+PEG, and PEG coatings showed continued
significant increase in formazan fluorescence at each culture time period reaching a peak proliferation
intensity at day 7 statistically similar to that of the positive control coverslips. HOG and HOG+PEG
coatings appear to have moderate viability potential with proliferation reading showing significantly less
formazan intensity at day 7 compared to positive control coverslips. GO, and GO+PEG was the only
graphene-based coatings that showed significantly similar levels of rADSC viability at day 7 compared to
the control coverslips (Figure 2.3).
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Figure 2.3 Rat ADSC MTS Analysis on Graphene Iterations
Note: Sample size n=5 per group per day, ANOVA analysis of day 7 MTS values relative to control groups. *P ≤ 0.05
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Control

2.3.2 Live/Dead Calcein AM Propidium Iodine Stain
Calcein AM and PI Live/dead stains were analyzed under fluorescent microscope with images taken at the
center of each 24-well. Minimal PI dye was detected on each coating iteration most likely due to the process
of washing each surface coating twice with HBSS solution before applying staining solution, thus removing
any loosely adhered or floating dead rat MSCs to stain with PI. The images of positive Calcein AM staining
for all coatings at day 7 are shown in (Figure 2.4). The qualitative assessment of these images indicates
that live rADSC cultures are present on each iteration of graphene coating at day 7. Quantitative assessment
of the intensity of calcein stains was performed using ImageJ by grey scaling the green fluorescence of
calcein and measuring the total area coverage of the stain at five random locations at day 7 5X images with
no replicates (Figure 2.5). Quantitative assessment showed that positive control material had significantly
higher positive calcein coverage at day 7, compared to all other coating iterations.

Rat ADSC (Control)

Rat ADSC (GO+PEG)

Rat ADSC (GO)

Rat ADSC (PEG)

Rat ADSC (HOG)

Rat ADSC (HOG+PEG)

Figure 2.4 Calcein AM staining of hADSC cultures on graphene iterations
Note: Day 7 single 24-well sample of each Graphene/PEG surface coating iteration thru air spray techniques. 5x magnification using fluorescent
microscope directed at center position of each 24-well. Calcein AM stained green as an indicator for viable cells present on surface coating iterations.
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Figure 2.5 Day 7 Calcein AM average area coverage quantification
Note: Day 7 Calcein Am staining for GO and HOG coating iteration and PEG surface coating as an indicator of cell viability. Surface area coverage
measurements were taken at n=5 random locations selected on each 5X magnification using ImageJ. ANOVA analysis of day 7 calc ein coverage
relative to the control well. *P ≤ 0.05

2.3.3 Day 6 Immunofluorescence-Vimentin
Vimentin proteins were visualized on day 6 of hADSC culture period using a fluorescent microscope.
Images were taken at 20X magnification (Figure 2.6).
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Figure 2.6 Day 6 1µg vimentin/well. Counter cytoplasm stain DiI and nuclear stain DAPI
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Vimentin along with its counter DiI and DAPI showed positive on positive control glass cover slips under
both neural and control induction media. smooth PCL under control media did not show positive expression
of vimentin counter stained with positive DiI and DAPI at day 6 culture, while this material under neural
induction media did show positive expression of vimentin counter stained with DiI and DAPI at day 6. Both
the smooth PCL+GO and smooth PCL+GO+PEG iterations under neural and control media at day 6 showed
positive expression of vimentin counter stained with DiI.Control media showed cellular spreading
morphology, while neural induction showed profound extensions of the cell from the nucleus similar to
bipolar cell morphologies. All fiber mesh iterations showed either negative expression of vimentin or
vimentin expressions difficult to make out cell morphologies even when countered stained with DiI and
DAPI. Vimentin and DiI staining showed that clear stable cell morphologies were profound on PCL
platforms with smooth surface topography by day 6 culture period, while PCL fiber mesh platforms showed
little indication of morphology or cell culture presence on the mesh surface.

2.3.4 Day 1 Immunofluorescence-S100β
S100β protein expression was visualized on day 1 of hADSC culture period using a fluorescent microscope.
Images were taken at 20X magnification. S100β along with its counter DiI and DAPI showed positive on
positive control glass cover slips under both neural and control induction media at day 1 culture. PCL
material of both smooth and fiber topography induced by neural or control media showed low or negative
expression of S100β at day 1, while smooth PCL showed positive counter stain of DiI and DAPI and fiber
PCL showed positive DAPI expression at day 1. Both smooth PCL+GO and smooth PCL+GO+PEG
iterations under neural and control media showed positive expression of S100β counter stained with DiI at
day 1. Control media showed cellular spreading morphology, while neural induction showed profound
extensions of the cell from the nucleus similar to bipolar cell morphologies. fiber PCL+GO meshes showed
positive expression S100β counter stained with DiI under neural and control media at day 1. Profound
elongation of hADSC along with parallel orientation and organization of cells relative to each other is
present on Fiber PCL under neural and control media at day 1. Results show positive expression of S100β
on PCL+GO, PCL+GO+PEG smooth films and PCL+GO fiber mesh platforms with clear different cellular
morphologies detected from DiI staining at day 1 culture period. Induction of hADSC cultures towards
neural-like cells might be happening on these PCL platforms (Figure 2.7).
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Figure 2.7 Day 1 1µg S100β/well. Counter cytoplasm stain DiI and nuclear stain DAPI
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2.3.5 Day 1 S100β Intensity
Quantitative assessment of S100β intensity of hADSC cultured on both smooth PCL+GO films and fiber
PCL+GO meshes at day 1 post- neural induction media was performed using ImageJ by grey scaling the
green fluorescence of S100β and measuring the maximum intensity of the stain across the length of 10
randomly selected hADSC cell bodies in 5X images (Figure 2.8). Analysis showed that the intensity of
S100β expression on control glass exposed to control media induction was significantly similar only to
the PCL+GO fiber meshes exposed to control media. All other iterations had S100β intensities
significantly greater than the control glass under control media. Under neural induction media, Fiber
PCL+GO meshes showed similar S100β intensities to that of the control under neural induction media,
while all media iterations on smooth PCL+GO films had the highest S100β intensities compared to all
other groups. Results indicate that fiber PCL+GO mesh S100β intensities under neural induction at day 1
are comparable to that of the positive control material under neural induction media at day 1 (Figure 2.9).
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Figure 2.8 Day 1 1µg S100β/well 5X magnification.
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Figure 2.9 S100β intensity profile for hADSC
Note: hADSCs cultured under normal and neural induction media on PCL fiber and smooth platforms surface coated with GO. ANOVA analysis
*P ≤ 0.05

2.4 Discussion
Electrospinning and drop coating techniques resulted in thin film surfaces of PCL biomaterial composition
with either nanofiber or smooth surface topographies to be tested as platforms for delivering hADSC
therapy In-vivo.
In the MTS Profile, coating with graphene of higher oxygen content was shown to have similar formazan
intensity towards MSC cell model rADSC cultures compared to the control material (GO, GO+PEG, and
PEG only) while HOG, and HOG+PEG had significantly smaller formazan intensity compared to the
control at day 7. Since this study is interested in utilizing graphene based materials as a coating additive
and the GO-based coatings showed similar cytocompatibility to rADSC to that of the control it was decided
to continue further In-vitro studies using GO-based coatings on PCL platforms, even though PEG-only
coating showed the same degree of cytocompatibility to that of the GO-based materials. Positive expression
of calcein stain on graphene surfaces showed rADSC cultures at day 7. The coverage of calcein AM staining
at day 7 images for each graphene coating shows a similar quantitative projection to that of the formazan
intensity detected thru MTS suggesting that there might be a correlation of formazan fluorescence intensity
to that of calcein fluorescence when determining the number of live cells present in culture wells with
coating iterations.
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Observable differences in cell morphology and S100β expression intensity was detected between coatings
of different media and surface topography groups. Immunofluorescence expression of DiI, S100β, and
DAPI for positive control glass coverslips under neural and control media induction at day 1 culture period
was positive, indicating correct immunofluorescence protocol. Control material showed low intensity of
S100β under control media compared to neural media group, indicating a low expression of S100β in
undifferentiated normal hADSC cultures compared to neural induced hADSC cultures. Fiber mesh and
smooth film samples for PCL+GO showed positive expression of S100β and DiI staining. Fiber PCL+GO
mesh showed similar S100β intensity profile to that of the control material under different media groups.
Smooth PCL+GO showed a higher intensity of S100β under control media group compared to the neural
media group. This difference in S100β intensity between the media groups could be attributed to
background expression of S100β, or might be attributed to the difference in surface topographies between
the PCL film and mesh groups. While the control material and smooth PCL materials showed general
spreading under control media and profound extensions under neural media, the fiber PCL materials under
both media groups showed additional parallel orientation and organization that we would expect to b present
during endogenous nerve repair. While most iterations of human mesenchymal stem cells show very little
to no expression of S100β in undifferentiated form, in the presence of GO coating, specific surface
topographies and, neural stimulants could account for the differences seen in S100β and the cellular
morphologies in those groups. This indicates that PCL materials with fiber surface textures and coated with
GO has potential to not only support neural differentiated hADSC but stimulate specific growth patterns of
hADSC during differentiation.
Immunofluorescence expression of DiI, vimentin, and DAPI for positive control glass coverslips at day 6
culture period was positive, indicating correct immunofluorescence protocol and antibody concentrations
in 24-well plates. Our experimental nerve wrap material PCL+GO, and PCL+GO+PEG expressed positive
for vimentin along with counter stain DiI. DAPI was found to be difficult to image on materials coated with
GO but the presence of cell spreading and extensions by cells expressed by vimentin and DiI confirmed the
presence of these cells on the material surface. Slight difference in cell morphology can be detected between
the media cultures, with neural induction cells showing longer extensions from the nucleus with some
showing a bipolar shape reminiscent of a neuron, while control media shows cell with overall large
spreading on the platform but no profound extensions as noted in the neural media. Cell morphologies
showed profound spreading on PCL smooth film iterations while fiber surface iterations showed cell
morphologies with profound extensions and bipolar stretching exceeding past their original size as well as
signs of mobility and communication with surrounding cells to orient their cell bodies parallel to each other.
These characteristics were further enhanced by either induction by control media or neural media were
control media had profound spreading and neural induction had cultures with profound cell extensions.
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Although vimentin expression of hADSC cultures were not profound in fiber PLC+GO meshes compared
to smooth PCL+GO or PCL+GO+PEG by day 6 culture period, S100β expression along with DiI staining
on fiber PCL+GO meshes was the only sample that showed positive S100β with profound cellular
extensions oriented parallel to each other at day 1 culture period. This more closely compliments the neural
development and organization that we want our design to incorporate In-vivo. Also, these results share some
aspects of hADSC morphological changes at certain time points during neural induction recorded from
studies that have referenced using this particular neural induction media recipe to assess cell morphology
and neural potential by staining for S100β/ vimentin protein expression in hADSC [28].
Based on both direct and in-direct proliferation assays on MSC lines on different graphene iterations and
the performance of these coatings to support hADSC cell lines stimulated towards neural-like
differentiation In-vitro, GO nanomaterial films might have potential as a surface modifier of PCL fiber
meshes for delivering stem cell and biomaterial therapies to assist in the repair of critical neural defects. It
is also suggested from these results that the next step is to develop a functional 3D prototype of this
biomaterial mesh design that can be implemented in a small-animal to determine initial compatibility of
this design in critical nerve defect repair sites.

2.4.1 Implications/ Challenges
Neural Wrap Coating Characterization UALR’s Nanotechnology group previously characterized these
specific graphene solutions of varying oxygen group content used in this study. In their study, UALR was
able to identify the oxygen content and the presence of graphene on coverslips using X-ray Photoelectron
spectroscopy (XPS) and Raman Spectroscopy techniques that identified the molecular signature of
graphene and the oxidative group bonds as well as their percent ratios in order to identify different graphene
iterations produced by UALR’s manufacturing methods [29]. A collaboration with the UALR
Nanotechnology group was established to assist in replicating these graphene solutions and coating
techniques for this study. No characterization assessment tests were performed on this studies batch of
graphene coating iteration to determine with certainty that coating was successful or confirm the oxygen
content of the coatings. By using UALR’s controlled lab environment, equipment, and protocols used in
their previous study, it is assumed that the manufacturing of graphene coating iterations will have minimal
variation in characterization variables from the graphene coatings created in UALR’s previous study. This
study’s only means of determining successful graphene coating on material surfaces is subjective visual
confirmation of color changes on the material surface, most commonly changes towards a dark black or
brown confirms that the graphene coating was applied and was present on the material surface.
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Manufacturing While air spraying both 24-wells and PCL materials with graphene solutions by hand, it is
difficult to maintain consistency of equal amounts of solution sprayed onto each material sample or well
when spraying for long periods of time. Under heated conditions using a hot plate, it is difficult to regulate
the temperature the sample is exposed to so that it will not melt the PCL films but will not allow graphene
solution droplets to form during spraying creating a nonhomogeneous coating of graphene materials. It is
suggested that we translate UALR’s air spray and graphene solution protocols to our lab to improve our
efficiency in creating prototypes of our material for the next study phase. While comparing the
manufacturing process of this study with protocols used by UALR’s group, there is a high risk for variability
in manufacturing when translating protocols of one lab to another. To minimize this, we manufactured our
coatings by modifying the manufacturing protocols of UALR for this study to ensure that they are
compatible with our lab protocols. We do not expect much variability in manufacture results due to these
protocols being new to our lab or closely mimicking similar protocols that we utilize in our lab.
Electrospinning process involves many variables that must be considered to tailor the specific mechanical
and functional qualities of your fiber mesh. Altering theses variables will produce fibers with very different
characteristics than what is expected. It was noted that the electrospinning parameters often required
immediate changes during the spinning process in order to maintain jetting for the intended period of spray.
These and other complications such as polymer hardening in the needle head, and solution blockages will
have caused variations in the type of fibers that we manufactured for immunofluorescence testing. Any
changes in the electrospinning process will alter the texture of the material surface and thus directly impact
cell behavior on its surface as a possible explanation for unexpected cell behaviors.
Proliferation Assays The use of soluble MTT (MTS) assays to quantitate cell viability in well conditions is
a well-documented and popular indirect proliferation assay. However, the potential for indirect assays to
cross react with other compounds suspended with cells such as biomaterials or for biomaterials to affect the
cells physiology that results in false expression of MTS regents is a real concern. With graphene-based
materials the primary toxicity concern is its ability to stimulate over production of reactive oxygen species
in many cell lines that both directly and indirectly impacts the metabolic conditions inside the cells. This
could provide a false positive in activation of tetrazolium salt to fluorescent formalin as an indicator for of
good cell viability when in reality the cell is under stress. Therefore, it is suggested that direct proliferation
assays and other indirect proliferation assays be used in conjunction with MTS to determine if a potential
problem exist in the biomaterial [30,31].
The result from this study concerning viability of lower oxygen graphene materials appears to contradict
previous studies concerning the use of graphene with lower concentrations of oxygen groups as a platform
to support ADSC lines [15,32,33]. This is not uncommon when it comes to assessing the toxicity potential
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of graphene-based materials. In-vitro and In-vivo studies can often contradict each other due in part to the
lack of standards for In-vitro and In-vivo towards assessing nanomaterials and the need to further understand
the multiple forms and iterations of graphene-based materials that might play a role in other toxicity
pathways. Graphene as a nanomaterial does not yet have a complete toxicity profile to establish with
certainty what other toxic mechanisms it might play a role in, such as previously discussed concerning the
possible limitations of using MTS proliferation assays on graphene and the advantages to using multiple
assays in tandem with each other.
While it is standard to use an appropriate immortalized cell line as a model for assessing cytotoxicity on
biomaterial, it was felt for the purposes of determining the efficacy of our biomaterial platform to support
ADSCs, rat ADSC were chosen as the model for assessing cytotoxicity of PCL+GO biomaterials towards
MSC lines. However, this study could have further benefited from using cell lines intended for cell
therapeutic delivery in neural defects with hADSC lines. This would give the study a more accurate
assessment of our materials ability to support the proposed therapy provided by hADSC lines. While the
two cell lines are similar in general function and role, they play in mammalian physiological systems they
have different configurations of organelles, surface markers, and membrane channels that activate specific
functions that might not be found in a xenogeneic cell line. Statistical Confidence in the quantitative
assessment of Calcein AM intensity could be improved with the addition of multiple replicates instead of a
single well set for each time point during the MTS read out.
Immunofluorescence While a positive control material was selected to assess hADSC lines ability to adhere
to a pro-adhesion surface, a positive control cell line to assess the positive expression S100β protein in cell
lines where it should be highly expressed was not used. A cell line where S100β protein is highly expressed
should have been used to determine if our primary secondary antibody protocol would work as intended.
While previous studies have shown expression of S100β in ADSC lines it is not often certain of a positive
expression or if the signal can even be labeled as positive. A better cell line to use and compare in tandem
to hADSC lines would be a glial based cell line, either astrocytes, oligodendrocytes, or the most preferred
in the case of peripheral nerves Schwann cells.
There were difficulties in manipulating the PCL fiber mesh iterations when suspended in media solution
for visualizing cultured cells. Films were very flimsy and the surface charge of the material as well as the
current of the media and the presence of cells on its structure made it easy for the film to fold and collapse
in on itself. This made it difficult to straighten out on microscope slides to visualize cell morphology and
protein expression. An alternative method for ensuring static movement of the film when suspended in
media for the entire culture period would be advantageous and would benefit future studies involving these
films.
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PCL films coated with our GO surface coatings appeared to either block or absorb DAPI blue light under
fluorescence microscope. It has been shown that GO compounds can decrease the intensity of fluorescence
given off from other compounds such as DAPI. This process is known as quenching compounds in
fluorescence compounds[34]. Other alternative neural stains can be utilized on this type of graphene to
visualize the nucleus of cells adhered to its surface such as using Propidium Iodine dead staining that
fluoresces in the red spectrum when it binds to the nucleus of dead cells.

2.5 Conclusion
We have described the first initial set of In-vitro data supporting our hypothesis as a step towards further
developing a novel synthetic 3D nerve wrap that can assist in healing critical neurotmesis injuries. Our
assessment determined that PCL platforms of nano-fiber architecture with additional surface coating of GO
films can support both native hADSC and hADSC pre-differentiated towards neural-like cell lineages. Both
indirect and direct methods respectively MTS and Calcein AM/ PI live stain confirmed a higher degree of
MSC viability when rADSC cultures were seeded on GO coatings. This was further supported when PCL
meshes on both smooth and fiber architectures showed hADSC with characteristic morphology changes
such as cell adhesion and spreading during the culture period when staining with cytoplasm tracker DiI.
Distinct differences in cell morphology and S100β expression between the different media and surface
architecture groups for each coating iteration suggests that cells were beginning to differentiate in response
to media and surface chemical and mechanical niches. Films surfaces with fiber architecture showed a
higher degree of organization from that of smooth film surfaces. hADSCs with long extensions would often
align themselves to each other in parallel formation on fiber surfaces, while these same cells would often
be spread out in chaotic fashion on smooth surfaces. Majority of GO surface coatings showed excellent
culture of native and differentiated hADSC cultures compared to positive glass coverslips and PCL only
films. Both GO+PCL and GO+PCL+PEG coating showed similar cell response during the culture period
suggesting that the addition of unfunctionalized PEG surface coating dose not significantly improve or is
detrimental to the effect that graphene has on hADSC cultures.
The results of this study suggest that GO surface coating on PCL fiber mesh is an excellent platform for
culturing hADSC lines. We plan to move into the next phase of In-vivo assessments using a rodent small
animal model to create critical neurotmesis and assess the potential of our surface coated 3D wrap to assist
in its repair. The success of these techniques used to manufacture PCL coated platforms at UALR has
suggested plans to translate UALR’s manufacturing technology and setup to our lab at UT CVM for more
precise and rapid production of 3D nerve wraps when designing prototypes for our further planned In-vitro
studies.
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Chapter 3: Biometric Data Comparison Between Lewis and Sprague
Dawley Rats
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Abstract
Pressure mapping systems are a commonly utilized instrument for indirect assessment of the repair of
critical defect in small-animal models. For the purposes of our study we are interested in utilizing Tekscans
VH4 pressure map system for assessing the degree of critical size repairs in real time during the healing
process with rodent models. Previous studies have reported normal kinematic data from common rat
species. However, there does not appear to be any literature that compares the normal gait pattern of
Sprauge Dawley rats to Lewis rats using a Tekscan VH4 pressure mat system. The purpose of this study is
to assess the gait profile of Lewis and Sprauge Dawley rats generated by Tekscan’s VH4 system to detect
similarities and/or differences gait parameters involving both force and temporal variables to prepare for
future critical defect In-vivo models that require careful selection of animal participants based on gait
profile. The gait profile of 14 Lewis and 14 Sprauge Dawley rats was recorded and gait parameter data was
normalized and compared for statistical variance between the two rodent strains. The results showed that
the temporal and normalized force parameters were not significantly different between the two strains.
Variation in some of these parameters were considered due to the significant difference in overall body size
between the two strains and how each rodent act as its own independent group. For future critical size Invivo models, either rodent strain would be acceptable for assessing critical repair in any model that uses the
Tekscan VH4 pressure map system since the base line gait profile recorded from both strains were found
to be statistically similar to each other.
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3.1 Introduction
Animal models are the primary component in the establishment of acceptable In-vivo testing of implantable
medical devices. Animal models have been designed to assess the standard clinical requirements expected
of class II or III medical devices and a focused assessment of the functional properties of the device. This
is for the purpose of studying the different variations of the device’s actual performance in a physiological
system similar to that of humans compared to its expected or intended performance in order to prepare the
device for consideration for clinical trials. In order for a class II or III medical device to be considered for
clinical evaluation in human trials, the data collected from In-vivo studies must be quantifiable in order to
be normalized to human physiologic parameters when translating from an animal model [1–3]. Biometric
data comparing changes in gait profiles is a critical step when using animal models to study musculoskeletal
and peripheral nerve injury. Assessment tools used in the measurement of the biometrics of locomotion are
common tools for quantitatively assessing the quality of tissue repair [4–6]. Depending on the animal model
and species selected, the tissues being studied to determine the performance of the device, and the tools for
collecting and assessing gait parameters, the biometric data can be included as quantitative evidence for
support of a class II or III device prior to human clinical trials. It is therefore important to fully understand
the normal gait pattern for any animal species used in an animal model were gait parameter data will be
recorded for the purposes of assessing implant performance as a prerequisite for approval to begin clinical
trials in humans.
While the types of animal species used and the specific tissues assessed in critical size defect models has
changed by a small margin, the tools and techniques used to assess gait patterns and report quantitative data
has markedly improved [7–9]. This is due, in part, to the inclusion of novel technologies that can more
precisely and accurately detect specific gait parameters with minimal background noise, the augmentation
of previous methods by combining different technologies together creating instruments capable of
producing a more extensive gait profile, and the increased practice of using exogenous gait biometric data
from previous tissue repair studies as an acceptable control standard for quantifying implant performance
In-vivo. Rats are one of the most common animals used in critical defect models for preclinical testing of
class II and III medical devices [10–12]. As the instrumentations for assessing gait parameters continues to
develop new technologies, it is important that normal gait parameters of different species of rats are
determined to provide data upon which to plan experiments. It is also valuable to compare normal gait
biometrics between different species of rats that use similar gait assessment tools in order to evaluate
differences among species used for specific defect models. This is especially relevant for biometric tools
that find significant differences in the gait parameters between different strains of rats, where one species
gait pattern is more consistent and less varied for a particular tissue defect model than other species. A more
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predictable gait pattern could have a greater advantage in profiling tissue repair in specific critical defect
models In-vivo.
Recently, pressure sensing mat technology has been developed as a more accurate and precise tool for
quantifying gait [13–15].We aimed to utilize a commonly used pressure sensing mat tool to measure the
kinematic and timing variables in both the forelimb and hindlimbs of two species of rats. Studies that have
utilized the VH4 system have reported excellent calibration reliability of the 5101 sensors in In-vivo studies
of 1.2–4.4%, well within the established acceptable cut-off range of 5%. A previous study also reported
this as an acceptable range when reporting sensor reliability ranges of 3–4% [16]. Two of the most common
rat species used in In-vivo critical defect testing are Sprague Dawley and Lewis rats [17,18]. While previous
studies have reported normal kinematic data from these rat species, there does not appear to be any literature
that compares the normal gait pattern of Sprauge Dawley rats to Lewis rats using a pressure mat system
[19–22]. In this study we will be comparing the gait parameters between Sprauge Dawley and Lewis rats.
The type of data output from pressure mat systems concerns both temporal and force gait data. Temporal
data analyzed in this study includes stance time (how long each limb makes contact with mat), swing time
(the time it takes between two hits on the mat with the same hindlimb), stride time (the time it takes between
right forelimb and left hindlimb to make contact with the mat at the same time as well as the opposite limb
pattern), stride length (distance between right forelimb and left hindlimb as well as its opposite limb pattern)
stride velocity, stride acceleration, and limb surface area coverage. Force data assessment includes the limb
forces generated on the mat with respect to pressure difference, normalized force data to the body weight
of each rodent, impulse force in each hindlimb.
We hypothesized that the normal walking gait motion between the two species would be similar. The
objective is to comparing the gait parameters between Sprauge Dawley and Lewis rats. The type of data
output from pressure mat systems concerns both temporal and force gait data. Temporal data analyzed in
this study includes stance time (how long each limb makes contact with mat), swing time (the time it takes
between two hits on the mat with the same hindlimb), stride time (the time it takes between right forelimb
and left hindlimb to make contact with the mat at the same time as well as the opposite limb pattern), stride
length (distance between right forelimb and left hindlimb as well as its opposite limb pattern) stride velocity,
stride acceleration, and limb surface area coverage. Force data assessment includes the limb forces
generated on the mat with respect to pressure difference, normalized force data to the body weight of each
rodent, impulse force in each hindlimb and its normalized version to the rodent bodyweights, and the peak
pressure generated in each hindlimb. The system is also capable of comparing specific limbs to each other
as a ratio profile for maximum force generation, stance time, stride time, stride length, and stride velocity
variables. These ratios concern 4 areas of comparison towards these variables: forelimbs to hindlimbs, all
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limbs on the right side of rodent to all limbs on the left side, right forelimb to left forelimb, and right
hindlimb to left hindlimb.

3.2 Methods
The study was approved by the Institutional Animal Care and Use Committee (IACUC) at the University
of Tennessee, Knoxville (IACUC# 2574-0318). Lewis and Sprague Dawley rats were selected for use in
the study of gait biometrics. Sprague Dawley and Lewis rats used in this study were eight-week old males
(n=14, each) and allowed to acclimate to their environment for one week before gait assessment. Animals
were directed to walk two passes on the pressure mat during each testing period before the testing began in
order for the animals to get familiar to the mat and become comfortable with handling and being directed
across the mat.

3.2.1 Pressure Sensing Mat Specifications
Gait patterns were analyzed using a pressure sensor mat (Tekscan VH4, Tekscan, Boston, MA). This mat
is composed of four 5101 high-resolution pressure sensor matrix grids layered in series to each other. The
sensing area uses rows and columns of sensels and converts the change in electrical resistance to a force
based on calibration to known applied weight. Each sensor has a grid of 44 columns and 44 rows (11.2 cm
x 11.2 cm) of sensels, creating 176 sensel columns x 44 sensel rows for a total area of 11.18 cm x 44.7 cm
(499.75 cm2) with a 0.127-cm gap between sensels in each row and column. The total grid has 7,744 sensels
at a density of 15.5 sensels/cm2. The sensors/handles were aligned to place the origin (0,0) in the upper left
corner of the sensel grid [23]. For the purpose of this experiment, The gait testing unit was modified to
include a tinted Plexiglas tunnel (width 17.0 cm, height 17.0 cm, length 44.7 cm) and a Styrofoam side wall
(width 2.54 cm, height 2.54 cm, length 44.7 cm) for the purpose of guiding the rats across the mat and to
insure that the rats remained in the sensel area so that the rats would perform normal walking gait patterns
across the entirety of the mat. This minimized false data recordings from animal miss-steps on the edges or
outside the sensor matrix area (Figure 3.1).
The pressure sensing mat was calibrated using a phantom device designed to support a known mass (2,006.8
g; 4.42 lb.; 19.7 N). The instrument was programmed to record gait parameters at a sample rate of 50
frames/sec, with start and stop recordings being manually controlled. Calibration accuracy was tested by
comparing five repeated measures of the phantom weight. Tekscan software records the raw data of each
gait variable as an average mean value for each trial walk in an ASCII file format. Each limb must record
at least 3 footfalls (“hits”) on the mat to calculate an average value, otherwise the software will record an
N/A for the calculated variable.
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VH1-4
A

B

Figure 3.1 Tekscan VH4 Pressure-mat system setup.
Note: Testing apparatus consists of a tinted Plexiglas tunnel (A). The tunnel is positioned over the Tekscan pressure mat aligned t o Styrofoam
borders placed at the edges of the sensel area (B). Four sensors (VH1–4) connect the four 5101 sensors to the Tekscan mat.

3.2.2 Gait Testing Protocol
Calibration of the pressure sensors was carried out before each use of the device. Each rat was weighed
using a digital scale before starting walk trials on the mat. The rats were released on either side of the
pressure mat facing the open end of the transparent Plexiglas tunnel centered over the sensel area on the
mat. The tunnel was designed with dimensions that encompassed the Styrofoam walls attached to the mat
without making contact with the sensel area. After the rats had been acclimated to their environment for at
least 1 week and body weights were recorded, the rats were positioned and held by the operator at either
end of the tunnel openings and released when the test was initiated by manually starting the recording
procedure in the software by the operator. The animal then traversed the length of the tunnel until they
reached the other end at which time the recording was stopped manually for either a successful trial or an
incomplete trial as determined by the software operator.
Criteria for a successful walk across the mat was determined if the rats were able to walk continuously from
one end of the mat to the other with minimal to no pause in gait motion and at least three strikes were
detected for each limb as confirmed by reviewing video recording of the measured biometric data on the
software. All data recorded for the gait parameters were average values from each successful trial. The
procedure was repeated for each animal until 2 successful trials were achieved, giving a total of 28 data sets
per rodent group. Data was reported as the average peak measures of each gait variable and for each limb
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as recorded by the sensels and identified as either the right forelimb (RF), left forelimb (LF), right hindlimb
(RH), or left hindlimb (LH) as a whole for the trial.
A video camera was attached to a strip located directly above the Plexiglas tunnel and synced to the gait
profile to capture the motion of the animals as they walked across the mat to observe the subject’s behavior
and match the limbs with the corresponding limb strikes in the gait profile. The operator had to use video
synchronization in order to identify any software selection of the wrong limb strike box and when it the
software was unable to discern multiple limb strikes at a single location during the trials due to ipsilateral
forelimb and hindlimb contact which often overlap each other. This made it necessary to manually correct
boxes by following the subject’s motion on both the camera and gait force profile for corrected gait
assessment (Figure 3.2).

A
B

C

Figure 3.2 Tekscan software display.
Note: A: Example gait force profile during the subjects walk from right to left. Visual display of right forelimb (red), left forelimb (green), right
hindlimb (pink), and left hindlimb (blue) contact sensor boxes is represented as the summation of sensels activated and their corresponding limbs
recording location on the mat, time, and gait variables. B: Graph of force vs. time for the example gait profile of force peaks with their respective
limbs. C: Logitech camera visual output.
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Gait temporal variables measured included average stance time, swing time, stride time, stride length, stride
velocity, and stride acceleration based on the location of the limb strikes relative to the sensel area and
another subsequent limb strikes. Contact variables included contact area derived from the maximum
number of sensels loaded. Force generation parameters included contact force, impulse force, and contact
pressure derived from the maximum sensor readings at the time of impact. Contact pressure, impulse force
and contact force were normalized to the weight of the animals on the date of testing (average value divided
by body weight). Time variables (stance time, stride time, stride length, and stride velocity) and maximum
force were normalized to specific limb orientations (forelimbs to hindlimbs, left side limbs to the right sided
limbs, left forelimb to right forelimb and left hindlimb to right hindlimb) and compared for statistical
significance.

3.2.3 Statistical Analysis
All successful trials were included from each rodent group. Analysis of variance was used to compare all
28 data sets per rodent group as a means comparison for each gait variable. Two-way analysis of variance
for comparisons between the groups followed by Bonferroni’s post-hoc analysis. Signiﬁcance was set at P
≤ 0.05.

3.3 Results
3.3.1 Normal Gait Assessment
All 28 rodent subjects from the Sprague Dawley (n=14) and Lewis (n=14) rat groups completed two
successful walk trials. This resulted in a total of 28 successful gait trials per group, giving a total of 56 data
sets to assess mean values of gait parameters for rodent groups. The body weight of each rat was recorded
before beginning trials. Significant difference was detected in the initial body weight of the rat groups, with
the Sprauge Dawley rat group having a mean body weight 26.1% greater than the Lewis rat group (Figure
3.3).
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Figure 3.3 Mean Body weight distribution between Lewis and Sprauge Dawley Rats
Note: ANOVA analysis *P ≤ 0.05

3.3.2 Gait Analysis: Ratio Temporal Parameters
The ratio means values indicate the degree of variance between different limbs for specific temporal
variables (Figure 3.4). The mean and standard deviations applicable for each gait variable assessed are
presented as follows: Sprague Dawley Rat (SD), Lewis Rat (LR), Stance Time forelimb/hindlimb (Stance
TF/H), Stride Time forelimb/hindlimb (StrideTF/H), Stride Length forelimb/hindlimb (StrideLF/H), Stride
Velocity forelimb/hindlimb (StrideVF/H), and Maximum Force forelimb/hindlimb (MFF/H), Stance Time
Left side/Right side (Stance TL/R), Stride Time Left side/Right side (StrideTL/R), Stride Length Left
side/Right side (StrideLL/R), Stride Velocity Left side/Right side (StrideVL/R), and Maximum Force Left
side/Right side (MFL/R), Stance Time Left forelimb/Right forelimb (Stance TLF/RF), Stride Time Left
forelimb/Right forelimb (Stride TLF/RF), Stride Length Left forelimb/Right forelimb (Stride LLF/RF),
Stride Velocity Left forelimb/Right forelimb (StrideVLF/RF), and Maximum Force Left forelimb/Right
forelimb (MFLF/RF), Stance Time Left hindlimb/Right hindlimb (Stance TLH/RH), Stride Time Left
hindlimb/Right hindlimb (StrideTLH/RH), Stride Length Left hindlimb/Right hindlimb (StrideLLH/RH),
Stride Velocity Left hindlimb/Right hindlimb (StrideVLH/RH), and Maximum Force Left hindlimb/Right
hindlimb (MFLH/RH).
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Figure 3.4 Ratio temporal and force parameter values
Note: ANOVA analysis. *P ≤ 0.05

Table 3.1 Ratio values for normalized temporal parameters
Species

StanceTF/H

StrideTF/H

StrideLF/H

Stride VF/H

MFF/H

SD

0.77±0.16

0.97±0.155

1.06±0.166

1.12±0.25

0.83±0.2

LR

0.79±0.16

1.02±0.08

1.03±0.101

1.02±0.1

0.76±0.09

Species

Stance TL/R

Stride TL/R

Stride LL/R

Stride VL/R

MFL/R

SD

1.00±0.18

1.02±0.16

0.99±0.11

0.98±0.16

0.95±0.21

LR

0.97±0.13

0.988±0.10

0.99±0.105

1.0±0.08

0.96±0.12

Species

Stance TLF/RF

Stride TLF/RF

Stride LLF/RF

Stride VLF/RF

MFLF/RF

SD

0.97±0.21

1.08±0.26

0.98±0.17

0.96±0.28

0.894±0.21

LR

0.97±0.32

0.98±0.13

0.98±0.1

1.01±0.13

0.94±0.204

Species

Stance TLH/RH

Stride TLH/RH

Stride LLH/RH

Stride VLH/RH

MFLH/RH

SD

1.06±0.34

1±0.24

1.01±0.17

1.06±0.28

1.02±0.28

LR
1.02±0.26
1±0.15
1±0.17
1±0.13
0.99±0.13
Note: Stance Time, Stride Time, Stride Length, Stride Velocity, and Maximum Force comparative analysis based on limbs. The closer the
mean values are to 1.0, the less variance there is between limbs of the animals
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Table 3.2 Values for # of Stance, Gait time, Gait Distance, Gait Velocity, Gait Cycle Time, Cycle min

Species

No_Stance

Gait_Time
(sec)

Gait_Distance
(cm)

Gait_Velocity
(cm/sec)

Gait_Cycle_Time
(sec)

Cycles_min (sec)

SD

14.43±2.3

1.88±0.86

30.47±5.64

19.85±9.8

0.62±0.233

110.43±39.5

LR

17.93±1.94

2.04±0.57

37.32±3.67

19.85±6.2

0.5±0.104

125.3±25.45

Table 3.3 Values based on specific limbs for both species.

Species

Extremity

Stance_time (sec)

Swing Time
(sec)

Stride_time
(sec)

Stride_length
(cm)

Stride_velocity
(cm/sec)

Stride_Acc
(cm/sec²)

LR

LF

0.30±0.142

0.2175±0.076

0.493±0.112

9.37±1.41

20.27±6.44

-2.05±26.93

LH

0.4±0.15

0.129±0.05

0.49±0.119

9.22±1.48

19.8±5.57

2.81±36.63

RF

0.32±0.109

0.212±0.052

0.51±0.109

9.62±1.27

20.21±6.30

1.15±24.38

RH

0.408±0.184

0.136±0.23

0.491±0.099

9.34±1.42

19.88±5.64

14.8±35.85

LF

0.356±0.133

0.295±0.174

0.629±0.235

10.58±2.29

19.73±9.63

5.93±25.34

LH

0.499±0.2

0.181±0.077

0.63±0.275

10.54±2.28

19.3±8.08

-8.95±20.7

RF

0.368±0.13

0.249±0.16

0.60±0.257

10.96±2.24

21.73±10.44

5.12±32.47

RH

0.486±0.2

0.178±0.075

0.651±0.252

10.33±1.88

18.94±10.01

13.4±35.93

SD

Species

Extremity

MF_BW
(%)

MF (gr)

Impulse_BW
(%)

Impulse (gr)

MPr (kPa)

Cont_Area
(cm²)

Adj_Pr
(g/cm²)/BW

LR

LF

61.93±10.53

133.9±29.83

10.86±3.06

23.64±8.25

47.7±9.74

0.508±0.08

1.3±0.353

LH

84.71±9.7

183.6±37.17

20.09±7.86

44.46±22.52

55.53±9.74

0.611±0.1

1.46±0.26

RF

67.02±10.55

144.3±26.82

12.2±3

26.57±8.49

49.04±7.9

0.515±0.07

1.35±0.203

RH

86.55±10.52

187.3±35.34

20.5±6.27

44.8±17.1

56.2±10.1

0.633±0.12

1.441±0.253

LF

63.64±13.17

161.0±33.93

12.7±4.54

31.93±10.73

51.75±9.56

0.568±0.11

1.127±0.203

LH

84.48±15.0

215.9±43.05

24.57±9.53

62.96±25.73

61.4±6.96

0.704±0.14

1.215±0.174

RF

74.83±19.3

189.8±45.03

14.18±5.45

35.86±12.66

56.46±9.95

0.611±0.112

1.225±0.225

RH

85.29±16.63

217.9±46.1

24.6±12.14

63.11±32.71

64.07±8.45

0.726±0.133

1.19±0.214

SD
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3.3.3 Gait Analysis: Force and Temporal Parameters
Force and temporal parameter values specific to the four limbs that make up the gait profile of each animal
group (Figure 3.5). Mean variance analysis showed that there were no significant differences for both the
Sprague Dawley and Lewis rat groups in the stride velocity and stride acceleration temporal parameters for
each limb. The analysis also determined that the normalized maximum and impulse forces in the groups for
each limb were statistically similar. Stride length, impulse force, maximum force, contact area, and
normalized pressure showed statistical differences between the groups for each limb tested. Swing time,
and stride time showed statistical differences between the groups for the hindlimbs and the left forelimb
while the right forelimb showed no significant difference. The stance time showed a significant difference
for the left hindlimb only. The maximum peak force showed significant differences for all limbs except the
left forelimb.
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Figure 3.5 Analysis of variance of gait variables
Note: Two-way ANOVA Bonferroni’s post-hoc and Tukey’s grouping analysis. Statistical comparison of values between Lewis Rats (LR) and
Sprague Dawley rats (SD), subcategorized by left forelimb (LF), right forelimb (RF), and left hindlimb (LH), and right hindlimb (RH). All values
are presented as group means and SD error bars. *P < 0.05.
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Gait parameters recorded from left and right hind limbs were also assessed for mean variance grouping
between the limbs for each rat group to determine how similar the mean force and temporal values are
compared to each limb. In the Lewis group stride time, stride length, stride velocity, stride acceleration, and
normalized pressure in each limb were found to be statically similar to each other. Swing time, maximum
force, normalized maximum force, impulse force, normalized impulse force, and contact area showed
statistical differences between the forelimbs and the hindlimbs with the hindlimb mean values having a
higher value compared to the forelimb. Maximum pressure and stance time mean variables for Lewis limbs
were grouped based on their statistical mean variance from each other.
Similar to the Lewis group, the Sprague Dawley group stride time, stride length, stride velocity, stride
acceleration, and normalized pressure in each limb were found to be statically similar. Stance time, impulse
force, normalized impulse force, and contact area showed statistical differences between the forelimbs and
the hindlimbs with the hindlimb mean values having a higher value compared to the forelimb. Swing time,
maximum pressure, maximum force, and normalized force mean variables for Sprague Dawley limbs were
grouped based on their statistical mean variance from each other.
Mean temporal parameters concerning gait distance and gait cycle time were found to be significantly
different between the two groups, while all other variables cycle min, gait velocity, gait time, and number
stance were found to not be significantly different between the two groups.
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Figure 3.6 Mean temporal parameter values
Note: Sprauge Dawley (SD) and Lewis (LR) rats -ANOVA analysis. *P ≤ 0.05
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3.4 Discussion
To our knowledge, this is the ﬁrst study to compare the gait pattern between Sprague Dawley and Lewis
rat species using the pressure mapping system. We have identified specific differences in the gait pattern
between these rat species that might be a factor to consider when choosing appropriate rodent species for
critical defect models. Large variances were detected in both the Sprauge Dawley and Lewis rat groups
when comparing the forelimbs to the hindlimbs for variables concerning the maximum force and stance
time. All other limb iterations and variables assessed showed mean values with variances that did not exceed
deviations greater than 0.12, indicating small differences in gait temporal values between the limbs of the
rats. ANOVA analysis of each gait variable was assessed between the animal groups, these results are
identified in Table 3.4.

Table 3.4 Mean values statistical comparison between Sprauge Dawley and Lewis groups based on limbs.
Stride_velocity
(cm/sec)

Stride Acceleration
(cm/sec²)

1

0

0

1

1

0

0

0

0

1

0

0

1

1

1

0

0

Species

Stance_time
(sec)

Swing Time
(sec)

LF

0

LH

Stride_time (sec)

Stride_length (cm)

1

1

1

1

RF

0

RH

0

Species

MF_BW
(%)

MF (gr)

Impulse_BW (%)

Impulse
(gr)

Max_Peak_Pressure (Pa)

Cont_Area
(cm²)

Adj_Pr
(g/cm²)/BW

LF

0

1

0

1

0

1

1

LH

0

1

0

1

1

1

1

RF

0

1

0

1

1

1

1

RH

0

1

0

1

1

1

1

Note: Sprague Dawley rats (SD), subcategorized by left forelimb (LF), right forelimb (RF), and left hindlimb (LH), and right hindlimb (RH). 1=
(P < 0.05), 0= (P ≥ 0.05)
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Variables concerning speed, acceleration and normalized forces generated in each limb of Sprague Dawley
and Lewis rats are expected to have similar values and variations given the conditions of the rat population
studied. The analysis also showed expected differences between the groups concerning the unadjusted
impulse force, maximum force, contact area, stride length, and adjusted pressure values detected in each
limb. The temporal parameters concerning stance time, swing time, and stride time were unexpected in that
the results indicated similar swing and stride times for the right forelimb yet significant difference in the
stance time for the left hindlimb between the two groups. The most likely cause for these differences
between the two groups is the presence of some rats with gait patterns that favor a particular limb over the
others, creating an uneven gait kinematics and locomotion during normal gait motion. This theory is
corroborated when grouping the mean values of the limbs for each group (Table 3.5 and Table 3.6) which
showed swing and stances times which had different mean grouping profiles between the limbs for each
group indicating partial unevenness to the normal gait of these groups. This has been confirmed from
previous studies that have noted similar observations in the normal gait pattern of rodents.

Table 3.5 Lewis mean value group comparison between limbs

Lewis

Stance_time
(sec)

Swing Time
(sec)

Stride_time
(sec)

Stride_length
(cm)

Stride_velocity
(cm/sec)

Stride Acceleration
(cm/sec²)

LF

1

1

0

0

0

0

LH

1, 2

2

0

0

0

0

RF

1, 2

1

0

0

0

0

RH

2

2

0

0

0

0

Lewis

MF_BW
(%)

MF (gr)

Impulse_BW
(%)

Impulse
(gr)

Max_Peak_Pressure
(Pa)

Cont_Area
(cm²)

Adj_Pr
(g/cm²)/BW

LF

1

1

1

1

1

1

0

LH

2

2

2

2

2, 3

2

0

RF

1

1

1

1

1, 2

1

0

RH

2

2

2

2

3

2

0

Note: Right forelimb (RF), and left hindlimb (LH), and right hindlimb (RH). 1, 2, 3= individual groups for mean variance, 0= similar mean
variance group
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Table 3.6 Sprague Dawley mean value group comparison between limbs
Sprague
Dawley

Stance_time
(sec)

Swing Time
(sec)

Stride_time
(sec)

Stride_length
(cm)

Stride_velocity
(cm/sec)

Stride Acceleration
(cm/sec²)

LF

1

1

0

0

0

0

LH

2

2

0

0

0

0

RF

1

1, 2

0

0

0

0

0

RH
Sprague
Dawley

2
MF_BW
(%)

2
MF (gr)

0
Impulse_BW
(%)

Impulse (gr)

0
Max_Peak_Pressure
(Pa)

Cont_Area
(cm²)

LF

1

1

LH

2

2

RF

1, 2

RH

2

0
Adj_Pr (g/cm²)/BW

1

1

1

1

0

2

2

2, 3

2

0

1, 2

1

1

1, 2

1

0

2

2

2

3

2

0

Note: Right forelimb (RF), and left hindlimb (LH), and right hindlimb (RH). 1, 2, 3= individual groups for mean variance, 0= similar mean
variance group

Forward motion variables such as velocity and acceleration were consistent between both groups, including
the additional analysis of individual limbs regarding these variables. This would indicate that the motion of
each of the limbs of the rats was the same for both groups. Due to the difference in animal size between the
groups, swing time and stride length variables were statistically different between the two groups, where
the Sprauge Dawley rats showed greater stride length and swing time than the Lewis rats [24]. This also
explains why the Sprague Dawley group had on average a lower mean value of stances number, gait length,
and gait time compared to the Lewis group. As expected, normalized maximum and impulse forces were
consistent between both groups. Meaning that the force generated in each limb during both deceleration
and acceleration of the limbs on the mat were the same between both groups when normalized to the weight
distribution of the rats in each of their respective limbs. This was further confirmed when grouping the
mean values of the limbs for each group, which showed statistically similar stride velocity and acceleration
for each limb while normalized force and contact area values remained statistically different between
forelimbs and hindlimbs. Previous studies have used rodents as a control group for normal gait motion and
have described this gait pattern were the hindlimbs will support more of the rodent’s weight compared to
the forelimbs due to the unequal distribution of the rodent weight across the body frame from the front end
to the back end [7,21]. This also explains why the stance time variable has a large variance between the
forelimbs and hindlimbs for both rodent groups, as the greater weight supported by the hindlimbs needs
more time to stabilize and propel the body forward during normal gait motion. This is why during normal
gait motion in rodents the hindlimbs are considered more responsible for producing forward motion, while
the forelimbs are more concerned with directing forward motion in the intended direction.
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3.5 Conclusion
In summary, we highlighted specific differences in the gait pattern between Sprague Dawley and Lewis rat
groups using the VH4 Tekscan pressure mapping gait system. This in an effort to establish a control
standard gait model to assist in selecting appropriate animals for critical defect models where animal gait
biometric data is relevant and the tool for assessing gait patterns is similar to Tekscan’ s VH4 model. We
have shown for the ﬁrst time, comparative quantitative assessment of normal gait patterns in Sprague
Dawley to Lewis rats using Tekscan’ s VH4 pressure-map system. Our results concerning normalized force
and stride velocity/acceleration variables shows that both groups maintained statistically similar weight
distributions and forward motion in each limb during normal walk patterns. Unadjusted variables
concerning contact area, force and stride length showed significant differences between the two groups for
each limb and fore limbs from each group having significantly different values compared to the hind limbs.
We also detected irregular patterns in the swing, stride, and stance time variables between the two groups
which we attribute to uneven gait motion during the trial due to favoring or odd sensation from one or more
limbs.
This data would suggest that the gait pattern for Sprague Dawley rats are statistically similar to that of the
gait pattern of Lewis rats when using Tekscan’ s VH4 model pressure mat system. Careful consideration
must be taken for possible variations in the temporal data due to specific rodent biometric specification,
asymmetrical gait patterns due to limb sensations or favoritism, and the rodent’s behavior and degree of
training prior to testing on the pressure mat. This would indicate that for the purposes of collecting gait
biometric data as a quantitative assessment of tissue repair in critical size defect models that the use of
either Sprauge Dawley or Lewis rat normal gait patterns might both be used interchangeably as acceptable
positive gait control models. Certain limitations to this study should be considered such as a much-focused
set of rodent specifications that might overlook other biometric variables that have a larger impact on
normal rodent gait patterns such as male vs female and other rodent species, the time and form of training
and conditioning prior to test, ease and difficulty to house and handle, and potential physiological changes
brought on by stress or pathogens. Comparison of the Tekscan VH4 model results with other highly
sensitive pressure mat systems results might be prudent to help establish control rodent gait patterns for
other commonly utilized gait assessment tools. The statistical power of this study could also be improved
by amending the number of trials performed by each rat to a higher number than 2 or by increasing the
number rodents acquired for the study.
Moving forward with assessing the performance of our neural wraps in a sciatic nerve defect model In-vivo,
rodents are the most commonly used animal model for assessing nerve regeneration in critical nerve defects
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[25]. While both Lewis and Sprague Dawley rats are considered active rodent strains suitable for gait
analysis for assessing nerve repair, it is suggested that Lewis rats are used as the subjects in critical nerve
defect models over other alternative rodent strains due to minimal occurrence of autotomy behavior after
an extended period post transection of the sciatic nerve gap. This is supported by previous studies that have
highlighted the physiological behavior changes in different rodent strains after induction of critical size
nerve defects [26,27].
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Chapter 4: Critical Nerve Defect Model using Lewis Rat Subjects to
Assess In-vivo Performance of PCL+GO+hADSC Fiber Neural
Wrap
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Abstract
The successful establishment of PCL+GO platforms and the successful In-vitro testing for biocompatibility
towards adipose derived MSC and ability to support neural stimulated hADSC culture has provided the first
round of data that supports this material as a potential biomaterial candidate for creating neural wraps to be
used in the repair of critical neural defects. In this study, we have established a rodent model using Lewis
rats to simulate a critical nerve defect and determine the potential of this material with hADSC cultures is
at assisting in the repair of critical nerve defects In-vivo. 24 total Lewis rats were separated into 4
independent treatment groups. Treatment was left to provide its intended therapy for 12 weeks before being
removed for histology assessment of the repair. Gait assessment of the rodent’s gait pattern was also
collected using a Tekscan pressure mat system as an indirect assessment for return of neural function.
Results of our gait analysis indicate a significant deviation from normal rodent gait patterns after creating
the neural defect in rats as expected, however data could not conclude if nerve function was beginning to
return at the defect site by 12 weeks repair. Histology sections of the neural wraps at 12 weeks show new
tissue growth present inside the neural wrap tubing with tissue growth expanding across the material
towards the distal section of the defect. Staining shows that new tissue has similar characteristics to the
tissue found in native peripheral nerves in terms of tissue layering and organization. However, we cannot
yet fully identify what the new tissue is until a more specific set of staining protocols are used. Most likely
these stains will search for tissue that we expect to make up a significant component of the new tissue that
is growing such as axon, myelin, and Schwann cell specific stains. From this study we determined that this
material has potential to grow new tissue at critical nerve defects while remaining intact for up to 12 weeks
In-vivo. The effectiveness of the material to regenerate new neural tissue, or how effective the addition of
hADSC therapies is in repairing the defect remains unknown and is the center of new studies being
developed to address the limitations of this current study.
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4.1 Sciatic Nerve Transection Model
4.1.1 Introduction
Neurotmesis is one of the most damaging forms of peripheral neuropathy that affects approximately 3 %
of trauma patients around the globe. Severe forms of neurotmesis involves significant gaps (>2-3 cm) along
peripheral nerve sections that often require surgical intervention to successfully repair. Currently, the gold
standard for repair of severe neurotmesis is the use of autograft nerve segments taken from a different area
of the patient were the nerve type, diameter size, and length are similar to the nerve gap. The limitations of
this method are well known and the expected degree of repair from such technique are quite varied which
has opened to discussions of finding alternative methods of tissue repair. The use of scaffolds to regenerate
damaged peripheral nerve presents a possible solution to healing severely damaged peripheral nerve
segments. For peripheral nerve injuries a preferred scaffold implant is one that can support the damaged
nerve at the wound site as well as stimulate and guide the growth of new peripheral nerve tissue through
the scaffold.
In our previous study, we assessed the cytocompatibility of our novel biomaterial to support hADSC in a
combined therapeutic approach to assist in peripheral nerve repair using manufacturing techniques
developed thru our collaboration with the University of Arkansas Little Rock (UALR) Nanotechnology
group. We have also provided the methods and resources to assess the compatibility of novel biomaterials
developed by UALR intended also for assisting in the repair of severe neurotmesis injuries. All iterations
regarding the development of these candidate neural scaffolds have been assessed in vitro using MSC
culture systems. Previous In-vitro analysis of cytotoxicity and stability as a cell platform have been assessed
via cultures of established Mesenchymal stem cell lines (hADSC and rADSC) by evaluating cell
proliferation, viability. We also have assessed the biomaterials potential to guide MSC lines in vitro towards
neural-like lineages when artificially increasing cAMP messenger proteins to guide differentiation of MSCs
towards a neural-like phenotype by evaluating the changes in expression intensity of proteins present during
neural differentiation such as S100β.
We determined that Electrospun PCL fiber meshes surface coated with GO nanomaterials were capable of
supporting hADSC lines in both their undifferentiated form and their differentiated states towards neurallike phenotypes. It is suggested from these results that In-vivo testing is the next reasonable step to
determine the scaffolds ability to stimulate nerve regeneration, re-establish functional activity of the nerve,
and return to function of tissues innervated by target nerves. This work must be done using animal models
of induced nerve defects so that the biological response can be assessed [1–3]. These in vivo models also
allow for study of the biocompatibility of the scaffolds to determine candidacy for clinical use. In this study
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we modified the films into 3D neural wrap prototypes to be assessed In-vivo for their potential in assisting
in actual nerve repair. We utilized a rat sciatic nerve model in which a segmental defect is made in the
sciatic nerve of rats which is then repaired with our 3D neural wraps consisting of PCL fiber meshes
modified with GO surface coating.
The sciatic nerve defect model utilizing rodents is the most commonly used small-animal model for
evaluating neural repair. The model consists of transecting a segment of the animal’s peripheral nerve on
either the left or right hind limb. The segment having a gap that is considered a critical defect based on the
species and size of the animal subject. The peripheral nerve gap is then connected by an open-end
cylindrical conduit/wrap biomaterial or a peripheral nerve graft that is surgically aligned to the distal and
proximal ends of the gap with minimal tension and impairment to new growing native tissue. The animal
subject remains under observation until either partial repair or complete repair of the nerve gap is reached
in order to assess the quality of tissue growth. This time variable is dependent on the animal species and
the size of the nerve gap based on the expected rate of peripheral nerve growth to span the defect. The most
common methods for evaluating the return of normal peripheral nerve function can use both direct
(electrophysiology, muscle mass, histochemical staining) and indirect (gait analysis, pain sensation)
methods. Multiple methods used in tangent with each other can assess the presence of new nerve tissue
growth and whether it is functional.
Rodents are a validated, extensively published, and common model used in evaluating neural conduit or
wrap In-vivo cytotoxicity and regenerative capability of these biomaterials due to their relevant neural
physiology, ease of handling, small size and affordability, and the shortened time required to reach end
points successful peripheral nerve healing. There are studies that have attempted to standardized the sciatic
nerve model by controlling for specific variables present in the rodent subjects to determine the optimal
rodent variables to use in the sciatic nerve model. Such variables include species, age range, sex, rodent
body dimensions, and breeding vendor in an attempt to improve the precision of end-result data and quality
of tissues extracted for assessment. Studies have also noted asymmetrical or abnormal behavior in rodent
species in response to transection of their sciatic nerves including differences in normal gain motion. One
such behavior is self-mutilation or atotomy at limbs affected by the transection of the sciatic nerve. The
current consensus in the appropriate animal subjects to use for the sciatic nerve model are Lewis rats due
to minimal occurrence of atotomy behavior after prolonged exposure to sciatic nerve transection compared
to other common rodent species used in this model (Sprauge Daweley, Wistar). Male rodents have reported
greater lengths in newly regenerating peripheral nerves compared to female, while the rate of nerve
regeneration and quality of tissue in younger rodents is at a markedly higher degree than that of older rodent
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populations. It is suggested that healthy male Lewis rats that fall within the demographic of 8 to 12 weeks
old is the best subjects for this model.
The objective of this study is to assess the In-vivo potential of neural wrap designs to assist in healing
critical neurotmesis defects through changes in gait parameters, and histochemical staining assessment. It
is hypothesized that PCL biomaterials enhanced with the addition of GO, or Gold-nanorod thin film surface
coatings with the addition of hADSC therapy can support the growth of new peripheral nerve in an In-vivo
system. At 12 weeks post-repair of critical defect, we expect that new peripheral nerve will span the defect
gap and reach the distal stump by growing along the scaffolding designs. Attention to new tissue
organization compared to native peripheral nerves and the distance of new tissue growth thru the nerve
scaffolding are critical for this assessment. Results of these studies will guide further research to improve
the designs of these nerve scaffold prototypes and determine the functionality of any potential nerve tissue
growth on these scaffolds. The end result is to create a peripheral nerve scaffold that is capable repairing
severe neurotmesis cases in both humans and animals. If we can design a biomaterial platform that meets
or exceeds the quality of repair achieved in autologous neural grafts, we can begin the process of
establishing clinical trials for assessment in humans which will hopefully result in a successful translation
of our patent into the neural graft market.

4.2 Methods
The study was approved by the Institutional Animal Care and Use Committee (IACUC) at the University
of Tennessee, Knoxville (IACUC# 2574-0318). 24 Lewis rats were selected for use in the study of gait
biometrics and histology assessment. Lewis rats used in this study were eight-week old males and allowed
to acclimate to their environment for one week before the surgery date. Animals were organized into 6
independent groups as follows: Group 1- control only (sciatic nerve defect with no treatment of the defect,
Group 2-3 represented electrospun PCL wraps with GO surface coating. and electrospun PCL wraps with
GO surface coating pre-cultured with hADSC lines. Group 4- Autologous nerve graft. Each group included
a sample size of n=6. Lewis rats were subjected to critical size neurotmesis nerve injury to their sciatic
nerves as described in previous similar nerve models [1,4]. Animals in each group were maintained for up
to 12 weeks post-surgery with gait analysis data collection at each 2-week interval from each rat.
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4.2.1 Electrospinning
The creation of 3D PCL meshes of nanofibrous architecture was performed with the same solution and
electrospinning parameters as discussed in Chapter 2 methods section (pg. 6) with modifications in the
parameters including changing the voltage applied to 15 kV charge and altering the needle tip-to-collector
distance setting to 6 inches to create PCL fiber meshes of greater rigidity and easier to manage when wetted
in cell culture media. To create a thicker PCL nanofiber mesh deposit on the collector mandrel, the solution
was left to spin for 4 hours which used a total of 4 ml of spinning solution per spin which created a projected
film thickness of approximately 0.01 mm. The entire PCL mesh was removed from the collector plate and
cut to the dimensions of 9cm x 12cm sections. The sections were attached to a 24-culture well lid using
tape and pre-sterilized under UV sterilization for 4 hours prior to air spraying GO solutions onto the surface
of the mesh. GO solution was prepared under the same parameters as discussed in Chapter 2 (pg. 5). GO
solutions was bath sonicated for 30 min to evenly disperse graphene oxide films in solution that have settled
to the bottom of the container after 24 hours or more in storage before being used to coat the materials.
Under fume hood conditions, 10ml of GO solution was used to coat the surface of PCL fiber meshes using
air spray technique on hot plate set to between 45-55°C. Solutions were sprayed at 21 psi. PCL meshes was
removed from 24 culture-well lid and placed into sterile glass dishes with glass cover lids. Under cellculture sterile hood conditions, PCL GO coating fiber mesh sections were cut to dimensions of 12mm x
6mm sections as appropriate to span the expected sciatic nerve defect length with a 1 mm margin of error
for attaching the proximal and distal sections.

4.2.2 Animal Surgery
Prior to surgery, all neural wrap prototypes were UV sterilized for 4 hours under cell culture sterile hood
prior to culturing cells. 24 hours prior to implanting the PCL nerve wraps into rodent subjects, hADSC cell
lines used in the previous Chapter 2 In-vitro study were cultured onto the surface of nerve wraps that were
placed into 30mm diameter sterile non-tissue culture polystyrene wells. 1*10 total hADSC cells were
6

seeded at a concentration of 1*10 cells/ 200μl DMEM-F12 stem cell culture media to the surface of nerve
6

wraps. The cells were left to adhere to the surface of the nerve wrap for 3 hours before adding an additional
800μl of DMEM-F12 culture media to the well to support the cell lines for the remaining 21 hours in culture
period. To determine if hADSC cell lines successfully adhered to the surface of nerve wraps in 24 hours
post seeding, DiI staining was used to track the remaining viable cells found on the surface of the nerve
wraps. If the nerve wraps showed a majority of its surface covered with hADSC cell lines with characteristic
stretching and spreading indicative of cells successfully adhered to biomaterials the wrap remained in
incubation until needed for implantation. All films were transferred into sterile wells filled with sterile
saline solution for transport to the surgical environment.
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All subjects were initially weighed and injected with 0.03 mg/kg; subcutaneous injection of buprenorphine
just before prepping for surgery. Under isoflurane anesthesia, all rats were positioned into lateral
recumbency and prepped for surgery by shaving the right hind leg and sterilized using isopropanol and
iodine solutions. A skin incision of 3 cm was made longitudinally to the posterior aspect of each thigh, from
the greater trochanter to the knee. Blunt dissection of the gluteus maximus and biceps femoris muscles will
expose the sciatic nerve directly underneath. A critical size nerve defect in rats is approximately 10 mm
which was made by removing a segment of the sciatic nerve. The defect was repaired using our PCL fiber
mesh coated with GO that includes with or without hADSC cultures to span the defect and attach to the
proximal and distal nerve stumps using 10-0 absorbable suture material (Figure 4.1).
Negative control group (n=6) had 10 mm sections of sciatic nerve removed but did not receive any scaffold
treatment. Positive control group (n=5) had sciatic nerve sections re-implanted to the distal and proximal
stump using 10-0 vicryl sutures to mimic gold standard autologous peripheral nerve repair. The muscle
tissue was returned to its original position and the skin was closed with 5-0 vicryl sutures. Each animal was
administered buprenorphine (0.03 mg/kg; subcutaneous) every 6–12 hours for 72 hours and provided with
free access to water containing Enrofloxacin (Baytril) oral antibiotics (100 mg/400 mL) and Gatorade
powder for 72 hr. We applied E-collars to each rat for 24 hours post-surgery. This model of transecting the
Sciatic nerve causes all animals to be affected by diminished use of the operated leg to various degrees over
the duration of the study. This should not be interpreted as lameness or an indication of pain, but rather a
result of the disability associated with the nerve model used. Signs of autotomy by the rats on the affected
leg was also considered in our normal checkup of the rats as previous sciatic nerve studies have reported
cases of potential self-mutilation most likely caused by abnormal sensations in the hind foot digits after
transecting the sciatic nerve.

Figure 4.1 GO+PCL neural wrap repair of 10mm peripheral nerve defect in Lewis rat subject.
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4.2.3 VH4 Pressure Sensing Mat Assessment
Gait patterns were analyzed using a pressure sensor mat (Tekscan VH4, Tekscan, Boston, MA) for each rat
when they reach each 2-week interval post-surgery. The mat was prepared using the same tinted Plexiglas
tunnel and Styrofoam borders to ensure the rats stay on the sensel areas during normal rat gait motion. The
procedures for calibrating the, protocols for guiding rats to walk across the mat, and criteria for selecting
successful runs are based on our previous gait comparison analysis between Sprague Dawley and Lewis
rats referenced in chapter 3. All mean values for normalized body weight, and surface area contact from
each successful trial was recorded to assess any changes in gait profiles that could indicate a return to
function of motor and sensor endplates due to newly regenerated functional nerve tissue reaching the distal
end of the sciatic nerve gap.

4.2.4 Histology
At 12 weeks, the neural scaffolds and grafts were removed from the rats and aligned on sections of
cardboard before being placed in 10% formalin to preserve the tissue sections. The tissues were embedded
into paraffin and sliced longitudinally for histochemical analysis of the newly regenerated nerve tissues
inside the nerve scaffolds extending from the proximal start to distal end. Based on the previous methods
described by Carriel, Víctor, 2011 in the use of H&E and MCOLL histology methods for labeling layers of
different tissue sections present in the peripheral nerve anatomy [5]. While H&E is a common method of
staining for collagen tissues and the nucleus of cells, MCOLL staining involves the combined approach of
using Luxofast Blue to stain for lipoproteins that should be found on the surface of myelin sheath tissue
and Picrosirus Red stain for specific staining of different collagen tissues which makes up the majority of
the perineurium and epineurium sections of peripheral nerves. This combination allows for clear
identification of myelin sections present in newly regenerated nerve tissue for comparing the organization
of myelin sections and their dimensions to that of native peripheral nerve tissue.

4.3 Results
4.3.1 PCL Neural Wrap Extraction
96 % of the original 24 rat subjects made it to week 12 euthanasia. The study resulted in 6 Negative control
rats, 5 autologous graft rats, 6 PCL+GO rats, and 6 PCL+GO+hADSC rats at week 12. One rat was removed
due to complications during recovery post-surgery. No animal subjects showed any signs of discomfort of
atotomy behavior caused by transecting the sciatic nerve during the 12-week study period.
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Electrospun PCL+ GO

Electrospun PCL+ GO+ hADSC

Figure 4.2 Week 12 neural wrap/conduit removal from Lewis rat subject’s post-euthanasia
Note: Stance Time, Stride Time, Stride Length, Stride Velocity, Maximum Force distribution, and surface contact area based on limb.

All neural conduits and wraps extracted from animal subjects that reached week 12 in the study showed
stable platforms with both ends securely attached to both the distal and proximal ends of the nerve gap.
Neural wraps showed slight indications of early deterioration most likely due to hydrolyzes, on porous thin
films. All neural wraps were extracted from all 12-week rats. Wraps, and autologous grafts were placed on
cardboard sections then preserved in 10% formalin as histology slides.

4.3.2 Gait Assessment of Lewis Rats During 12-Week Nerve Repair
At pre-op and at each 2-week interval during nerve repair, each Lewis rat was placed on a Tekscan Pressure
Mat system to assess the return of nerve function thru tracking of normal gait motion. Data pertaining to
normal gait motion included maximum normalized force distribution, and surface contact area which were
collected from both the right and left hind limbs as a means value. This gave us a profile of the rats’ gait in
each group during nerve repair.
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Table 4.1 Tekscan pressure mat raw data of mean temporal parameters
Time

Group

Negative

Autologous
Week 2
PCL+GO

PCL+GO+hMSC

Negative

Autologous
Week 4
PCL+GO

PCL+GO+hMSC

Negative

Autologous
Week 6
PCL+GO

PCL+GO+hMSC

Negative

Autologous
Week 8
PCL+GO

PCL+GO+hMSC

Limb

Stance_
time

Swing Time

Stride_
time

Stride_
length

MF_BW

MF_gr

Max_
Peak_Pressure

LH

1.00±0.65

0.16±0.087

1.03±0.65

8.60±1.72

90.95±9.92

202.80±31.07

56.57±8.84

RH

0.92±0.67

0.26±0.13

1.01±0.71

8.24±1.91

68.87±17.7

152.20±35.9

60.30±9.52

LH

1.43±0.96

0.14±0.056

1.36±0.71

7.15±1.07

90.52±10.9

227.92±37.2

59.40±8.2

RH

1.25±0.91

0.21±0.12

1.25±0.75

6.60±1.5

66.21±15.2

167.16±44.4

60.52±9.2

LH

1.06±0.43

0.11±0.062

1.10±0.51

8.18±1.89

86.81±11.5

192.40±24.37

57.03±5.77

RH

0.82±0.31

0.30±0.24

0.99±0.49

7.73±1.62

56.97±17.82

127.03±42.14

51.60±12.44

LH

0.84±0.52

0.13±0.037

0.83±0.57

8.32±1.25

85.12±14.11

196.0±35.18

56.17±9.61

RH

0.67±0.4

0.24±0.11

0.75±0.44

7.62±1.58

58.78±12.85

135.17±30.32

54.37±8.68

LH

0.99±0.38

0.13±0.044

1.11±0.45

8.60±1.36

94.44±9.62

236.03±33.44

62.63±7.92

RH

0.81±0.36

0.25±0.17

0.99±0.43

7.73±1.91

64.92±12.4

161.3±29.32

60.83±8.05

LH

1.18±0.62

0.14±0.068

1.17±0.56

7.60±1.52

88.70±10.8

250.32±32.7

67.68±6.96

RH

0.96±0.52

0.25±0.057

1.06±0.48

6.68±1.3

64.66±12.24

181.04±27.61

62.88±8.16

LH

1.38±0.85

0.12±0.04

1.34±1.06

9.35±1.78

92.32±12.8

238.47±38.03

64.63±9.75

RH

0.97±0.73

0.31±0.21

1.07±0.88

7.79±2.35

52.69±11.92

136.10±32.42

52.60±9.5

LH

1.05±0.6

0.12±0.056

1.13±0.76

8.41±1.83

86.43±19.12

237.43±56.6

63.17±10.62

RH

0.84±0.46

0.21±0.11

0.89±0.51

7.25±1.83

55.32±21.1

150.17±54.5

54.43±15.0

LH

1.17±0.57

0.13±0.061

1.20±0.64

8.17±1.78

96.02±16.74

260.77±58.7

67.43±10.83

RH

0.84±0.51

0.26±0.21

1.01±0.54

7.08±2.17

60.96±15.62

163.40±39.9

60.60±9.83

LH

0.90±0.43

0.13±0.06

0.95±0.49

8.26±1.59

91.55±11.27

280.0±34.51

66.60±6.02

RH

0.80±0.52

0.18±0.07

0.81±0.56

7.10±1.74

71.38±12.15

218.04±35.7

71.48±8.97

LH

1.70±0.99

0.13±0.1

1.89±1.26

8.94±1.67

94.01±16.47

264.97±49.24

67.83±9.77

RH

1.31±0.95

0.28±0.17

1.56±1.19

7.28±2.25

57.63±14.6

162.0±40.9

57.50±10.8

LH

1.24±0.77

0.12±0.05

1.26±0.7

8.55±1.66

91.23±15.93

273.07±51.14

67.83±9.16

RH

0.95±0.71

0.27±0.13

0.96±0.56

6.67±1.3

57.66±15.2

171.67±43.09

57.63±11.7

LH

1.34±0.64

0.15±0.11

1.33±0.59

8.40±1.92

92.20±13.35

259.80±55.8

67.30±9.52

RH

1.26±0.73

0.24±0.084

1.31±0.72

7.81±1.79

64.52±12.75

178.67±30.24

67.50±9.24

LH

1.22±0.58

0.15±0.05

1.20±0.66

8.21±1.89

86.18±10.38

277.40±38.0

68.32±9.5

RH

1.14±0.65

0.18±0.09

1.14±0.71

7.73±2.16

70.88±14.85

226.56±40.02

72.60±8.98

LH

1.54±1.02

0.10±0.03

1.57±1.17

9.41±1.58

90.83±14.15

274.0±47.14

68.70±9.0

RH

1.22±0.88

0.24±0.08

1.26±0.91

7.77±2.16

56.73±11.45

170.37±32.5

60.37±10.34

LH

1.01±0.47

0.11±0.043

0.89±0.56

8.99±1.75

95.87±13.9

303.90±41.61

72.03±7.98

RH

0.79±0.35

0.25±0.17

0.77±0.41

8.53±3.28

56.70±19.65

179.70±61.7

59.83±14.73
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Table 4.1 Continued
Time

Group

Negative

Autologous
Week
10
PCL+GO

PCL+GO+hMSC

Negative

Autologous
Week
12
PCL+GO

PCL+GO+hMSC

Limb

Stance_
time

Swing Time

Stride_
time

Stride_
length

MF_BW

MF_gr

Max_
Peak_Pressure

LH

1.11±0.54

0.14±0.069

1.20±0.57

8.70±1.85

95.35±10.65

280.93±55.07

68.57±8.98

RH

0.93±0.56

0.19±0.096

0.98±0.53

7.38±1.99

64.04±13.25

186.13±36.51

67.60±9.36

LH

0.90±0.39

0.14±0.05

0.97±0.47

9.18±1.89

91.48±8.53

308.72±35.93

71.92±7.75

RH

0.78±0.32

0.16±0.065

0.79±0.36

7.84±1.37

72.32±9.92

243.0±29.35

75.56±8.22

LH

1.16±0.56

0.13±0.13

1.25±0.67

9.56±1.84

91.14±13

286.60±42.39

71.37±7.12

RH

0.88±0.45

0.27±0.16

1.01±0.56

8.21±2.34

58.27±16.51

183.80±53.62

64.40±12.87

LH

0.99±0.4

0.11±0.045

0.85±0.37

8.54±2.19

91.54±12.09

304.83±48.19

68.97±9.66

RH

0.81±0.35

0.22±0.098

0.81±0.38

7.52±1.78

58.64±12.78

194.07±40.42

66.80±12.27

LH

1.23±0.55

0.12±0.046

1.24±0.56

8.46±1.23

92.55±11.34

285.77±57.39

70.10±8.14

RH

0.95±0.44

0.21±0.076

0.99±0.53

7.18±2.03

60.03±9.54

184.33±36.25

68.53±10.58

LH

0.81±0.32

0.14±0.064

0.86±0.43

9.10±2.05

85.44±9.63

299.76±44.91

71.36±7.63

RH

0.62±0.26

0.16±0.11

0.68±0.31

7.23±1.26

66.58±10.3

232.56±36.86

72.80±7.39

LH

0.84±0.3

0.10±0.026

0.81±0.33

9.05±1.9

84.62±11.6

283.50±42.5

73.37±8.3

RH

0.71±0.32

0.19±0.057

0.69±0.33

7.99±1.98

58.12±9.68

193.90±30.88

66.40±9.37

LH

1.04±0.68

0.12±0.038

0.91±0.65

9.40±1.97

91.90±9.59

318.47±38.23

71.40±6.41

RH

1.00±1.0

0.21±0.059

0.94±0.98

8.37±2.19

64.81±12.06

223.70±38.87

70.60±10.36
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Figure 4.3 Mean surface area coverage profile of left and right hind limbs for each group.
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Figure 4.4 Normalized mean body weight percentage profile of left and right hind limbs for each group.
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LH

RH

Week 12

In order to compare these results between each group given that each rodent is independent from all other
rodents in the sample size it is essential that we normalize the results as a ratio between the hind limbs
impacted by the neural defect (right hind limb) and the control hind limb with no neural defect impact left
hind limb). Table 4.2 compares the mean surface area contact and normalized body weight ratios over the
period of 12 weeks of nerve repair using the pre-surgery time point (week 0) as the base line for fully
functional nerves. A value close to 0 indicates LH and RH hind limb values that are similar to each other
in terms of either the surface area contacts or force distribution in the hind limbs.

Table 4.2 Mean ratios of hind limbs mean
Autologous
Week 0

Week 2

Week 4

Week 6

Week 8

Week 10

Week 12

SAC

0.036766

0.624656

0.657499

0.596527

0.600062

0.542816

0.487804

BW max

0.019401

0.367206

0.371938

0.282616

0.215733

0.264808

0.283345

Week 0

Week 2

Week 4

Week 6

Week 8

Week 10

Week 12

SAC

0.072203

0.881526

0.944491

0.887065

0.979261

0.809786

0.708114

BW max

0.021006

0.523932

0.752135

0.631211

0.601034

0.563951

0.45587

PCL+GO

PCL+GO+hMSC
Week 0

Week 2

Week 4

Week 6

Week 8

Week 10

Week 12

SAC

0.034916

0.838589

0.921013

0.904774

1.034102

0.957124

0.734144

BW max

0.043607

0.448086

0.562425

0.582355

0.69087

0.560962

0.417867

Negative
Week 0

Week 2

Week 4

Week 6

Week 8

Week 10

Week 12

SAC

0.026312

0.649361

0.690812

0.826862

0.753592

0.820436

0.759931

BW max

0.015267

0.320492

0.454587

0.57499

0.42894

0.488836

0.541729

Note: mean surface area coverage (SAC) and mean max body weight percentage (BW max): Week X (LH Week X/RH Week X)-1
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4.3.3 Histology
Autologous, normal Lewis rat sciatic nerve section, and nerve wrap tissue samples were removed from 10%
formalin solution and embedded in parafilm. Tissue samples were oriented in order to cut longitudinal
histology sections of the tissue to visualize the organization and distance of new tissue growth thru the
nerve scaffold across the length of the critical defect. MCOLL staining of longitudinal sections from each
euthanized rat was carried out and images from 1 random rat subject from each group was assessed under
light microscopy with images taken at 4x and 40x magnification at 5 specific areas along each tissue section.
These areas were determined by establishing areas at the two ends of the longitudinal sections as the
proximal and distal ends and half way in between as the center position. Areas between the two ends and
the center area were labeled as proximal center and distal center positions.

Distal

Distal_Center

Center

Normal
Sciatic nerve

Autologous

PCL+GO

PCL+
GO+hADSC

Figure 4.5 Week 12 MCOLL staining
Note: Extracted nerve repair groups at 5 primary regions along the sciatic nerve gap.
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Center_Proximal

Proximal

4.3.4 Luxofast Blue Coverage/Myelin Diameter
20x magnification MCOLL images at all areas of the longitudinal histology sections excluding the distal
areas were used to assess luxofast area coverage. A lack of luxofast blue staining present at the distal stump
for all tissue sections besides the normal sciatic nerve tissue is most likely due to new nerve growth not
having reached the distal stump by 12 weeks of nerve repair in the nerve wrap groups. 20x images from the
proximal region to the distal center region was processed thru ImageJ to grey scale luxofast blue to
determine its area coverage across each of these regions as a positive stain for myelin tissue (Figure 4.6).
5 random areas in each 20x image was selected for luxofast blue area coverage. This resulted in a total of
20 data points for 1 histology section from each repair group with no replicates. (Figure 4.7).
Results showed that the normal sciatic nerve had the highest luxofast blue stain coverage across the entire
span of the tissue section indicating a potential large presence of myelin tissue in native Lewis rat sciatic
nerves. The Gold standard autologous group showed significantly lower levels of luxofast blue coverage at
12 weeks repair compared to all other groups tested. PCL+GO and PCL+GO+hADSC experimental nerve
wraps showed luxofast blue coverage significantly greater than the autologous group with the PCL+GO
groups showing coverage comparable to that of the native nerve tissue.
40x magnification MCOLL images from 3 selected areas of the longitudinal histology sections excluding
the distal area was selected for the presence of intense luxofast blue intensity organized into characteristic
myelin sheath dimensions as described in previous studies using MCOLL staining on peripheral nerves.
Using ImageJ, lines were drawn transecting the axons perpendicular to the axonal axis of the myelin
sections. Diameters of myelin sections at their widest point were recorded at random areas in each 40x
image to assess myelin thickness by 12 weeks nerve repair. This resulted in a total of 30 data points for 1
histology section from each repair group with no replicates. (Figure 4.8).
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Figure 4.6 ImageJ grey scaling of luxofast blue staining of myelin sheath
Note: Quantified myelin area coverage for each group at week 12 extraction.
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Figure 4.7 Luxofast Blue stain area coverage quantification spanning the neural defect at week 12
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Figure 4.8 Myelin diameter assessment: tracking for presence of myelin tissue at week 12

Results showed that the normal sciatic nerve had the highest myelin sheath thickness compared to all other
groups tested. The Gold standard autologous group showed significantly lower myelin thickness at 12
weeks repair compared to all other groups tested. PCL+GO and PCL+GO+hADSC experimental nerve
wraps showed myelin sheath diameters significantly greater than the autologous group by week 12 with
expected new immature myelin tissue to be in abundance around the experimental nerve wraps.

4.4 Discussion
3D PCL fiber meshes coated with GO were successfully created using slightly modified manufacturing
protocols from previous In-vitro study. Films selected to support hADSC growth were confirmed to have
cell culture growth thru DiI staining 24 hours prior to film implant. The study lost one Lewis rat due to
complications during recovery.
Temporal data of rats did not show signs of significant changes during the 12-week period of nerve
regeneration. Force distribution and surface area contact ratios between the right and left hind limbs were
found to be significantly similar to each other at pre-surgery time points for all rodent groups. After sciatic
nerve transection, the ratios for force distribution and surface area contact between the hind limbs was
found to be significantly different to each other. These results show a similar pattern to Boyds study
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involving transecting a section of the Sprague Dawley spinal cord that affected the right leg only and
recorded both the pre-surgery and post-surgery changes in gait parameters for both hind limbs using the
same system and software used in the study [6]. Results comparing surface area contact and body weight
distribution between all experiment groups showed that by week 12 no group ratio values for either surface
area contact and body weight distribution parameters was significantly similar to the base line ratios. This
would suggest that the repair groups implemented to repair a 10 mm sciatic neural defect in Lewis rats did
not reach full functionality by 12 weeks In-vivo
MCOLL staining of tissue sections showed positive staining on control normal sciatic nerve sections with
clear tissue organization similar to that of previous longitudinal histology sections of peripheral nerves
stained with MCOLL. This type of organization was also present along the regions of PCL+GO and
PCL+GO+hADSC nerve wrap experimental groups. Identification of neural wrap tissue sections stained
with luxofast blue, and picosirus red was not clear in all sample tissues stained. PCL+GO nerve wrap with
and without the inclusion of hADSC showed nonspecific staining of other tissue components present in the
neural defect that could not be identified at present. Peripheral nerve anatomy structures are not as
pronounced as what is shown in normal sciatic nerve tissue sections. Autologous clinical gold standard
showed minimal expression of luxofast blue staining across all regions indicating a potential lack of myelin
tissue in new regenerating tissue by 12 weeks. High density of hematoxylin staining for cell nucleus is
present in all experimental groups compared to the normal sciatic nerve groups most likely due to the
intrusion of fibroblasts, Schwann cells, and macrophages to regulate endogenous nerve repair.
Quantitation of luxofast blue surface coverage in histology images showed normal sciatic nerves had the
highest coverage of luxofast blue staining. This is most likely attributed to its abundance of mature and
developed myelin sections present in the native peripheral nerves. Autologous showed the lowest coverage
of luxofast blue, indicating that newly regenerated myelin sheath production has not started by week 12.
The neural wrap design both with and without hADSC showed statistically greater coverage of the stain
than the autologous group, with the neural wraps without hADSC cultures showing stain coverages almost
comparable to that of normal sciatic nerve tissue. This would suggest that new myelin sheath production
has started along the length of the neural wrap.
Quantitation of the diameter of myelin sections showed that normal sciatic nerves had the highest myelin
sheath diameter sections. This is most likely due to that most of the myelin present in native sciatic nerve
tissue is mature and well developed as a thick myelin sheath. Autologous showed the lowest myelin sheath
diameter, indicating that newly regenerated myelin sheath production has not started by week 12. The neural
wrap design both with and without hADSC showed statistically greater myelin sheath diameter sizes than
the autologous group.
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4.4.1 Implications/Challenges
Sciatic nerve defect model The selection of the animal subjects regarding strain of rats was initially using
Sprague Dawley rats. However, these strains were found to be very susceptible to sensations in the hind
limbs after transecting the sciatic nerve eventually leading to them self-mutilating their affected hind limbs
in a behavior pattern known as autotomy. The study started out with 17 total Sprague Dawley rats following
the protocols stipulated in IACUC# 2574-0318. 70.6% of the Sprague Dawley population was affected by
autotomy behavior during different time points of the 12-week nerve repair. Multiple methods were
considered to try and reduce the onset of autotomy behavior including the use of bitter apple and
metronidazole coatings to dissuade biting at the effected hind limbs. These methods showed no indications
of improving or preventing autotomy as the study progressed. It was decided to change the strain of the rat
subjects to Lewis rats due to their recorded history of showing less autotomy behavior in neural defect
models. 100% of the Lewis rat population showed no signs of autotomy throughout the entire duration of
nerve repair.
Multiple passes were needed from each rat to achieve the required 5 successful walks to be assessed for
gait analysis. The ease of handling of Lewis rats on the gait pressure mat could be improved if the rodents
are given an extended period of time to adjust and trained to use the mat system to reduce the number of
false walks or passes on the pressure mat during data collection. This can also be managed by making
appropriate modifications to the pressure mat design by installing higher border sections at the sensel edges
and smaller tunnel dimensions so that the rats can’t walk off the mat or stand on their hind limbs while
recording gait.
Histology While the MCOLL staining method did well in establishing the presence of new tissue growth
in the biomaterial without any observable interference from the scaffold. The non-specificity of the stain
makes it difficult to identify with confidence the types of tissue that stains with the MCOLL. Other more
specific staining methods are needed to evaluate specific components of newly regenerated nerve tissue
such as staining for specific myelin sheath protein 0 or specific axon protein markers β 3 tubulin, or GAP43. Embedding aligned tissue sections in parafilm sections were made difficult by the thin film
characteristics of the biomaterial. Longitudinal cuts of the tissue sections potentially missed large sections
of tissue across the length of the neural scaffold. The additions of cross-sectional cuts would also assist in
identifying the exact location of new tissue growth relative to the biomaterial. Multiple layered cuts of the
tissue are needed in order to make a complete assessment of the materials potential for new tissue growth.
Histology assessment concerning data on stain intensity and tissue dimensions between different repair
groups only looked at one tissue sample from each group. Need to assess the remaining tissue sections
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stained with MCOLL as replicates to further improve the statistical confidence of the data. Current
measurements concerning luxofast blue and myelin sheath diameter would not be publishable if they came
from tissue sections of just one rat replicate. More specific measurements of the tissue sections dimensions
such as tissue length and size will make locating regions on the tissue more precise as opposed to simply
saying the proximal, or center region. This will also improve the precision of selecting areas in these regions
for data measurements as opposed to saying the top left corner of the proximal region was assessed for
myelin sheath dimensions. Quantitative intensity assessment of nonspecific luxofast blue staining was
subjective with each image to maximize intensity of the myelin sections while minimizing the intensity of
other nonspecific tissues stained with luxofast. This emphasizes the need to stain for specific markers rather
than nonspecific surface properties to identify and measure tissues we expect to be present in regenerating
nerves.
Manufacturing The initial PCL with GO surface coatings of this In-vivo study had similar characteristics
to the PCL fiber meshes created in the manufacturing phases of the In-vitro study discussed in chapter 2.
Similar to our discussions in this chapter, it also determined that the ease of handling these 3D biomaterials
of similar fiber designs after being placed in a wetted environment was difficult to manage in both the initial
assessment of visualizing hADSC cultures on the material surface after 24hours incubation and positioning
the biomaterials in at the neural defect site during surgery. Slight modifications in the electrospinning
protocol by reducing the voltage and reducing the distance of spinning produced PCL fiber meshes that
were more rigid and less able to fold on itself making visualization and handling in surgical settings easier
to manage.
Gait analysis The pressure mapping system detected differences in hind limb force distribution and surface
area contact to assess the return of neural functions. As an acceptable indirect format for evaluating return
of nerve function it is necessary to note that these results might not correlate well to more direct approaches
to evaluating nerve function such as electrophysiology and histomorphometric analysis. One of the most
common indirect methods for assessing nerve function in the sciatic nerve of rodents is the standard Sciatic
Function Index (SFI). Studies have shown that the SFI is highly correlated to that of direct methods for
assessing nerve function including histomorphometric analysis. It would be a beneficial component to this
study to use SFI assessment in tandem with the Pressure mapping system to bridge the results of the gait
analysis to that of the histology results to determine if a correlation is present.
The results from this study leave many questions concerning how the new tissue develops and grows at
different time points and whether they correlate to the gait patterns at these time points as well during the
nerve repair cycle. This suggests that the design of this experiment should be altered to euthanize a number
of rodents from each group at different time points during the 12-week period to establish a more accurate
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assessment of the how the new tissue grows on the nerve wrap and see if a correlation exist between the
growth pattern and the gait pattern. It might also be prudent to extend the period of nerve repair to a further
time period to see if the gait pattern of or neural wraps will eventually become significantly similar to the
baseline values that would indicate a return of full functionality of the sciatic nerve.
It is also unclear what impact that hADSC therapy had at repairing the critical nerve defect in rats when
cultured onto the neural wrap design. It is expected by week 12 that the exogenous hADSC cultures will
have been removed by the rat physiology, but no clear indications of the cells impact at the injury site are
obvious when assessing both gait and histology data. As suggested before it might be beneficial to divide
rats in each group to be euthanized at early stages of nerve repair to increase the chances of observing how
these cells respond in this type of environment and what immediate or lasting impact they might have on
the repair of neural defects. If future studies plan to move toward this setup, it is imperative that methods
for tracking these cell cultures In-vivo are utilized and careful extraction of the tissue so as to not disrupt
any remaining live cells for analysis, such as staining for specific human markers to differentiate between
cells of human origin from native exogenic tissue. The decision to keep cell cultures allogenic or exogenous
must also be considered as is likely that allogenic cultures will survive longer and provide more therapeutic
effects at the injury site compared to exogenous therapy.

4.5 Conclusion
We have described the first initial set of In-vivo data supporting our hypothesis as a step towards further
developing synthetic 3D PCL fiber GO coated wraps for consideration into clinical trials. Our assessment
determined that PCL platforms of thin film nano-fibers surface coated with GO in combination with or
without hADSC line cultures were capable of supporting new tissue that mimics closely in tissue layering
and orientation to that of native peripheral nerve tissue at different areas of the neural scaffolds. Indirect
gait analysis of the rats over the period of recovery showed significant differences in the gait of the rats
after transection of the sciatic nerve in terms of weight distribution and surface area contact ratios between
the hind legs. By week 12 of neural repair, all repair groups showed significant differences in weight
distribution and surface area contact ratios compared to the pre-surgery baseline values, indicating full
recovery of sciatic nerve defects had not been reached by week 12. Pressure map systems cannot discern
the potential implication of asymmetrical pattern and behavior inherent in complex physiological systems.
To determine if this data is dependent or not on the nerve injury induced in the rats, the end period time
point should be extended to a later date to see if these patterns persist or subside according to what is
expected. Direct histochemical staining of each group confirmed the presence of new tissue at multiple sites
along each neural scaffold tested. New tissue showed areas of similar organization to that of native sciatic
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nerve tissue. Neural wraps had additional tissue growth that were non-specific to the MCOLL stain making
areas of the tissue difficult to clearly differentiate organization that is expected in native neural tissue. All
iterations of the nerve wrap showed signs of extensive growth thru the scaffolds at 12 weeks of neural
healing, with potential signs of early myelin sheath production occurring along the length of the material
compared to the gold standard autologous.
The results of this study suggest that PCL fiber meshes with GO surface coatings with or without the
addition of hADSC cultures were successful in supporting new tissue growth and possibly assisting in
guidance of new tissue across the peripheral nerve defect. Based on our histochemical nonspecific staining
for myelin and collagen tissue in native peripheral nerve and the organization of this tissue leads us to
suggest that the new tissue is most likely new peripheral nerves that are extending from the proximal stump
with endogenous repair and support being provided by the neural wraps. It is suggested that the next phase
of In-vivo assessments use the same rodent small animal model but extend the time of the study to ensure
that new tissue reaches the distal stump, with the addition of other direct methods for assessing neural
function such as electrophysiology and staining for more specific nerve markers. These additions should
help us determine with a higher degree of confidence that the new tissue is in fact new peripheral nerves
and whether it is active nerve segments capable of propagating their own electrical signals without
assistance. This should also determine if we can correlate the pressure map system data to that of data
established from direct methods for assessing neural function as new neural tissue reaches the distal stump.
Further studies may involve making alterations to these scaffold designs such as improving tracking of
hADSC cultures In-vivo, better techniques for improving the amount of MSC seeded to the PCL platforms,
and improving material mechanics of neural wraps to prevent material collapse when it is wetted.
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Chapter 5: Conclusions
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5.1 Final Remarks
This body of work represents the careful steps and assessments required to determine proof of concept and
functionality in the early stages of developing novel tissue engineering devices. This study has resulted in
the successful manufacturing of a neural wrap material composed of electrospun nanofiber PCL matrices
with surfaces modified by thin coating GO films by air spray methods to support hADSC therapies. This
design was pursued in an attempt to address the problem of inadequate repair of critical size defects in the
peripheral nerves of trauma patients. The design was created to function as a conduit bridge across the
defect gap that will deliver hADSCs to the site of injury while guide and stimulate early axon regeneration
that would culminate in early and or improved tissue repair. Early In-vitro studies showed that this
biomaterial was biocompatible to MSC cultures and could support hADSC cultures for up to 6 days in
culture while hADSCs were artificially stimulated towards neural-like lineages. To assess the In-vivo
potential of this biomaterial design a rat sciatic nerve defect model that simulates a critical size neural defect
expected in patients with severe neurotmesis was utilized. The wraps were sutured to the defect site and
left In-vivo for 12 weeks to provide assistance in repairing of the neural defect. At 12 weeks it was found
that the wraps could support and guide new tissue growth along the longitudinal axis of the neural defect
site both with and without hADSC cultures. This suggests that nanofiber PCL+ GO surface coating material
iterations might be a suitable candidate for further preclinical studies in developing biomaterial wraps
designed to assist in critical nerve defect repairs.
While this material has shown great potential in supporting new tissue growth In-vivo, further preclinical
studies are needed to determine the materials effectiveness at specifically supporting and stimulating growth
of axons as a targeted therapy approach. This involves tweaking the design of the material based on the
suggested improvements and complications addressed in the In-vivo study, and altering the experimental
design of the In-vitro tests to address the complications noted there. Of primary concern is to determine
what type of therapy hADSC cultures have during the initial stages of nerve repair and whether their
presence significantly improves or has a neutral or insignificant affect on neural regeneration. By carefully
considering the appropriate neural cell line to co-culture with hADSCs and further control for specific
extracellular compounds present during endogenous nerve repair, we can see how hADSC cultures will
behave as an early look at what types of therapy effects hADSC cultures might express In-vitro. In the Invivo study if we euthanize rats at earlier time points, we might be able to track the stem cells as the new
nerve tissue regenerates. We can also use this time to look for specific neural markers expressed during
axonal growth and improve techniques in handling rodent subjects during gait analysis and techniques for
extracting and embedding neural tissue samples for histology slides.
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One other complication of concern is determining whether the gait parameters measured during the In-vivo
study can be correlated to the histology results at their respective time points. By using in conjunction to
our pressure mat another indirect method that has been well established as having a high correlation to
histology results when assessing a return of nerve function, there would be a greater chance of establishing
a correlation pattern if one exists. The Sciatic Function Index (SFI) method is the most commonly used and
reported method in conjunction with histomorphology results, with a high record of these reports stating a
high correlation to histology results.
As I conclude this study, I am reminded of the prodigious responsibility that tissue engineers owe to the
people we serve. While it is often enough to simply follow the standards and guidelines of assessing new
devices, I feel it is our obligation to remind ourselves to why we follow them. Medical devices are some of
the most dangerous items available to the market. A device specifically engineered to function with or
within a system that is not yet fully understood, where stimulation from a medical device can cause a
cascading effect that if not corrected could have severe acute or long-term effects on a person’s health or
wellbeing. These standards are in place more so to protect the customers who trust that our products will
target to resolve their immediate or future medical related problems without causing complications in the
form of new medical problems. As engineers, scientist, researchers, and inventors it is our duty to discover,
create, and seek out new and innovative ideas/products out of the public’s interest or our own, but I feel
that it is our responsibility to always actively seek out and pursue faults in our ideas and designs. This is
more relevant today than in any other period in history for developing medical devices. With the rate at
which new technologies are being developed comes the need to revise the current standards to assess how
these new technologies will impact the public’s health should they be used in developing new medical
devices. By critiquing ourselves, we indirectly proclaim to the public that it is in our concern for their
wellbeing as the reason why we develop medical devices in the first place. This will only further our creed
to create devices that will improve the public’s wellbeing and thus further solidify the public’s trust in us.
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